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Abstract 
Synthesis and Evaluation of Structural Analogs of Escherichia coli Lipid A for 
Application Towards CD14-Targeting Glycotherapeutics 
 
Aileen Fay Galos Bongat 
Doctor of Philosophy 
University of Missouri - St. Louis 
Prof. Alexei V. Demchenko, Chairperson 
 
Lipid A is a glucosamine-based phospholipid that anchors carbohydrate molecules to the 
outer membrane of most Gram-negative bacteria. During severe infection, this 
amphiphilic macromolecule invoke a strong and acute pro-inflammatory response that 
leads to sepsis and ultimately to septic shock, organ failure and death. Thus, following 
the convention that the best antidote is often a derivative of the parent agonistic molecule, 
researchers have actively pursued the idea of creating an analog of Lipid A that can block 
the cellular receptor for this molecule and thereby arrest the cascade of events that lead to 
sepsis. Consequently, we became interested in creating monosaccharide and disaccharide 
analogs of Lipid A, anticipating that our targeted design may exhibit the desired 
antagonistic effect without being harmful to the host cell. Since our target compounds 
share a structural motif prevalent in biologically relevant carbohydrates – the presence of 
1,2-trans linked residues of 2-amino-2-deoxysugars - we investigated the application of 
our novel thioimidoyl methodology to the synthesis of 1,2-trans glycosides of 2-amino-2-
deoxysugars. We reported previously that, along with providing a flexible approach to the 
Bongat, Aileen, 2008, UMSL, p. III 
 
synthesis 2-amino-2-deoxyglucopyranosides, our method allowed for the chemoselective 
assembly of oligosaccharides containing multiple residues of 2-amino-2-deoxyglycoses. 
Herein, the application of the aforementioned thioimidoyl methodology to the selective 
activation approach to oligosaccharide assembly is described. More importantly, this 
dissertation will detail the synthesis of Lipid A analogs that contain three interesting 
structural features – the aminosugar core, (R)-3-hydroxy-fatty acids, and amino acids. 
This unique structural configuration has never before been synthesized and tested for 
antagonistic activity against enteric Lipid A. Therefore, it is to be anticipated that the 
synthetic approaches described herein could pave the way for expanding the range of 
antiendotoxic compounds prepared to date.  
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1.1. Bacteria and Endotoxins 
Interactions between the animal and microbial worlds are intimate, complex, and 
vital to the good health of both.
1
 Over the course of almost a billion years, the mutual 
accommodation between microorganism and multi-cellular host has enabled both to 
survive and adapt to a changing environment. Without intracellular microbial parasites, 
the evolution of multicellular organisms would not have been possible. Indeed, the basic 
processes of cellular respiration in eukaryotes are possible only because of the presence 
of a microbial parasite in the cell called the mitochondrion.
2
 As the endosymbiotic theory 
purports, mitochondria are descended from ancient proteobacteria engulfed by eukaryotic 
cells billions of years ago. 
This intricate, symbiotic relationship between humans and microbes, however, 
has had its darker side. From parasitic and acute infections to chronic illnesses such as 
peptic ulcer disease,
3
 cancer, and coronary heart disease,
4
 microorganisms have triggered 
a plethora of human diseases. In response, the innate immunity in humans has evolved 
into a complex system that enables it to respond to a microbial threat and achieve a 
survival advantage. The latter is often accomplished by exploiting features unique to the 
threat, just as the microbes have used the same defensive and subversive strategies to 
circumvent our immune system.
1
 Evidence of this evolutionary transformation also 
manifests in our genome as genetic mutations, i.e. thalassemia have permitted local 
populations to survive in areas where malaria is endemic.
5
  
 Amongst the billions of microorganisms present on earth, bacteria are the most 
diverse and abundant group. Based on their response to a staining procedure developed 
by Christian Gram in 1884, bacteria are classified into two broad groups – Gram-positive 
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and Gram-negative.
6
 This procedure is reflective of the fundamental differences in the 
composition and organization of the bacteria’s cell wall.
7
 Accordingly, Gram-positive 
bacteria have a multi-layered cross-linked polymer of peptidoglycan surrounding its 
plasma membrane while Gram-negative bacteria only have a monolayer of peptidoglycan 
(Figure 1.1.a, b).  Furthermore, the latter are further encapsulated with a second 
membrane exterior to its peptidoglycan, whereas no comparable structure is observed in 
the former.  
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Figure 1.1 Representation of the Bacterial Cell Wall and Lipopolysaccharide: a) Gram-positive 
bacterial cell wall, b) Gram-negative cell wall, c) Lipopolysaccharide of Escherichia coli. 
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Given the marked difference in the structure of the cell envelope, the Gram-stain 
reaction also tends to correlate with the susceptibility of the bacteria to a variety of 
antibacterial agents. In general, Gram-negative bacteria are intrinsically more resistant to 
antibiotics and antibacterial compounds. This observation is perhaps counterintuitive 
when we consider that Gram-positive bacteria have thicker cell walls. Apparently, while 
the peptidoglycan surrounding the latter is mechanically strong, it offers little resistance 
to the diffusion of small molecules such as antibiotics because its meshwork is quite 
porous.
8
 As such, the higher intrinsic resistance of Gram-negative bacteria can only be 
rationalized in terms of the permeability restrictions imposed by their outer membranes.
9
 
The Gram-negative outer membrane is an asymmetric lipid bi-layer interspersed 
with proteins. Like the plasma membrane, its inner leaflet is composed of 
glycerophospholipids; i.e. phosphatidylethanolamine, with smaller amounts of 
phosphatidylglycerol and cardiolipin. The outer leaflet, in contrast, is comprised almost 
exclusively of lipopolysaccharide (LPS) molecules. LPSs are amphiphilic glycolipids 
whose unique structural features primarily dictate the selective permeability and barrier 
function of the outer membrane.
6
 Interest in LPS as a target for the development of novel 
antimicrobial compounds stems both from its essential role in outer membrane stability 
(and consequently, cell viability) and from the realization that this complex structure was 
responsible for the diverse immunological and biological effects attributed to 
“endotoxins”.  
In 1892, Pfeiffer and Centanni independently described a heat-stable pyrogenic 
toxin intrinsic to Vibrio cholerae and Salmonella typhi.
10
 Pfeiffer initially called it 
“endotoxin” and it was not until the 1930s that Boivin was able to extract this endotoxin 
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using the trichloroacetic acid technique.
11
 Endotoxin purified through this method, 
however, was essentially a crude fraction containing many cell wall proteins.  This made 
any progress towards understanding the biological impact of this molecule slow and 
inconclusive.  After a decade or so, Westphal and Luderitz were finally able to develop a 
method for obtaining pure active fractions of this endotoxin, which was shown to be 
lipopolysaccharides (LPSs).
12
  
 LPSs are composed of three genetically, structurally, and antigenically distinct 
regions (Figure 1.1c) namely: 1) a hydrophobic membrane anchor called Lipid A, 2) a 
short chain of sugar residues with multiple phosphoryl substituents referred to as the core 
oligosaccharide, and 3) a structurally diverse, serospecific polymer composed of 
oligosaccharide repeats called the O-antigen. The LPS of Escherichia coli (E. coli), 
Salmonella enterica (S. enterica), members of the family of Enterobacteriaceae, and 
important pathogens including representatives of the families Vibrionaceae and 
Pseudomonadaceae all share the same aforementioned structural organization. In 
contrast, the LPSs of many mucosal pathogens lack the typical long-chain, repeating O-
antigen unit i.e. the genera Haemophilus and Neisseria. Instead, the latter possess short, 
stereospecific oligosaccharides extending from the core called lipooligosaccharides 
(LOSs). In general however, the basic tripartite LPS-framework holds true for all 
characterized Gram-negative bacteria.   
 Lipid A, the covalently linked lipid component of LPS, is composed of six or 
more fatty acid residues linked to two phosphorylated glucosamine residues (Fig. 1.1c 
and elaborated later).
13
 Four of the fatty acids have a (R)-3-hydroxyl group and the other 
two are devoid of it. Each Gram-negative bacterial species has a unique Lipid A 
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configuration and the structural features that differentiate each molecule are as follows. 
First, the acylation pattern on each glucosamine residue can have either a symmetric 
(3+3) or an asymmetric (4+2) arrangement. Second, 3 or 4 different fatty acids can be 
present in the molecule, with a length that can be anywhere between 10-16 carbons. 
Finally, a 4-amino-deoxy-L-arabinose and or phosphonoethanolamine can be linked to 
the C-1 axial or C-4’ phosphate groups on the glucosamine residues.  
 The second part of the LPS molecule, the core region is a short chain of 
polysaccharides with moderate inter-bacterial variability. The inner core consists of 2 or 
more 2-keto-3-deoxyoctonic acids (KDO) linked to C-6’ of the glucosamine residues on 
one side and 2 or 3 L-glycero-D-manno-heptose residues on the other (Fig. 1.1c).
14
 KDO 
and L-glycero-D-manno-heptose are unique to bacterial species.
15
 Under natural 
conditions, the smallest LPS produced by Gram-negative bacteria is Re-LPS - it consists 
of Lipid A with 1 or 2 KDO sugars – but longer LPS are more common.
16
 The Rd1- and 
Rd2-LPS serotypes contain a complete inner core and an inner core without 2 heptose 
sugars, respectively.
17
 The outer core, on the other hand, consists of common sugars and 
is more variable than the inner core. It is normally 2 to 3 residues long with one or more 
covalently bound polysaccharides as side chains.
18-21
 LPS consisting of the Lipid A and 
the complete inner and outer core are denoted Ra-LPS, whereas the Rb- and Rc-LPS 
serotypes only contain a part of the outer core. 
 The last part of the LPS molecule, the antigenic outer core, is the most variable 
part and consists of repeating units of oligosaccharides. Attached to the terminal sugar of 
the inner core, this portion extends from the bacterial surface and is highly 
immunogenic.
22-25
 The chemical composition and structure of the O-antigen can be 
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strain-specific (inter-strain LPS heterogeneity) or it can vary within one bacterial strain 
(intra-strain LPS heterogeneity).
26
 The inter- and intra-strain heterogeneity is 
characterized by variations at different levels.  The first variation can occur through non-
stoichiometric modification of the O-polysaccharides with sugar moieties, i.e. with 
glucosyl and fucosyl residues.  The second variation occurs via addition of non-
carbohydrate substituents – i.e. acetyl or methyl groups – to the O-antigen. This may 
arise with regularity but in most cases, these modifications are also non-stoichiometric. 
The length of the O-antigen may vary from 0 to as many as 40 repeating units, but it 
generally consists of 20 to 40 repeating units. If the O-antigen is present, colonies of the 
bacteria have a smooth (S) appearance on a Petri dish culture. Absence of the O-antigen, 
in contrast, gives the bacterial colony a rough (R) appearance on a Petri dish culture. 
As mentioned, LPS participate in physiological membrane functions and are 
therefore essential for bacterial growth and viability.
27
 They contribute to low membrane 
permeability and enhance the resistance towards hydrophobic agents. LPS is not toxic 
while it remains incorporated in the bacterial outer membrane. When released from the 
bacterial surface – either following cell division or death, as a consequence of 
antibacterial action of the immune system, or interaction with antibacterial agents – LPS 
may form aggregates and interact with the cells of the immune system. Following this 
interaction, LPS elicit multiple acute pathophysiological effects such as fever, toxicity, 
Schwartzman reactivity, macrophage and B-lymphocyte activation, among others.
28
 In 
1954, it was proposed that the Lipid A portion alone is responsible for the endotoxic 
properties of LPS and the polysaccharide portion is dispensable.
29
 After Shiba and co-
workers completed the first target synthesis of Escherichia coli Lipid A,
30
 comparative 
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experiments between the natural LPS and the synthetic Lipid A confirmed that Lipid A  
represents the toxic principle of LPS.
31-33
  
1.2. Immune Response to Lipopolysaccharides 
The immune system of an organism consists of homeostatic mechanisms that 
protect against disease by identifying and killing pathogens and tumor cells. It detects a 
wide variety of agents – from viruses and bacteria to parasitic worms and fungi – and 
discriminates them from the organism's own healthy cells and tissues. Basic immune 
mechanisms evolved in ancient eukaryotes and remain in their modern descendants, such 
as plants, fish, reptiles, and insects. These mechanisms include the use of antimicrobial 
peptides (defensins), phagocytosis, and activation of the complement system. With the 
evolution of vertebrates, more sophisticated mechanisms have developed. The immune 
systems of vertebrates such as humans consist of many types of proteins, cells, organs, 
and tissues, which interact in an elaborate and dynamic network. Over time, this more 
complex immune response has also allowed the vertebrate system to recognize and adapt 
to particular pathogens more efficiently. The ease by which pathogens can adapt and 
evolve new means to infect the host organism has made the recognition event crucial and 
complicated. On the other hand, the immunological memories created by the process of 
adaptation have allowed more effective protection in future encounters with the pathogen.  
The immune system is typically divided into two categories that are not mutually 
exclusive: the more primitive innate immune system and acquired or adaptive immune 
system of vertebrates. The innate immunity is an ancient part of host defense mechanisms 
and has evolved over time. It features similar molecular modules as those found in plants, 
suggesting its existence during the period before the plant and animal kingdoms had 
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split.
34
 The innate immune response is always the first line of defense against microbial 
pathogens.
35-37
 It lies behind most inflammatory responses triggered in the first instance 
by macrophages, polymorphonuclear leukocytes (PMN), and mast cells through their 
innate immune receptors. The adaptive immunity, in contrast, is a relative newcomer on 
the evolutionary landscape and is further divided into the humoral line and the cellular 
line. What it adds to the innate immune system is specific recognition of proteins, 
carbohydrates, lipids, nucleic acids, and pathogens using the same activated but not 
antigen-specific cells generated by innate immune recognition. The basic features of the 
innate and adaptive immunity are summarized in Table 1.1.
35
 
Table 1.1. Characteristics of Innate and Adaptive Immunity 
Property Innate Immune System Adaptive Immune System 
Receptors Fixed in genome 
Rearrangement is not 
necessary  
Encoded in gene segments 
Rearrangement necessary 
Distribution Non-clonal 
All cells of a class identical 
Clonal 
All cells of a class distinct 
Recognition Conserved molecular patterns 
(LPS, LTA, mannans, 
glycans) 
Details of molecular structure 
(proteins, peptides, 
glycoconjugate) 
Self-Nonself Discrimination Perfect: selected over 
evolutionary time 
Imperfect: selected in 
individual somatic cells  
Response time Immediate activation of 
effectors 
Delayed activation of effectors 
Response Co-stimulatory molecules 
Cytokine (IL-1!, IL-6) 
Chemokines (IL-8) 
Clonal expansion or anergy 
IL-2 
Effector cytokines: (IL-4, 
IFN") 
 
Overall, the immune system protects organisms from infection with layered 
defenses of increasing specificity. Most simply, physical barriers prevent pathogens such 
as bacteria and viruses from entering the organism. If a pathogen breaches these barriers, 
the innate immune system provides an immediate, but non-specific response. In the event 
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that pathogens successfully evade the innate response, vertebrates put in motion a third 
layer of protection, the adaptive immune system, activated in turn by the innate response. 
As mentioned earlier, the adaptive immune system confronts the pathogen with two lines 
of defense – the humoral line and the cellular line. The humoral line consists of the 
complement cascade, antibodies, and acute-phase proteins (the class of proteins whose 
serum concentrations increase or decrease in response to inflammation). The cellular line 
of defense, on the other hand, consists of mononuclear cells (such as monocytes and 
macrophages) and neutrophils. These cells may recognize bacterial cell wall constituents 
directly or indirectly, after the complement proteins bind to the bacterium and its 
consitutents.
38-40
 After the host fails to control the invasion and proliferation of the 
microorganism, the pathological process of a disease begins. During the initial stages of 
tissue invasion, host factors that contribute to microbial growth – i.e. deficiencies in 
complement, antibody, or other immunological components – will determine whether the 
initial localized infection is allowed to disseminate and produce bacteraemia, fungimia, 
or parasitemia. 
Infection is defined as a pathologic process caused by invasion of normally sterile 
tissue, fluid, or body cavity by pathogenic or potentially pathogenic microorganisms.
41
 If 
not treated efficiently, infection may evolve into bacteraemia or the presence of a high 
volume of bacterial population in the bloodstream. As a result of bacteraemia, a high dose 
of bacterial antigens comes in contact with serum components of the immune system. 
Endotoxin or LPS, mentioned earlier, is the best-characterized bacterial antigen. Whereas 
LPS itself is chemically inert, recognition of LPS by extracellular receptors is the first 
step in the development of endotoxemia. Under normal homeostatic conditions, the 
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immune response to LPS provides protection against bacterial infection and is under 
stringent control of specific inhibitors. During severe infection, however, LPS can set off 
a cascade of exaggerated host responses – i.e the excessive production of intrinsic 
mediators of systemic inflammation – leading to systemic inflammatory response 
syndrome (SIRS). In the context of a bacterial infection, SIRS is also known as sepsis.
41
   
Sepsis is a clinical disorder defined by the presence of both infection and systemic 
inflammation.
41
 The disruption of homeostatic balance as a consequence of sepsis leads 
to massive production of pro-inflammatory mediators and dysregulation of the anti-
inflammatory mechanisms. Sepsis, therefore, can be described as a pro- and anti-
inflammatory disequilibrium syndrome.
42
 The uncontrolled, overwhelming, abrupt 
systemic inflammatory response to sepsis ultimately manifests clinically in the frequently 
fatal syndrome called septic shock. The latter is characterized by endothelial damage, 
coagulopathy, loss of vascular tone, myocardial dysfunction, tissue hypoperfusion, and 
multiple organ failure.
43
 Sepsis and its accompanying multi-organ dysfunction syndrome 
(MODS) remains as a leading cause of mortality in intensive care units.
44,45
 A study by 
Angus et al. linking 1995 state hospital discharge records from the seven large states in 
the United States identified 192,980 cases of severe sepsis out of the 6,621,559 patients 
admitted.
46
 This yields national estimates of 751,000 cases (3.0 cases per 1,000 
population and 2.26 cases per 100 hospital discharges), of whom 383,000 (51.1%) 
received intensive care and 130,000 (17.3%) were ventilated in an intermediate care unit 
or cared for in a coronary care unit.  They also found that incidence increased greater 
than 100-fold with age (0.2/1,000 in children to 26.2/1,000 in those 85 yrs old and older).  
Mortality was 28.6% or 215,000 deaths nationally and also increased with age, from 10% 
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in children to 38.4% in those greater than 85 yrs old.  Women were found to have a lower 
age-specific incidence and mortality, an observation that is easily accounted for by the 
differences in underlying disease and site of infection. The average costs per case were 
$22,100 and it adds to annual total costs of $16.7 billion nationally.  Costs were higher in 
infants, non-survivors, intensive care unit patients, surgical patients, and patients with 
more organ failure. Angus et al. projects that the incidence of sepsis will increase by 
1.5% per annum. Similarly, Martin et al. found that from 1979 to 2000, the incidence of 
sepsis and the number of sepsis-related deaths are increasing, although the overall 
mortality rate among patients with sepsis is declining.47  
In recent years, pathogenesis-oriented supportive therapy has been proven to 
reduce morbidity and mortality of sepsis. These include early and vigorous fluid 
replacement, strict blood glucose control, low-dose corticosteroid reposition, protective 
mechanical ventilation and activated protein-C.48 The need to spread the importance of 
sepsis to the average population, train medical teams and measure the adherence to 
prescribed therapies formed the basis for launching the Surviving Sepsis Campaign. 
Thus, in October 2002, this campaign was launched during the European Society of 
Intensive Care Medicine annual congress.49 The campaign issued a "Barcelona 
Declaration" – a document imploring critical care providers, governments, health 
agencies and lay people to join the fight against sepsis.  The aim of the campaign was to 
reduce the sepsis mortality rate by 25% within 5 years (this deadline has been extended 
from 2007 to 2009). The policy, goals and strategies of this campaign are outlined by 
Silva et al. in an article.49  
Bongat, Aileen, 2008, UMSL, p. 13 
  
 
Despite efforts of the campaign, along with more than two decades of extensive 
research, the heterogeneity of the sepsis syndrome has provided serious limitations to the 
development of an anti-sepsis agent.
50-53
 Recently, a recombinant human activated 
protein C, Drotrecogin-! (Xigris), was launched on the market.
53,54
 Thus, based on a total 
of 1690 randomized patients treated (840 in the placebo group and 850 in the 
Drotrecogin-! activated group), it was found that Drotrecogin-! significantly reduced 
mortality rates in septic patients from 30.8% (placebo group) to 24.7% (Drotrecogin-! 
activated group).
54
 The observed mortality difference between Drotrecogin-! and 
placebo, however, was limited to patients with a high risk of death. In addition, since 
Drotrecogin-! increases the risk of bleeding, it is contraindicated in patients with active 
internal bleeding and recent intracranial surgery.
55
 To this end, there is still a major 
unmet medical need for more effective and safer anti-sepsis agents.   
 
1.3. Molecular Basis for the Pathogenesis of Sepsis: Extra-cellular Signaling 
Pathways for Microbial Antigens 
Before an effective anti-sepsis agent can be designed, every aspect of the 
pathophysiological role of LPS in endotoxemia must first be understood. Information on 
how LPS is processed, recognized, and signaled by the immune system is necessary so 
that the agent will treat the underlying cause and not the symptoms. It is well known that 
the infection of a host by bacteria is a complex process and the outcome is usually the 
elimination of bacteria. Indeed, all species can rely on a myriad of elimination strategies 
to deal with the severity of a particular infection. Accordingly, a host can use a very 
sensitive and aggressive method of elimination, using every counter-measure available. 
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The drawback of this quick and full-blown reaction, however, is the large collateral 
damage of surrounding tissue. As such, a very mild immune response, wherein the host 
only uses a limited repertoire of mechanisms, also exists. Such a response leads to a 
smaller damage of surrounding tissue, but the bacteria is allowed to remain longer in the 
host and impair the host’s health.  The choice of elimination strategy depends on the 
different signaling pathways available to the host and the manner by which the invading 
entity activates it. It is therefore vital to elucidate the signaling pathways by which LPS 
activates the immune system in order to control the latter’s exaggerated response to 
LPS.  
Under physiological conditions, the immune cells are continuously exposed to 
low levels of LPS derived from gastrointestinal bacteria. This LPS is taken up by 
macrophages and may be essential to maintain a basal level of attentiveness of the 
immune system. It was originally believed that LPS activated immune cells through a 
non-specific mechanism that involved intercalation of Lipid A into the mammalian lipid 
bilayer.
56
 In the early 1980s, however, reports emerged suggesting that the biological 
actions of LPS were facilitated many fold by its binding to endogenous proteins. Indeed, 
the response of a host cell to LPS is highly dependent on whether it encounters the latter 
in free or bound form.
57
  
Over the past 20 years, one of the major aims in LPS research has been to 
elucidate the exact sequence of events from when the LPS binds to the cell to when it 
elicits a response from the cell. As mentioned earlier, distinct plasma membrane proteins 
mediate the initial interaction between LPS (Lipid A) and phagocytes (monocytes, 
macrophages, polymorphonuclear leukocytes). Some of these interactions may be solely 
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involved in the removal and eventual degradation of LPS whereas others may play a 
critical role in trans-membrane signaling.  
 
Figure 1.2. Recognition of LPS on the surface of phagocytes. LPS is opsonized by 
lipopolysaccharide-binding protein (LBP), and the LPS-LBP complex is recognized by cluster of 
diffrentiation 14 (CD14). CD14 is incapable of generating a transmembrane signal and 
subsequently, the LPS–LBP–CD14 ternary complex activates toll-like receptor 4 (TLR4). TLR4, in 
turn, signals through the Myeloid differentiation primary response gene (88) (MyD88) and the 
interleukin-1 receptor-associated kinase (IRAK). Myeloid differentiation 2 (MD-2) is a secreted 
protein that binds to the extracellular domain of TLR4 and is an important component of its 
signaling pathway.
36
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For interactions that are limited to facilitating the removal of LPS, the lipoprotein 
scavenger receptor cluster of differentiation 18 (CD18) appears to be the receptor of 
choice. The R-form LPS, lipid A, and partial lipid A structures (e.g. lipid IVa) are the 
preferred ligands of this receptor; S-form LPS appears not to interact with these 
membrane proteins.
58
 The receptors involved in trans-membrane signaling (Figure 1.2) 
and the resulting release of proinflammatory cytokines, on the other hand, will be 
discussed in detail below. 
1.3.a. Lipopolysaccharide Binding Protein (LBP) 
While studying LPS binding to high-density lipoprotein (HDL) in normal and 
acute-phase rabbit serum, Tobias and co-workers observed that LPS was mainly 
complexed to a protein in the acute-phase serum.
59
 Isolation of this protein from the 
rabbit serum led to the discovery of the lipopolysaccharide binding protein (LBP). LBP 
was recovered as a 58- and 60.5-kDa glycoprotein, wherein the difference in molecular 
mass reflect different degrees of glycosylation.
59,60
 It is synthesized primarily by 
hepatocytes and released into the bloodstream after glycosylation.
61
 Other sources of LBP 
include epithelial cells of the skin, the lung, the intestine and human gingival tissues as 
well as the small muscle cells of the lung arteries, heart muscle cells and renal cells.
62,63
  
LBP is a member of the lipid transfer/lipopolysaccharide binding protein 
(LT/LBP) family along with bactericidal/permeability increasing (BPI) protein, 
cholesteryl ester-binding protein (CETP) and phospholipid transfer protein (PLTP).
64
 
More distant homologues of LBP have also been identified in the upper airway epithelia 
(palate, lung, nasal epithelium carcinoma associated proteins or PLUNC) and are 
collectively termed the BPI/PLUNC superfamily.
65
 Similarly with LBP, BPI, and PLTP, 
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PLUNC genes are also located on chromosome 20, suggesting that the latter may also 
participate in host defense.
65
 
Human LBP consists of 452 amino acids and has the typical 25-amino-acid signal 
sequence characteristic of secreted proteins.
61
 Its amino acid sequence revealed a 
sequence homology to BPI, CETP, and PLTP of 45%, 23%, and 25%, respectively and 
suggested a similarity in their tertiary structure. After the three-dimensional structure of 
BPI was determined by X-ray crystallography, it provided a useful framework for 
modeling the three-dimensional structure of the LT/LBP family.
66
 BPI appears as a 
boomerang-shaped molecule and consists of two symmetrical barrel domains connected 
by a proline-rich linker region. Each domain is composed of an anti-parallel !-stranded 
layer twisted around a long "-helix and forms a hydrophobic pocket that can incorporate 
one phosphatidylcholine molecule. From these observations, Beamer et al. proposed a 
simulated three-dimensional model for LBP that is very similar to the structurally and 
functionally related BPI.
67
 Analogously with BPI, the LPS-binding domain of LBP is 
located at the N-terminal region. Indeed, the three-dimensional LBP model showed that 
the cationic cluster of the LPS binding site is fully exposed at the N-terminal tip.
67
  
To verify the veracity of the claim that the LPS-binding site of LBP is at the N-
terminus, Lamping et al. performed mutagenesis experiments.
68
 LBP mutants with amino 
acid exchanges within the N-terminal region were expressed and tested in five different 
functional assays – binding to immobilized LPS, facilitation of binding of LPS 
aggregates to monocytes, transfer of LPS monomers from aggregates to other LPS 
receptors, transfer of LPS monomers to high density lipoprotein (HDL), and 
enhancement of LPS-induced cell activation. The double mutant glutamic acid 94/95 was 
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completely lacking LPS binding, transfer, and cell stimulatory activity, indicating that the 
integrity of amino acids 94 and 95 is required for LBP function.
68
 While mutations of 
amino acids Arginine 94 or Lysine 95 into alanine reduced the LPS binding activity of 
LBP dramatically, the ability to facilitate binding of LPS aggregates to membrane-bound 
cluster of differentiation 14 (mCD14) at the cell surface was retained. These findings 
emphasize the distinction between binding of LPS aggregates to cells and binding of LPS 
monomers to CD14 – the former is not associated with cell stimulation and the latter 
leads to cell stimulation. The role of CD14 in LPS recognition will be discussed in detail 
later.  
Consequently, structure/function studies were aimed at identifying the functional 
domains and elucidating the mechanism of action of LBP, BPI and CETP.
67-69
 On the one 
hand, several studies showed that a peptide fragment at the N-terminal region (tethered 
by a disulfide bond) has endotoxin-neutralizing activity and forms a hairpin.
70-72
 One the 
other hand, Taylor and co-workers identified overlapping 15-mer peptides corresponding 
to residues 91-108 of human LBP that specifically bound the lipid A moiety of LPS with 
high affinity.
70
 Along with inhibiting the binding of LPS to LBP, these peptides also 
inhibited chromogenic Limulus amebocyte lysate reaction and blocked release of tumor 
necrosis factor alpha (TNF!) following LPS challenge in vitro and in vivo. It is strongly 
believed then that residues 91-108 of LBP form part of the LPS binding site. In contrast, 
Bosshart et al. showed arginine-rich polypeptides can stimulate monocyte activation and 
act synergistically with LPS; this indirectly supports the role of cationic residues of LBP 
in destabilizing the LPS aggregates.
73
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Studies show that LBP has a dual role in interactions with LPS. At low LPS 
concentrations, LBP enhances LPS signaling by extracting it from the bacterial 
membranes (LPS monomerization) and transferring the LPS monomers to CD14 at a rate 
of 150 molecules/minute.
74,75
 At high concentrations, it inhibits the LPS signaling by 
shuttling the LPS to the serum lipoproteins and by forming aggregates with LPS.
76,77
 
Indeed, the increased secretion of LBP as a result of LPS stimulation serves as an 
inhibitor of excessive response to LPS in the serum of septic patients.  
The two domains of LBP have different functions. Similarly for LBP and its 
homologue BPI, the amino-terminal domain has a high affinity for LPS.
78
 LBP binds to 
smooth and rough LPS, Lipid A, and Lipid IVA. With a stoichiometry of 1:1 and Kd’s 
varying from 1 to 58 nM, LBP has a high binding affinity for Lipid A. 
79,80
 Since Lipid A 
is the endotoxically active part of LPS, it is possible then that the N-terminal residues of 
LBP, between 91 and 108, are binding Lipid A. The C-terminal domain, on the other 
hand, is required for the interaction with CD14 or the cell membrane.
81
 LBP intercalates 
into the cellular membranes suggesting that the C-terminal domain may be important for 
cell activation.
77
  
Adding LBP to serum-free cell system enhances the LPS-mediated stimulation of 
CD14-positive cells by 100- to 1000-fold.
61,82
 In addition, LBP also transfers LPS to 
soluble CD14 (sCD14) resulting in the activation of mCD14-negative cells (endothelial 
and epithelial cells). Thus, the ability of LBP to transfer disaggregated LPS to both 
mCD14 and sCD14 supports the view that LBP has a central role in mediating LPS 
responses. It was proposed that a single LBP molecule is able to transport hundreds of 
LPS molecules to sCD14 and that LBP is not consumed by this reaction.
83
 Consequently, 
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Yu and Wright demonstrated first order kinetics for this enzymatic transfer and were 
further able to define catalytic constants for this reaction.
75,83
 To explain the catalytic 
reaction mechanism for the transfer of LPS to sCD14, two models were proposed. The 
“binary complex” model details that the initial step in the transfer involves a bimolar 
reaction between LBP and an LPS micelle. Following dissociation from the micelle with 
one molecule of LPS bound, LBP then binds to sCD14.
83
 The “ternary complex” model, 
on the other hand, suggests a simultaneous interaction amongst LBP, LPS micelles, and 
sCD14.
84
 
Finally, it must be noted that LBP binding to LPS is not restricted to the 
molecular level; LBP also binds viable bacteria. Thus, LBP-binding to Salmonella spp. 
and Klebsiella pneumoniae results in phagocytosis and clearance of these 
microorganisms.
85,86
 In a respiratory tract infection model, it has been demonstrated that 
the binding of LBP to one colony of non-typeable Haemophilus influenzae already 
induced strong signaling in cells.
87
 
1.3.b. Cluster of Differentiation 14 (CD14) 
While it was clear that the CD18 complex interacts with LPS by bridging bacteria 
to the surface of phagocytes,
58
 it was not clear whether this interaction triggers cellular 
responses. Studies show that the CD18 complex recognizes the presence of E. coli by 
binding LPS embedded in the outer membrane of E. coli.
40
 Macrophages also bind to 
LPS (purified) inserted into the membranes of erythrocytes (ELPS), and down-
modulation of the CD18 complex with anti-CD18 antibodies eliminates the capacity of 
macrophages to bind both E. coli and ELPS. Accordingly, cells from patients genetically 
deficient in the CD18 complex fail to bind either E. coli or ELPS.
88
 Thus, to elucidate the 
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exact role of CD18 in cellular activation by LPS, Wright et al. performed experiments on 
mononuclear cells from CD18-deficient patients.
86,89
 They observed, however, that these 
cells can still bind LPS and that the binding event resulted in cellular activation.  Clearly, 
additional receptors must be present on the surface of macrophages and 
polymorphonuclear leukocytes (PMN).  
In a series of experiments, Wright and co-workers identified this unknown 
receptor to be CD14 – a differentiation antigen of monocytes.
90
 Based on their report, 
CD14 binds complexes of LPS and LBP and the blockade of CD14 with anti-CD14 
antibodies prevents further binding of LPS-coated erythrocytes to macrophages. With the 
absence of a binding event, macrophages are unable to produce an LPS-induced 
inflammatory response. Golenbock et al. corroborated these findings by demonstrating 
that LPS-induced responsiveness can be transferred to a heterologous non-responder cell-
type by expression of a single leukocyte-specific gene product.
91
 Thus, transfection of 
human CD14 into Chinese hamster ovary (CHO) fibroblasts and treatment of CD14-
bearing CHO cells with LPS led to a macrophage-like responsiveness in otherwise LPS-
unresponsive cells. Similarly, Lee and co-workers showed that CD14-bearing 70Z/3 cells 
bind LPS and when LPS is complexed with LBP, the binding activity is even higher.
92
 
Consequently, Kirkland et al. determined the binding affinity of the LPS-LBP complex to 
CD14-transfected CHO cells and THP-1 cells and found Kd values of 2.7 x 10
-8
 to 4.8 x 
10
-8
 M.
93
  
CD14, a serum/cell-surface glycoprotein and the first described pattern 
recognition receptor, is usually found in two forms: membrane bound (mCD14) and 
soluble (sCD14).
90,94,95
 Since sCD14 lacks the glycosyl phosphatidylinositol (GPI) 
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anchor, mCD14 and sCD14 have molecular masses of 53 and 48 kDa, respectively.
96,97
 
To determine the amino acid composition of CD14, Ferrero and Goyert cloned the CD14 
gene and revealed a transcript encoding a 356-amino acid protein.
98
 It was also found to 
have a high leucine content (15.5%) and four putative N-glycosylation sites.
98,99
 The site 
involved with LPS-binding, as well as the sites involved in the interaction of human 
CD14 with supposed accessory receptors, have been identified in the N-terminal part of 
CD14.
100,101
 This was determined by generating and transfecting 23 mutants in the N-
terminal 152 amino acids of human CD14.
102
 In each mutant, a block of 5 amino acids 
was substituted with Ala. Thus, Stelter et al. found that the region between amino acids 
39 and 44 forms an essential part of the LPS-binding site of human CD14.
102
 Moreover 
for human sCD14, two other regions were found to be essential for eliciting LPS-induced 
responses from endothelial and smooth muscle cells: aa 9 to 13 and aa 91 to 101.
103,104
  
CD14 is expressed by various cells i.e. cells of the myeloid lineage (monocytes, 
macrophages, PMN), B cells, liver parenchymal cells, gingival fibroblasts, and microglial 
cells.
105-110
 Each source expresses CD14 differentially: peritoneal and pleural 
macrophages exhibit a high level of constitutive CD14 expression while (murine) 
Kupffer cells, alveolar macrophages, monocytes, and PMN have a low level of 
constitutive CD14 expression.
105,111-113
 In addition, LPS and TNF-! induce the release of 
sCD14 by mononuclear cells and PMN in a dose-dependent manner, whereas interferon-" 
(IFN-") and interleukin 4 (IL-4) inhibit the release of sCD14.114,115 In the steady state, 
human serum contains 2 to 6 µg/mL of sCD14.116 This level increases in response to the 
presence of LPS and consequently, Landmann et al. suggested the use of sCD14 levels as 
a diagnostic marker in patients with severe infections.
117
 The level of sCD14 in human 
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milk also explains why newborn infants are innately immune to bacteria with their 
hitherto sterile intestines. Thus, Labeta and co-workers found that the concentration of 
sCD14 is 10-fold higher in human milk than that in serum.
118
  
Binding of LPS to a cell does not result in immediate response – a time lapse of 
15 to 30 minutes is usually observed between LPS binding and LPS-induced cellular 
responses. Detmers et al. along with Lichtman et al. suggested that monomeric LPS is 
internalized in vesicles, and uptake may be required for signaling.
119,120
 Indeed, several 
studies have revealed that blocking the internalization or endosome fusion also blocks 
LPS-induced signaling.
119-122
 Although the precise mechanisms of this blocking event are 
not completely understood, it has been shown that monomeric LPS is transported into the 
cell to the Golgi complex and activates the cell from thereon.
123
 To determine if mCD14 
directs the movement of LPS to the Golgi apparatus, Vasselon et al. used an mCD14 
chimera containing enhanced green fluorescent protein (mCD14-EGFP) to follow 
trafficking of mCD14 in stable transfectants.
124
 Thus, it was found that monomeric LPS 
is transferred out of mCD14 at the plasma membrane and traffics within the cell 
independently of mCD14 involvement. In contrast, particulate (bacterium) and 
aggregated (micelles) LPS were internalized to the lysosomes via a CD14-dependent 
pathway called macropinocytosis – a process resembling that of phagocytosis.
122
 After 
internalization, LPS induces mononuclear phagocytes (MPs) to produce three groups of 
powerful mediators; the reactive oxygen intermediates (O2, H2O2, ·OH, and singlet 
oxygen), the pro-inflammatory cytokines, and a number of arachidonic acid metabolites, 
including prostaglandins and leukotrienes.  
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Since CD14 is a glycophosphatidylinositol-linked receptor that lacks a trans-
membrane domain, it was anticipated that it requires an accessory molecule for signal 
transduction.
125
 This hypothesis was confirmed using different anti-CD14 antibodies that 
either blocked LPS binding to CD14, or did not block LPS binding while preventing 
LPS-induced cell activation.
84,126
 
126
 This accessory receptor has been identified as a 
member of the TLR family.  
1.3.c. Toll-like Receptor 4 (TLR4) 
 Approximately 8 years after the importance of LBP and CD14 was initially 
delineated in seminal discoveries, the next main advance in understanding the 
mechanisms of innate immunity emerged – the identification of the putative 
transmembrane protein that acted with CD14 to generate a transmembrane signal for 
LPS-induced cell activation. Two highly original and influential discoveries gave the 
impetus for this advance. First, it was found that Toll-like receptors (TLRs) play an 
important role in the innate immune response of Drosophila flies.
127,128
 Second, a TLR 
homolog was identified as the gene responsible for LPS responses in two natural mouse 
mutants.
129-131
 These results formed the basis for understanding how the innate immune 
system regulate responses to infection and how plasma membrane receptors control 
adaptive immune responses.
36
 
 It was well known that despite the lack of an adaptive immune system, Drosophila 
flies are very resistant to microbial infections. The only rationale for this attribute, at the 
time, had been its demonstrated ability to synthesize potent antimicrobial peptides. Then, 
in the early 1980s, Anderson et al. conducted a mutagenesis screen for genes involved in 
dorso-ventral patterning of the Drosophila embryo.
132
 Their studies revealed a mutant 
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gene that had an unusual appearance. Consequently, the authors named this gene “Toll”, 
meaning weird. The Toll gene, which encodes a single-pass transmembrane receptor, 
became highly important after it was found that it activates the signaling pathways that 
induce the synthesis of drosomycin, an anti-fungal peptide in Drosophila flies.
127,132
  
Twelve years after Anderson’s discovery, Williams et al. showed that 18-wheeler 
– another TLR gene found in Drosophila – could induce the release of attacin.
128
 Attacin 
is one of the potent antibacterial peptides synthesized by Drosophila. As a result, it was 
established that the activation of a proteolytic cascade that produces peptidic ligands for 
the TLRs leads to the induction of these antimicrobial responses. Whether or not this 
mechanism is unique to Drosophila or has been conserved in mammalian cells remains 
unanswered. What was remarkably inferred from these results, however, was that 
Drosophila TLRs were capable of discriminating between fungi and bacteria and 
consequently, of inducing an appropriate and distinct antimicrobial response. 
Subsequently, Imler and colleagues showed that the activation of TLR-induced pathways 
in Drosophila initiates an intracellular kinase cascade that ultimately produces a 
translocation of transcription factors, Dif and Relish, from cytoplasm to nucleus.
133
 Dif 
and Relish are homologous to nuclear factor-kappa B (NF-kB), a transcription factor 
known to activate inflammatory mediators in humans, thereby linking Drosophila TLRs 
to the study of LPS biology.
132
  
The apparent importance of TLRs as well as the observation that the Toll gene 
shares a certain homology with the human IL-1 receptor provided impetus for the field of 
Toll biology to move beyond flies.
134
 Thus, in the mid-1990s, Janeway and colleagues 
began a search for dToll-related proteins in mammalian gene sequences. As a result of 
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their efforts, the first human homolog of Drosophila Toll, initially termed human Toll and 
subsequently termed TLR4, was identified.
135
 Human TLR is an 841-amino acid protein 
with a molecular mass of 92kDa.
135
 After cloning and characterization, human Toll was 
found to be a type I transmembrane protein, the cytoplasmic domain of which bears a 
structural homology to human interleukin (IL)-1 receptor. Janeway and colleagues also 
determined that similarly with Drosophila Toll, human Toll could induce activation of 
NF-!B and subsequently, induce the expression of NF!B-controlled genes for the 
inflammatory cytokines. Finally, their observation that TLR4 could induce members of 
the B7 family – molecules that are required for the activation of naive T cells by antigen-
presenting cells – provided a potentially important link between pathogen detection and 
induction of the adaptive immune response.  
Other compelling evidence on the importance of TLRs in LPS-induced responses 
came when TLRs addressed the issue of why some strains of mice were unresponsive to 
LPS. For years, LPS has been known to be a very active mediator of inflammation in 
most mammalian system.
136
 It was found, however, that LPS is relatively ineffective at 
inducing responses in the C3H/HeJ or C57BL/10ScCr strains of mice.
137
 Then in 1998, 
Poltorak et al. showed via positional cloning techniques that mutations of a gene termed 
the “LPS gene” selectively reduced the ability of C3H/HeJ and C57BL/10ScCr mice to 
sense LPS. The co-dominant Lps
d
 allele of the C3H/HeJ strain was a result of a mis-sense 
mutation in the third exon of TLR4, a mutation that was predicted to result in a 
Pro712!His substitution.
129,130
 When this mutation was introduced into wild-type TLR4, 
the receptor was converted into a dominant-negative mutant that inhibited LPS-dependent 
responses in a transfected macrophage cell line.
138
 Similarly, Hoshino et al. demonstrated 
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that C3H/HeJ mice have a single point mutation of the amino acid that is conserved 
among the Il-1/Toll receptor family.
131
 Using genetically modified mice in which the 
TLR4 gene was deleted, the latter showed that TLR4 was essential for sensing LPS and 
that mutations in this gene explained the lack of responsiveness in C3H/HeJ mice. 
Together, these seminal publications provided the first direct connection between TLRs 
and the physiological responses to LPS. Heine and co-workers provided further proof of 
this connection by showing that Chinese hamsters respond normally to LPS even though 
they carry a null allele for TLR2.
139
 Their results implied that expression of TLR2 is 
sufficient but not essential for mammalian responses to endotoxin.  Finally, it was shown 
that a dominant-negative mutant of TLR2 did not effect LPS responsiveness in 
transfected macrophages.
138
  
 By 1998, five human TLR homologues had been identified.
140
 Presently, at least 
ten TLRs have been found in humans and thirteen in mice.
141
 Humans and mice share 
TLRs 1-9 but TLR 10 is only found in humans and TLR11 is functional only in mice.
142
 
Subsequent studies provided a detailed analysis of the structural features that link these 
proteins to Drosophila Toll and to the IL-1 receptor family.
140
 Thus, Rock et al. 
highlighted the general structural features of the TLR family – an ectodomain 
characterized by multiple leucine-rich repeats and a Toll-homology domain found in the 
cytoplasmic tail.
140
  
1.3.d. Myeloid Differentiation Antigen 2 (MD-2) 
Despite the fact that several groups have already shown evidence of LPS-induced 
signal transduction through Toll-like receptors, direct binding of LPS to the latter is yet to 
be demonstrated.
143,144
 Moreover, it was found that in vitro transfection of TLR4 cDNA 
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did not confer LPS responsiveness on two LPS-unresponsive cell lines: human 
embryonic kidney-derived and a mouse IL-3-dependent pro-B cell line Ba/F3.
145,146
 Then 
in 1999, Shimazu and co-workers reported and characterized a novel LPS binding protein 
called myeloid differentiation antigen-2 (MD-2).
146
 In a series of experiments, they 
showed that MD-2 is physically associated with TLR4 on the cell surface and confers 
responsiveness to LPS. In a similar fashion, da Silva Correia determined that LPS binds 
directly to each of the members of a tripartite LPS receptor complex.
144
 Using modified 
and radioiodinated LPS, they showed that LPS is cross-linked specifically to TLR4 and 
MD-2 when co-expressed with CD14. Thus, maximal cellular activation by LPS must be 
a cascade of events that likely involves transferring of LPS by LBP to CD14 and then to 
TLR4-MD-2. Moreover, although CD14 and LBP enhance cellular activation, activation 
of TLR4 by LPS was found to absolutely require MD-2.
147
  
MD-2 is 20-25-kDa extracellular glycoprotein that belongs to the MD-2-related 
lipid recognition family of lipid-binding receptors.
148
 Since MD-2 lacks a transmembrane 
domain that would anchor it to the cell membrane, several groups performed studies to 
verify the nature by which MD-2 associates with TLR4 – is it an intracellular soluble 
protein that binds to TLRs in the endoplasmic reticulum (ER) or is it first secreted into 
the medium and then binds to TLRs on the cell surface? To this end, Visintin et al. found 
that in some cells, MD-2 is synthesized in large excess to TLR4 and it saturates all 
available TLR4 molecules in the ER. The excess MD-2 is then secreted into the 
medium.
149
 Although proper glycosylation and trafficking of TLR4 to the cell surface 
requires intracellular association with MD-2,
150,151
 functional TLR4 can be presented on 
the cell surface without MD-2 in both transfected
152
 and human airway epithelial
153
 cells. 
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For reporter cells that expressed TLR4, but not MD-2, secreted MD-2 (sMD2) was found 
to restore LPS responsiveness.
149
 Thus, even at concentrations as low as 50 pM, Visintin 
et al. showed that MD-2 significantly enhances LPS reactivity and suggested that TLR4 
has a functional affinity constant for MD-2 in the range of 50–500 pM.
149
  
Human MD-2 contains 160 amino acid residues, prominent regions of which are 
the 17-amino-acid sequence at the N-terminus, 7 cysteine residues, and 2 N-glycosylation 
sites.
154
 To identify the regions of functional importance on human and mouse MD-2, 
common analytical methods – i.e. analysis of peptide fragments,
155
 mutation analysis,
156-
161
 and computational modeling
162
 – have been utilized. Computer modeling suggests that 
MD-2 is capable of forming a barrel-like structure with a hydrophobic cavity sufficient to 
accommodate the fatty acid moieties of lipid A.
162,163
 In addition, Visintin et al. reported 
that a positively charged region flanking the hypothetical hydrophobic cavity of MD-2 is 
required for stable binding to LPS.
164
 On the other hand, site-directed mutagenesis 
identified the regions of human MD-2 that are involved in TLR binding and 
consequently, in conferring LPS responsiveness.
159
 Thus, Re et al. found that MD-2 
binding to TLR4 took place via Cys95 and Cys105, probably through the formation of an 
inter-molecular disulfide bond.
159
 Several studies predict that Cys95 is located on the 
surface of the hypothetical barrel, along with the other Cys residues except for 
Cys133.
149,165,166
 This prediction is consistent with the idea that MD-2 is capable of 
forming covalently bound oligomers, but it does not preclude the existence of a 
monomeric form. Indeed, monomeric MD-2 has been reported to preferentially bind to a 
recombinant soluble TLR4 ectodomain.
167
 Hydrophilic and charged residues surrounding 
this area, such as R90, K91, D100, and Y102, also contributed to the formation of the 
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TLR4-MD-2 complex.
159
 Re et al. found, however, that a different region of MD-2 was 
responsible for conferring LPS responsiveness.
159
 This region is not involved in TLR4 
binding and is rich in basic and aromatic residues, several of which contribute to LPS 
responsiveness and might represent a LPS binding site. Consequently, mutations in the 
lysine residues of this region are correlated with the loss of LPS binding and as a result, 
the loss of activity.  
 Finally, it was found that binding of MD-2 by lipid A was greatly enhanced by 
serum components that have long been known to enhance LPS responses, i.e. sCD14 and 
LPS-binding protein (LBP).
152,165,168
 MD-2 is unstable at 37°C, but the binding of LPS to 
MD-2 has been reported to dramatically stabilize its activity.
169
 Overall, the evidence 
supports a model in which LPS interacts with the MD-2/TLR4 surface heterodimer. The 
interaction of LPS with the receptor complex occurs with high affinity, the Kd is 
estimated to be 3–10 nM.
170,171
 The binding of LPS to MD-2 is then responsible for the 
aggregation of TLR4 and the recruitment of intracellular signal transducers. 
1.4. Host-derived Mediators and the Pathogenesis of Sepsis 
 Once TLR4 binds to its LPS ligand, two possible pathways of cellular activation 
can occur – either through the myeloid differentiation factor 88 (MyD88) or through the 
TLR-domain-containing adapter-inducing interferon-! (TRIF) pathway.
172,173
 In each 
pathway, signaling events lead to the sequential activation of specific tyrosine and 
threonine/serine kinases. This signaling cascade ultimately results in phosphorylation, 
ubiquitination, and degradation of inhibitory kappa-B (I"B) and other transcriptional 
activators. I"B degradation leads to translocation of nuclear factor-kappa B (NF-"B) into 
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the nucleus. Once NF-!B is translocated into the nucleus, it binds to specific DNA 
sequences located in the promoter regions and participates in the activation of a large 
variety of genes including cytokines, chemokines, stress response proteins, and anti-
microbial and anti-apoptotic peptides.
174
 As a result, the outpouring of inflammatory 
cytokines and other inflammatory mediators after LPS exposure contributes to 
generalized inflammation, procoagulant activity, tissue injury, and septic shock.
175-177
  
In macrophages, lipid A activation of TLR4 triggers the biosynthesis of diverse 
mediators of inflammation and activates the production of costimulatory molecules 
required for the adaptive immune response.
178
 Once activated, macrophages are the 
fundamental secretory cells of the immune system.
179
 To date, more than one hundred 
macrophage products have been identified – with molecular weights ranging from 32 Da 
(superoxide anion) to 440,000 Da (fibronectin).
180
 Amongst these, inflammatory 
cytokines such as TNF-", IL-1#, and IL-6 are the most studied.  
1.4.a. The Cytokine Networks 
As mentioned above, monocytes/macrophages, neutrophils, and other 
inflammatory cells respond to LPS by secreting an array of microbial effectors and 
immunoregulatory mediators. The resulting autocrine (secretion of a substance that 
stimulates the secretory cell itself) and paracrine (secretion of cells into adjacent cells or 
surrounding tissue) activation results in synergistic potentiation of the inflammatory 
response and is critical in controlling the growth of pathogenic microorganisms. 
However, excessive production of these mediators is harmful to the host and can even be 
fatal, i.e. it can lead to the deleterious condition known as sepsis, or the dysregulation of 
regular hemodynamic and metabolic balances.
181
 Amongst the well-known macrophage 
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mediators are the pro-inflammatory cytokines, chemokines, prostanoids, and reactive 
oxygen and nitrogen species.  
Table 1.2. Pro- and anti-inflammatory mediators in sepsis.
182
 
Pro-inflammatory Mediators Tumor necrosis factor-!, lymphotoxin-a 
Interferon gamma 
Interleukins-1, -2, -8, -12, -18 
Soluble CD14, MD2 
Complement components, mannose-binding lectin 
Platelet-activating factor, leukotriene B4 
Bradykinin 
Nitric oxide, other reactive nitrogen intermediates 
Reactive oxygen species 
Granulocyte macrophage colony-stimulating factor 
Macrophage inhibitor factor 
High mobility group box I 
Histamine, thrombin, factor X, tissue factor: factor VII 
Triggering receptor expressed on myeloid cells (TREM-1) 
Necrotic cells 
Anti-inflammatory Mediators Interleukin-1 receptor antagonist 
Soluble tumor necrosis factor or interleukin-1 
Type II interleukin-1 receptor 
Transforming growth factor-b 
Interleukins-4, -6, -10, -11, -13 
Prostaglandin E2a 
Granulocyte colony stimulating factor 
Endogenous antioxidants, glutathione, selenium, vitamin E 
Anticoagulants (antithrombin, activate protein C, tissue 
       factor pathway inhibitor, soluble thrombomodulin) 
Interferon alpha, interferon beta 
Glucocorticoids 
Epinephrine, other catecholamines 
Cholinergic agonists 
Apoptotic cells 
 
Indeed, the multitude of pro-inflammatory molecules present in the blood of 
septic patients is matched by an equally astounding array of anti-inflammatory mediators 
(Table 1.2). The network of cytokines and inflammatory molecules transmit signals 
between neutrophils, monocytes, macrophages, and endothelial cells. Much of the 
inflammatory response is localized and compartmentalized in the primary region of initial 
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inflammation (e.g. lung, kidney, or the gastrointestinal tract). Once the inflammatory 
process is released into the systemic circulation, its sustained production ensues a 
generalized reaction that culminates in diffuse endothelial injury, coagulation activation, 
and septic shock.  
During the first 12 to 24 hours of sepsis, the pro-inflammatory mediators 
predominate locally. Thus, monocyte/macrophage-derived cytokines upregulate the 
expression of endothelial adhesion molecules such as ICAM-1, ICAM-2, and the P- and 
E-selectins.
183
 These surface proteins, in turn, mediate neutrophil attachment, 
recruitment, and persistence at inflammatory sites.  On the other hand, the anti-
inflammatory mediators prevail in the later phases of sepsis.
184,185
 Consequently, the loss 
of regulation by lymphocyte-derived cytokines and INFs ultimately determines the fate of 
patients with prolonged illness and septic shock.
186
  
The cytokine TNF!,  an endogenous monocyte/macrophage-derived protein, is 
one of the most important soluble mediators of inflammation. It is mainly synthesized by 
activated monocytes/macrophages and is responsible for a wide range of signaling events 
within cells. In response to an LPS challenge, TNF! is synthesized very quickly and the 
production peaks in a matter of 1.5 h.
187
 Secretion of this molecule triggers a 
proinflammatory response in neutrophils and endothelial cells and leads to cell 
damage.
188-190
 TNF! exerts most of its effects by binding, as a trimer, to either a 55kDa 
cell membrane receptor called TNFR-1 or to the 75 kDa cell membrane receptor TNFR-
2; both are members of the TNF receptor superfamily.
191
 In animal studies, the 
administration of tumor necrosis factor-! (TNF!), has been shown to have lethal 
consequences.
192
 In human volunteers, dramatic hemodynamic, metabolic, and 
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hematologic changes are observed after administration of TNF!.193 Perhaps the most 
dramatic demonstration of the pathophysiologic significance of systemic cytokine release 
was observed recently in a phase I study of an experimental anti-CD 28 monoclonal 
antibody.
175
 The antibody was well tolerated in animal studies but was found to be 
markedly toxic to humans. Within a few hours of receiving the antibody, all six healthy 
human volunteers developed shock, disseminated intravascular coagulation (DIC), and 
multiorgan failure. The “cytokine storm” that often accompanies septic shock was clearly 
demonstrated by the striking elevations in IL-1, TNF, IL-8, IFN-g and other cytokines 
and chemokines that were released almost immediately into the patient’s bloodstream.  
Another important cytokine in host defense during sepsis is the interleukin-1 (IL-
1) gene family.
194
 This family consists of three members: IL-1!, IL-1" (both agonists 
with proinflammatory character) and the IL-1 receptor antagonist (IL-1ra, anti-
inflammatory counterpart). While IL-1" is solely active in its processed and secreted 
form, IL-1! is active either in its intracellular precursor, membrane-associated, or 
secreted form.
195-198
 The activation of numerous cell types by IL-1! and IL-1" leads to 
diverse proinflammatory events.
199
 
 The relative contribution of IL-1 to the inflammatory cascade in sepsis, however, 
is still unclear. Although the plasma levels of IL-1" are enhanced in patients suffering 
from septic shock,
200
 systemic administration of LPS in IL-1"-deficient mice does not 
lead to changes in IL-1!, IL-6 and TNF!. Thus, on the basis of the response of LPS-
treated mice with normal genetic background, IL-1" is not essential for systemic 
response to LPS.
201
 Further examples for equivocal response within the IL-1 family are 
shown in IL-1ra deficient mice, which are highly susceptible to endotoxin-induced 
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death.
202
 However, the treatment of sepsis syndrome mice with recombinant human IL-
1ra did not lead to a statistically significant increase in survival time.
203
 
Both IL-1 and TNF! act synergistically in the initiation of the inflammatory 
cascade in sepsis, leading to the expression of further factors.
204
 These factors include 
other proinflammatory cytokines (IL-12, IL-18),
131,205
 and chemokines (IL-8, monocyte 
chemoattractant protein-1/MCP-1).
206,207
 The chemokines IL-8 and MCP-1 are key 
factors in chemotaxis – IL-8 is involved in neutrophil chemotaxis while MCP-1 is 
involved in the chemotaxis of monocytes. IL-8 also causes neutrophils to degranulate and 
cause tissue damage.
208
 In addition, inflammatory cytokines upregulate the expression of 
endothelial adhesion molecules such as intercellular adhesion molecule-1 and -2 (ICAM-
1, ICAM-2) as well as the P- and E-selectins.
209-212
 These surface proteins, along with the 
large variety of genes described herein as a consequence of a dysregulated inflammatory 
response, regulates the sequence of events that define sepsis.  
1.4.b. The Coagulation Cascade 
Activation of the coagulation cascade has traditionally been synonymous with the 
need for hemostasis (stoppage of bleeding) at sites of injury. Over the past several 
decades, however, it has been increasingly recognized that initiation of coagulation is an 
integral and consistent element of the local and systemic response to inflammatory 
stimuli. The precise mechanism whereby coagulation contributes to the full expression of 
inflammation is an area of active study.  
Tissue factor (TF) expression on the surface of endothelial cells and monocytes – 
induced by the presence of endotoxins or inflammatory cytokines – initiates the 
coagulation process.
213,214
 Thus, as demonstrated below (see Figure 1.4), TF on the cell 
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surface activates factor VII, and the resulting complex of factor VIIa and TF converts 
factor X to factor Xa. In concert with factor Va, factor Xa converts prothrombin to 
thrombin, which in turn results in the cleavage of fibrinogen to fibrin. Fibrin deposition 
plays a critical role in hemostasis and in the localization of microorganisms within an 
abscess cavity. This process, however, can impede oxygen delivery to tissues and can 
induce further inflammatory injury indirectly through the response to hypoxia (lack of 
oxygen) and directly through signals delivered to the thrombin receptor. Engagement of 
the thrombin receptor activates the nuclear transcription factor NF-!B,
215
 causing the 
transcription of a broad array of proinflammatory gene products and resulting in nitric 
oxide
216
 release. The thrombin receptor is not a unique mechanism through which an 
inflammatory response is amplified. Clustering of tissue factor has also been shown to 
initiate gene expression for proinflammatory cytokines, including TNF.
217
  
 
Figure 1.3. The impact of sepsis on the physiological network regulating thrombosis. 
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Two lines of evidence suggest that expression of TF is centrally important to 
initiation of the coagulation cascade during sepsis. First, TF expression is tightly 
regulated and is absent from the bloodstream during non-inflammatory conditions. TF is 
constitutively expressed by cells outside the bloodstream and therefore, it acts as an 
“extravascular envelope,” triggering coagulation whenever the vascular endothelial 
integrity is breached.
218
 Within the bloodstream only monocytes and the endothelium can 
be induced to express TF and have been demonstrated to do so both in vitro and in vivo in 
response to E. coli, LPS, and various cytokine mediators of the host response to 
infection.
219-221
 Second, various strategies directed toward the neutralization of TF or the 
TF–VIIa complex have demonstrated efficacy in preventing organ damage associated 
with endotoxemia or bacteremia in experimental models, including the use of anti-TF 
antibody,
222,223
 anti-factor VIIa,
224
 and administration of tissue factor pathway inhibitor 
(TFPI).
225,226
 In addition, a multitude of cytokines and inflammatory mediators known to 
play a role in local and systemic inflammatory responses — including TNF!, IL-1, IL-2, 
C5a, IL-6, platelet-activating factor (PAF) — have been demonstrated in vitro to either 
up-regulate or prime for TF expression. Moreover, these responses have been 
demonstrated to activate the coagulation cascade and contribute to septic mortality in 
primate models.
227-229
  
In general, the activation of the coagulation pathway induces anticoagulant 
mechanisms that function to limit progression of the coagulation cascade. Indeed, there 
are three major pathways by which inhibition of coagulation can occur. In the first 
pathway, antithrombin III (ATIII) – a member of the serine protease inhibitor (serpin) 
family – covalently binds to and inactivates all of the serine protease coagulation factors, 
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including TF–VIIa.
230
 Through binding to endothelial cells, ATIII–coagulation factor 
complexes will also initiate the release of prostacyclin, an inhibitor of platelet 
aggregation.
231
 The second pathway involves the synthesis of tissue factor pathway 
inhibitor (TFPI) by endothelial cells. The complex formed between TFPI and factors such 
as TF or blood protease factors leads to inhibition of thrombin generation and fibrin 
formation.
232
 Finally, the third pathway – the protein C pathway – is activated through the 
binding of thrombin to thrombomodulin on the endothelial surface. Protein C is a 
component of the protein C/protein S/C4bBP inhibitory axis. The endothelial surface 
protein thrombomodulin binds Xa, changing its specificity and leading to the activation 
of protein C.
233
 The effect of activated protein C (APC) is amplified by complexing with 
protein S. The APC–protein S complex efficiently degrades factors Va and VIIIa, thereby 
inhibiting coagulation; APC alone also promotes fibrinolysis.
234
  
During sepsis, however, an imbalance of the procoagulant and anticoagulant 
systems occur, resulting in a sustained hypercoagulable state. The specific abnormalities 
of the coagulation system that occur following endotoxemia and cytokinemia have been 
documented in detailed studies involving human volunteers and septic patients. Thus, in 
human volunteers injected with small doses of TNF! or lipopolysaccharide (LPS), there 
is gradual activation of coagulation as evidenced by increases in thrombin–antithrombin 
(TAT) complexes, prothrombin activation fragments, and fibrinopeptide A.
235-238
 This 
process begins by the 2
nd
 hour, peaks at 4 to 5 hours, and persists for 6 to 12 hours. There 
is also an early increase in plasma fibrinolytic activity (1–2 hours) due to the presence of 
plasminogen activators, which leads to plasmin generation. The anticoagulant effect of 
the latter, however, is rapidly neutralized by an increase in the amount of antifibrinolytic 
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plasminogen activator inhibitor-1 protein (PAI-1) released into the bloodstream. Both 
ATIII and protein C are also rapidly consumed during the septic state.
239,240
 Additionally, 
the down-regulation of thrombomodulin due to both local and systemic release of 
cytokines, such as TNF and IL-1, results in impaired activation of the anticoagulant 
APC–protein S complex.
241
  
The increased procoagulant activity, reduced anticoagulant activity, and impaired 
fibrinolysis in septic patients leads to the development of the clinical syndrome called 
disseminated intravascular coagulation (DIC). DIC is clinically defined as an 
overexuberant systemic clotting that depletes coagulation proteins and platelets from the 
blood and leads to bleeding complications.
219,242-248
 It becomes increasingly common as 
patients advance from sepsis (SIRS) to septic shock.
249
 The microvascular thrombosis 
that develops concomitantly results in organ injury, partly on an ischemic basis. As such, 
while DIC is considered in terms of bleeding complications, the clinical outcome is 
ultimately decided by the accompanying microvascular thrombosis and end-organ 
damage.  
In summary, multiple and diverse pathways lead to activation of the cytokine 
networks and the coagulation cascade. To alleviate the fatal outcome of sepsis and septic 
shock, many therapeutic interventions have been targeted towards the later stages of 
endotoxin response: a) blocking cytokine synthesis/release by interfering with the 
transduction of cell-surface signals,
250-254
 b) neutralizing released cytokines by passive 
immunization
181,255-257
 and soluble receptors,
258
 and c) blocking cytokine cell-surface 
receptors with a specific receptor antagonist.
259-261
 The majority of these approaches have 
demonstrated efficacy in both in vitro and animal models but none has proven to be 
Bongat, Aileen, 2008, UMSL, p. 40 
  
 
effective at treating human sepsis. Due to the large diversity and quantity of cytokines 
released by activated cells, it is likely that the approach of blocking only a single cytokine 
may be inadequate. Since no single therapeutic agent has proven to be unequivocally 
beneficial for managing the abnormalities of sepsis, it has become increasingly clear that 
the therapeutic path to sepsis doesn’t lie on the treatment of the downstream events. 
Under the assumption that end-organ damage ensues from an exuberant or 
hyperactivated immunological response that becomes unresponsive to supervening 
counter-regulatory mechanisms, the approach to sepsis treatment lies in interrupting 
the cascading inflammatory response by blocking the initial signaling events. Current 
progress towards this goal will be discussed below.   
1.5. Approaches to Therapy: Anti-endotoxin Strategies 
What we understand, thus far, is that endotoxin is essentially a signaling molecule 
that alerts the vertebrate host to the presence of an invasive Gram-negative bacterium 
within the body. It warns the host of the necessity to activate appropriate innate and 
adaptive immune defenses to effect clearance of the pathogen. This physiological defense 
mechanism has evolved into a well-coordinated survival strategy to localise, contain and 
eradicate invading bacterial pathogens. At the same time, the very same responses can 
precipitate a generalized and potentially fatal systemic inflammatory process once the 
infection enters the bloodstream. Thus, while the endotoxin molecule itself is not 
intrinsically toxic, the exaggerated host response to endotoxin accounts for septic shock 
from Gram-negative bacterial organisms. 
To summarize from above, endotoxin mediates its injurious effects through 
systemic activation of host-derived inflammatory mediators including: (a) the 
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proinflammatory cytokine networks; (b) neutrophil, monocyte and endothelial cell 
activation; (c) the complement system; (d) the extrinsic coagulation cascade and the 
fibrinolytic system; (e) platelet activating factor; (f) the kinins; (g) the prostaglandins and 
leukotrienes; (h) reactive oxygen intermediates; (i) nitric oxide; and (j) probably other 
systems as yet undetermined. As such, endotoxemia is an archetypal example of a self-
regulating complex system – it features multiple cascading nonlinear interactions and 
feedbacks that are mostly irreversible. Since the mechanisms regulating these events are 
amplifiable at the molecular level, the effects are allowed to expand from the source to 
the whole body and then combine to precipitate endotoxic shock.   
However, while the evolution of organ dysfunction in septic shock is a complex, 
highly variable and multifactorial process involving many mediators, the past few 
decades have seen enormous advances towards understanding the cellular and molecular 
basis of the initial events in this process. The thorough characterization of these events 
has allowed researchers to design rational therapies directed against endotoxins. As 
summarized in Figure 1.5, there are seven potentially therapeutic points of intervention 
during the initial events of the LPS signaling cascade:  
1. Inhibition of LPS synthesis,  
2. Neutralization of LPS with antibodies directed at the core glycolipid region,  
3. Binding and neutralization LPS with bactericidial/permeability-increasing (BPI) 
protein or endotoxin-binding columns,  
4. Absorbance and clearance of endotoxins with high density lipoprotein (HDL),  
5. Use of LPS analogues such as E-5531 and E5564 to antagonize LPS, 
6. Binding CD14 – the LPS receptor on monocytes and neutrophils – with 
monoclonal antibodies, and  
7. Neutralization of TLR4 and its accessory proteins to inhibit intracellular 
signaling pathways.  
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Figure 1.4. Schematic representation of various pathways of endotoxin activity and the seven 
potentially therapeutic points of intervention. Abbreviations: LBP = lipopolysaccharide binding 
protein; mAb = monoclonal antibodies; MAPK = mitogen-activated protein kinase; NFkB = nuclear 
factor k for B cells (important signal transduction protein for cytokine genes in monocytes and 
neutrophils); TK = tyrosine kinase. 
 
Table 1.3. Current anti-endotoxin therapies.
262
  
1. Enhanced LPS clearance 
Anti-LPS antibodies 
Haemoglobin derivatives 
Direct removal of LPS through filtration 
2. Direct neutralization of circulating LPS 
Anti-LPS antibodies 
LPS neutralizing proteins (ENP, BPI, defensins) 
Polymyxin B 
3. Inhibition of LPS-LBP and/or LPS-sCD14 interactions 
Lipid A analogues (E5531, E5564) 
Anti-LBP antibodies, anti-CD14 antibodies 
BPI 
4. Blocking cellular LPS receptors 
Lipid A analogues (E5531, E5564) 
Anti-CD14 antibodies 
5. Inhibition of cell signal transduction 
Tyrosine kinase or protein kinase C inhibitors 
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It is quite clear then that there are various avenues by which one can approach the 
design of therapeutic interventions against the inflammatory effects of LPS in the 
circulation. Table 1.3 summarizes a few examples of therapeutic agents that are under 
evaluation for each category. We believe, however, that the central role played by the 
Lipid A moiety of LPS in activating cells clearly indicates that blocking the cellular 
receptor for Lipid A may halt the chain of events leading to septic shock. Amongst the 
various receptors discussed above, we believe that targeting CD14 is the most promising. 
In fact, there is plenty of evidence to support this idea. First, the formation of the 
CD14/LPS complex significantly reduces (100 to 1000 fold) the concentration of LPS 
required for activation of macrophages when compared to LPS alone.
263
 Second, CD14-
deficient mice are highly resistant to LPS-induced shock and monocytes derived from 
CD14-deficient mice are insensitive to LPS.
264
 Finally, while CD14 seems to have the 
ability to discriminate between bacterial products and direct their signals to different 
TLRs, it does not have the fine binding specificity to discriminate Lipid A 
structures.
265,266
  
It is a widely accepted convention in the pharmaceutical industry that a 
pharmacological receptor antagonist is often best derived from modification of the parent 
agonistic molecule. Since Lipid A represents the toxic principle of LPS,
31,267
 synthetic 
endotoxin antagonists are structurally based on natural Lipid A and their biosynthetic 
precursors. To date, there has been a considerable effort expended towards modifying 
Lipid A from a variety of bacterial species as LPS antagonists. There are two 
observations that serve as a guiding principle for the synthesis of modified Lipid A 
substructures: 1) Lipid A of Escherichia coli is the most toxic amongst its class, and 2) 
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naturally derived Lipid A from bacteria such as Rhodobacter capsulatus and 
Rhodobacter sphaeroides are less toxic and can potently antagonize the agonistic activity 
of E. coli Lipid A.
268,269
. Studies toward elucidating structure-activity relationships on the 
synthetic Lipid A substructures have already provided valuable insight into the 
significance of key portions of the molecule. Broadly classified into either 
monosaccharides or disaccharides, the insights gleaned from each structural lead will be 
discussed below. 
1.5.a. Monosaccharide Antagonists  
 Concurrent with the classical target synthesis of E. coli Lipid A by Shiba and 
Kusumoto,
30
 seminal studies by Raetz and co-workers led to the identification
270,271
 and 
subsequent synthesis
272,273
 of Lipid X (1, see Figure 1.5). Lipid X (2,3 diacyl 
glucosamine 1-phosphate) is a monosaccharide precursor in the biosynthetic pathway of 
lipid A.
274,275
 This compound has been shown to possess the immunomodulating 
properties of LPS but not its toxicity.
276-278
 As such, Lipid X antagonizes LPS activity in 
vitro
279
 and has been reported to protect mice
280
 and sheep
281
 from LPS-induced lethality. 
In contrast, Lipid X has been shown to be ineffective in vivo in a canine sepsis model.
282
 
The structural similarity between lipid X and lipid A suggests that lipid X might be 
mediating its protective effect by specifically blocking endotoxin-triggered events, and 
possibly even competing directly with LPS for cellular binding sites, a hypothesis that 
can be tested in an in vitro system. However, more recent studies have shown that the 
beneficial immunomodulatory effects of lipid X were due to minor disaccharide 
contaminants.
283,284
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Figure 1.5. Structures of monosaccharide Lipid A analogs. 
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On the other hand, Rossignol et al. mentioned in a review that their efforts to 
develop monosaccharide-based endotoxin antagonists met with limited success, yielding 
compounds with low antagonistic potency.
285
 However, amongst the compounds they 
tested, they found that ERI-1 (2, see Figure 1.5) demonstrates good activity in in vitro 
assays utilizing cultured cells or primary cultures of monosaccharides containing low 
concentrations of plasma.
286
 When the compound was tested in vivo in the mouse 
endotoxin challenge or in vitro such as in whole blood assays, the activity of 2 was 
attenuated. 
 Two similar tri-acyl monosaccharides containing an anomeric carboxylic acid and 
O-4-phosphate (3 and 4, see Figure 1.5) were recently reported by researchers at 
Sankyo.
287,288
 These compounds were shown to be potent inhibitors of LPS-induced 
TNF! production in monocytes at 5 and 17 nM, respectively. The fascinating aspect of 
this work is that it corroborates findings by researchers at Sandoz that the use of 2-keto 
carboxylic acids prevents the formation of disaccharide contaminants that are 
agonistic.
283,284
 The in vivo activities of these potentially antagonistic monosaccharides, 
however, have not been reported.  
Matsuura et al. believed that further exploration of the beneficial applications of 
monosaccharide analogues to sepsis therapy requires a deeper understanding of the 
characteristic features of human cells that allow for the recognition of lipid A-like 
structures.
289
 Consequently, this group conducted more detailed studies of the effects of 
monosaccharide analogues on human cells in relation to their structures. Thus, a series of 
structurally related monosaccharide lipid A analogues were examined for their ability to 
activate human monocytic cells to induce cytokines such as TNF-! and IL-6, in 
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comparison with their ability to activate murine monocytic cells. To this end, they found 
that the monosaccharide analogue GLA-58 (5, see Figure 1.5), which has been found to 
be an LPS antagonist in murine
290,291
 cells, also exhibited antagonistic activity in 
human
289
 cells. In addition, they found that while monosaccharide analogues GLA-26, 
GLA-47, GLA-89, and GLA-64 (6, 7, 8, and 9, respectively, Figure 1.5) do not induce 
cytokine release in human monocytic cell lines, they showed significant potency to 
activate murine monocytic cells. More interestingly, however, despite the agonistic 
activity exhibited by compounds 6-9 in murine cells, they were found to have 
antagonistic activity to LPS-induced activation of human monocytic cells. To summarize 
their results, they found that the structure of lipid A analogues recognized as LPS 
agonists by human monocytic cells comprises D-glucosamine, phosphoryl groups, and 
acyl groups with defined carbon chain lengths of C14 and C12 in a ratio proportional to 
1:1:3. Moreover, human cells have stricter requirements toward recognizing elements of 
Lipid A substructures compared to that of murine cells. As such, Lipid A-like structures, 
recognized by the murine cells as LPS agonists and antagonists, are recognized as being 
LPS antagonists by human cells. 
Building on the hypothesis that derivative 1 might be mediating its protective 
effect by specifically blocking endotoxin-triggered events, and possibly even competing 
directly with LPS for cellular binding sites, Danner et al. evaluated several derivatives of 
1 for anti-endotoxin activity.
286
 Thus, lipid X and its diamino analog, 3-aza-lipid X (10, 
Figure 1.5),
279
 were evaluated for their ability to either prime or prevent LPS-mediated 
priming of human neutrophils. To this end, they found that compound 10 demonstrated 
marked inhibition of endotoxin-induced priming at low concentrations but an endotoxin-
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like priming effect at high concentrations.  However, when a phosphate group was added 
at C-4 of compound 10, the resulting compound (11, see Figure 1.5) exhibited pure 
antagonistic and increased anti-endotoxic
292
 activity. 
 Thus far, we find that in order for a monosaccharide analogue to exhibit anti-
endotoxin activity, it has to bear some structural similarity with that of E. coli Lipid A. 
Recently, however, it was shown that substances with chemical structures totally 
unrelated to Lipid A such as taxol,
293
 flavolipin,
293
 and vitamin D
294
 have LPS-like 
activity towards TLR4.  Moreover, Jerala et al. projected that the structural motif that can 
be recognized by LPS receptors can be essentially reduced from Lipid A to a structure 
with anionic groups and a large hydrophobic moiety.
295
 In an attempt to explore the 
verity of these observations, Peri et al. presented the synthesis and biological activity of a 
glucose-derived ammonium species (12, Figure 1.5).
296
 To this end, they found that 
despite the lack of a glucosamine backbone, ester- and amide-linked fatty acids, and 
phosphate residues, compound 12 inhibits lipid A-induced cytokine production in MT2 
macrophages in a dose-dependent manner. Interestingly, this seminal publication 
highlights that the presence of a five-membered ring and a positive charge on the nitrogen 
atom at C-6 was fundamental to the activity of compound 12.  
1.5.b. Disaccharide Antagonists  
 Reports describing that Lipid A from R. capsulatus (14, see Figure 1.6)
268
 and R. 
sphaeroides (15, Figure 1.6)
269,287,288
 were non-toxic compared to Lipid A from E. coli 
(13, Figure 1.6) verified the potential utility of disaccharide-based endotoxin antagonists. 
The proposed structures of nontoxic compounds 14 and 15 differ from 13 in the number 
of acyl chains on the reducing end, the difference in length of the individual acyl chains, 
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and the presence of unsaturation on the acyloxyacyl moiety of 14 and 15. Compound 14 
also possess two !-ketoacyl chains at the C-2 and C-2’ positions whereas only one !-
ketoacyl chain is present at the C-2 position on 15.  
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Figure 1.6. Structures of Lipid A derived from various bacterial species (13-15) and the 
biosynthetic precursor of E. coli Lipid A (16). 
 
Lipid IVA (16, Figure 1.6) is the biosynthetic precursor of LPS and is a potent 
LPS antagonist in human in vitro assays but is an agonist in murine systems.
297
 Since the 
structure of 16 presents a synthetically simpler disaccharide, various groups began 
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investigating the feasibility of using it as a lead structure. To this end, synthetic analogues 
of 16 were generated in order to investigate the structural constraints of the antagonistic 
activity of 16, to eliminate its agonistic activity, and to determine potential stabilization 
of the compound for pharmaceutical development.
285
 However, they found that similarly 
with 16, biological activity of these derivatives strongly depended on the assay system 
used.   
Both in vitro and in vivo, derivative 14 possesses an anti-endotoxin potency that is 
desirable for a pharmaceutical antagonist.
269
 While the synthetic version of 14 appears to 
retain the same antagonistic activity ascribed to the bacterially derived molecule, it was 
found that it cannot be readily synthesized and purified to pharmaceutical standards, 
especially on a scale necessary for development.
285
 To address this problem, Rossignol 
and co-workers decided to investigate O-3 and O-3’ ethers in place of esters.
285
 Although 
Shiozaki et al.
298
 have shown that stabilization of compound 13 with the generation of O-
3 and O-3’ alkyl chains produced an analogue without anti-endotoxin properties, 
conversion of derivative 14 to ERI-6 (17, Figure 1.7) yielded a potent LPS antagonist 
both in vitro and in mice. During the synthesis of this molecule, however, small amounts 
of impurities arose from nucleophilic attack of the free C-6’ hydroxy group toward the 
adjacent C-4’ phosphate and rendered final purification difficult. Since natural Lipid A is 
connected to the core region and O-antigen portion of the LPS molecule at the C-6’ 
position, alteration or “capping” of this position seemed to be a logical modification of 
derivative 17. Consequently, methylation of the C-6’ hydroxyl group not only eliminated 
the formation of impurities, it also blocked the formation of a cyclic phosphate. The 
resulting molecule, E5531 (18, Figure 1.7), is a fully stabilized endotoxin antagonist with 
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no detectable agonistic activity. Lack of toxicity and mutagenicity, along with the 
availability of a stable formulation, established 18 as a candidate for clinical 
development.
299-301
  
Concurrent with the clinical development of 18, Rossignol et al. also performed 
additional studies to determine the structural requirements for a second-generation anti-
endotoxin candidate possessing a much simpler structure.
285
 Thus, they found that 
methylation of the C-4 hydroxyl led to an approximate two-fold enhancement of the 
antagonistic activity in the resulting molecule ERI-7 (19, Figure 1.7). On the other hand, 
changing the configuration of the !-carbon of the C-3 alkyl chain to the (S)-configuration 
to give ERI-18 (20, Figure 1.7) enhanced the antagonistic activity approximately fivefold. 
Finally, the role of the phosphate functionalities on C-1 and C-4’ towards antagonistic 
activity was also evaluated. Unfortunately, dephosphorylation either gave a compound 
that was insoluble in the assay medium or devoid of a measurable antagonistic activity. 
The phosphate functionalities on the parent compound seemed necessary for biological 
activity. 
The lipid A from R. sphaeroides (15, see Figure 1.6) was also found to possess 
potent antagonistic activity in both human and murine systems.
302-304
 While the synthetic 
version was as potent as the bacterially derived material in terms of antagonizing LPS in 
human monocytes, human whole blood, and murine macrophages, it lacked the weak 
agonistic activity present in the latter.
305
 Attempts at developing a clinically acceptable 
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version of 15 were similarly focused towards obtaining a pure, stable material with high 
potency.  Thus, the C-3 and C-3’ acyl chains were converted to alkyl chains and the C-6’ 
hydroxyl was methylated, as in compound 18.
285
 
Rossignol et al. were also able to simplify the C-2’ acyloxy chain into a single 
acyl chain 18 carbons in length containing the (Z)-unsaturation at an approximated 
position. In addition, they found that removal of the !"hydroxyl moiety at C-3 increased 
the activity significantly and made the molecule more synthetically accessible. Finally, 
methylation of the hydroxyl moiety on the C-3’ alkyl chain optimized the series for both 
biological activity and synthetic ease. The resulting molecule, E5564 (21, Figure 1.7), is 
stable, more readily synthesized, and more potent than E5531. Consequently, 21 is being 
developed by the Eisai company as a second-generation antisepsis drug and is currently 
undergoing clinical trials. 
It was mentioned earlier that the phosphate moieties are essential to the biological 
activity of Lipid A derivatives. Boons and co-workers, however, have found that a 
“phosphate-free” derivative of Rhizobium sin-1 Lipid A (22, see Figure 1.8) lack the 
proinflammatory effects of E. coli LPS.
306
 Furthermore, compound 22 was found to 
emulate the ability of heterogeneous R. sin-1 LPS to antagonize enteric LPS, providing 
evidence for the critical role of the gluconolactone moiety in the antagonistic activity of 
R. sin-1 LPS.  
Finally, Nielsen et al. determined that LPS derived from Helicobacter pylori also 
exhibits no proinflammatory activity.
307,308
 This prompted Fukase and co-workers to 
explore derivatives of H. pylori Lipid A for possible antagonistic activity. Previously, this 
group had designed and synthesized monosaccharide analogues containing acidic amino 
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acid residues at C-6 and observed a switch in endotoxic or antagonistic activity based on 
the type of anionic residue present.
309
 To this end, they decided to synthesize H. pylori 
Lipid A derivatives containing 3-deoxy-D-manno-2-octurosonic acid  (Kdo) at C-6. Since 
natural Lipid A of E. coli is generally connected to the rest of the LPS domain via the 
Kdo residue, it was reasoned that attaching the acidic Kdo unit may aid in the recognition 
event that the anionic phosphate residue usually mediates. Indeed, it was found that 
compound 23 (Figure 1.8) antagonize E. coli LPS-induced immunostimulation.
310
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Figure 1.8. Lipid A derivatives from Rhizobium sin-1 and Helicobacter pylori. 
1.6. Statement of Research Goals 
As mentioned, there is still a major unmet medical need for more effective and 
safer anti-sepsis agents. Indeed, we raised several points regarding a feasible approach to 
sepsis therapy. First, the multiple and diverse pathways regulating the cytokine networks 
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and the coagulation cascade make it likely that blocking the downstream events following 
LPS-induced cellular activation will be completely inadequate. Unfortunately, this is the 
only strategy that has been approved and applied in hospital settings to date.
50,193
 Second, 
under the assumption that end-organ damage ensues from an exuberant immunological 
response that becomes unresponsive to supervening counter-regulatory mechanisms, it is 
reasonable to suppose that the approach to sepsis treatment lies in interrupting the 
inflammatory cascade by blocking the initial signaling events. Third, the central role 
played by the Lipid A moiety of LPS in activating cells clearly indicates that blocking the 
cellular receptor for Lipid A may halt the chain of events leading to septic shock. Finally, 
for compelling reasons that were elaborated earlier, it is rational to conclude that CD14 
presents the most promising target amongst the cell-surface receptors discussed above. 
Thus, to address the need for a single therapeutic agent that is unequivocally beneficial 
for managing the abnormalities of sepsis, the goals of this dissertation are as follows: 
1. Design monosaccharide and disaccharide analogs of Lipid A that will 
potentially bind with high affinity to the cell receptor CD14. 
2. Develop and optimize high-yielding, convergent, facile, scalable, and novel 
methods for the synthesis of the Lipid A analogues 
3. Evaluate the synthetic analogues for antagonistic activity towards LPS-
induced release of TNF!  in human macrophage cells in vitro 
While considering our targeted design for Lipid A analogues that will bind with high 
affinity to CD14, we took into consideration the lessons gleaned from the analogues 
described in Section 1.5. Since it has been well proven that disaccharide analogs usually 
provide more appreciable antagonism towards LPS for obvious reasons of structural 
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similarities, we were inclined to pursue the design and synthesis of disaccharide analogs. 
Subsequently, we found it essential to verify the idea presented by Jerala
295
 that the 
structural motif that can be recognized by LPS receptors can be condensed to the 
arrangement of anionic groups and a large hydrophobic moiety. Apparently, this type of 
arrangement provides a more likely complement to the cationic residues and the large 
hydrophobic binding site of the LPS receptors. To this end, we decided to build on the 
structural simplicity of Lipid IVA (16, see Figure 1.6) by having four hydrophobic chains 
attached to the disaccharide core.  Since previous research showed a distinct ambivalence 
towards the type of hydrocarbon chain necessary for antagonistic activity, we decided to 
try all three types – the simple alkyl chain, the acyloxy chain, and the acyl chain. Finally, 
to provide the anionic character to our design, we decided to attach an acidic amino acid 
on C-6. Therefore, our targeted design for the disaccharide analogues 24-26 are 
illustrated in Figure 1.9. 
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Moreover, since there are scarce examples of Lipid A analogues that lack the 
disaccharide core yet still maintain potent antagonistic activity, we felt it was essential to 
explore the design and synthesis of potent monosaccharide antagonists. To this end, the 
observation by Peri and coworkers that compounds structurally unrelated to Lipid A can 
still exhibit potent antagonistic activity was considered.
296
  
In this connection, the development of similar glucose-derived ammonium species 
(containing hydrophobic alkyl chains in place of the ester- and amide-linked acyl chains) 
would possibly offer a fruitful venue for further studies. Nonetheless, we found ourselves 
particularly interested in pursuing a different structural lead. Thus, we decided to 
investigate a structural motif that: 1) preserves the native glucosamine residue and the 
ester- and amide-linked (R)-3-hydroxy fatty acid chains, 2) lacks any unstable phosphate 
residue, and 3) contains a cationic residue on C-6. Basically, we wanted to explore the 
ramifications of Peri’s idea on a structure that is analogous to Lipid X (1, see Figure 1.5). 
In addition, following in the footsteps of Fukase et al., we wanted to utilize amino acids 
to provide the cationic character.
309,310
 Thus, our goal is to synthesize compounds 27-32 
(see Figure 1.10) and evaluate these targeted designs for possible antagonism towards 
LPS-induced proinflammatory activity. 
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Figure 1.10. Targeted design of monosaccharide Lipid A analogues. 
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2.1. Retrosynthetic Scheme 
Currently, the synthesis of disaccharide Lipid A derivatives and their biosynthetic 
precursors follow two common approaches. In the first approach, the monosaccharides 
are first functionalized with lipid chains and then coupled to form the beta-(1!6) linked 
disaccharide (route A, Scheme 2.1). This approach was utilized by Shiba and co-workers 
in the first reported synthesis of the proposed structure of E. coli Lipid A.
1-3
 In the second 
approach, the disaccharide core is formed first and then selectively functionalized with 
lipids (route B, Scheme 2.1).  
OHO
O
NH
O
OHO
O
NH
O
O
HO
O
HO
O
HO O
HO
OPO
HO
PGHN
O
OPO
HO
NHPG
O
OPO
HO
NHPG
OH
LG2
OPO
HO
NHPG
HO
+
OPO
O
NH
O
LG2
O
HO
O
HO
OPO
O
NH
HO
O
HO
O
HO
+
A A
B B
LG1
LG1
LG1
LG1
 
Scheme 2.1. Strategic approaches to the synthesis of Lipid A analogues. P = Protecting Group;    
PG = Participating Group; LG = Leaving Group. 
 
While the first approach has the advantage of having fewer linear steps, a significant 
amount of synthetic work in this area has preferentially employed the second pathway.
4,5
 
Amongst obvious reasons for these are: (1) the difficulty in obtaining analytical data as 
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the molecule gets more complex, (2) the abysmal yield usually obtained in glycosylating 
monosaccharides with bulky substituents, and more importantly (3) the formation of a 
stable by-product (oxazoline) during the glycosylation step. Hence, as shown in Scheme 
2.2, the retrosynthetic scheme for the target synthesis of our disaccharide analogues 
follows the second approach:  
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Scheme 2.2. Retrosynthetic scheme the synthesis of Lipid A analogs. P = Protecting Group;     
PG = Participating Group; LG = Leaving Group; R = Alkyl Group 
As illustrated above, our plan is to synthesize the beta-(1!6)-linked disaccharide 
from a differently protected glycosyl donor and acceptor. Once the disaccharide is 
formed, it will be selectively deprotected and functionalized into our target compounds. 
The monosaccharide analogues, on the other hand, will be synthesized from the same 
building blocks used to synthesize the disaccharides. Thus, based on the retrosynthetic 
scheme and the necessity of forming a glycosidic linkage with high stereocontrol, our 
initial concern in planning the synthesis was to choose a suitably derivatized 2-amino-2-
deoxy glycoside.  
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Glycosides of 2-amino-2-deoxy sugars are present in the most important classes 
of glycoconjugates and naturally occurring oligosaccharides, in which they are connected 
to other residues via either 1,2-cis (!) or, more frequently, 1,2-trans (") glycosidic 
linkage.
6-8
  In particular, 2-N-acetamido-2-deoxyglycosides, most commonly of the D-
gluco and D-galacto series, are widely distributed in living organisms as glycoconjugates 
(glycolipids, lipopolysaccharides, glycoproteins),
6
 or glycosaminoglycans (heparin, 
heparin sulfate, dermatan sulfate, chondroitin sulfate),
9
 and in blood group 
oligosaccharides,
10
 etc. Aminosugars on cell surfaces play an important role as receptor 
ligands for protein molecules such as enzymes,
11
 antibodies,
12
 and lectins,
13
 and 
participate in antibody-antigen interactions.
14
 As appreciation for the biological 
importance of 2-amino sugars has increased, so have efforts to develop chemical methods 
for the synthesis of oligosaccharides containing these residues. Special efforts for the 
synthesis of glycosyl donors of 2-amino-2-deoxy sugars have been focusing on the 
development of simple, efficient, regio-, and stereoselective procedures.  
Nowadays, a variety of synthetic approaches to the synthesis of 2-amino-2-
deoxyglycosides have been developed and the progress in this area has been previously 
reviewed.
15-17
 The synthesis starts either directly from a glycosamine or by introduction 
of a nitrogen functionality to glycose or glycal derivatives. To this end, various 
glycosamine donors with modified functionalities have been investigated, in particular, 
those bearing an N-2 substituent capable of either efficient participation via acyloxonium, 
but not (2-methyl)oxazoline, intermediate for 1,2-trans glycosylation. The reason for this 
is illustrated below.  
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Scheme 2.3. Synthesis of 1,2-cis and 1,2-trans 2-amino-2-deoxy glycosides. 
Thus, promoter-assisted departure of the leaving group of regular (O-2) glycosyl 
donors results in the formation of the glycosyl cation, which is stabilized by resonance 
from O-5 via flattened oxocarbenium ion (Scheme 2.3.a). Hence, the nucleophilic attack 
is almost equally possible from either the top (trans, !- for the D-gluco series) or the 
bottom face (cis, "-) of the ring. Even though the "-product is thermodynamically 
favored (anomeric effect), a substantial amount of the kinetic !-linked product is often 
obtained. Various factors such as temperature, protecting groups, conformation, solvent, 
promoter, steric hindrance, or leaving groups may influence the glycosylation 
outcome.
18,19
 If the use of a base-labile ester-protecting group is permitted, 1,2-trans 
glycosides can be reliably prepared with the assistance of a neighboring participating 
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group at C-2.
20
 These glycosylations proceed primarily via a reactive bicyclic 
acyloxonium ion intermediate directing the nucleophilic attack mainly to the top face of 
the ring and allowing stereoselective formation of a 1,2-trans glycoside (Scheme 2.3.b). 
Many traditional glycosyl donors such as halides, thioglycosides, or O-
trichloroacetimidates provide excellent stereoselectivity and high yields.
21,22
  
Since a vast majority of naturally-occurring 2-amino-2-deoxy sugars are N-
acetylated, it is synthetically desirable to utilize a 2-acetamido-2-deoxy substituted 
glycosyl donor and thereby minimize protecting group manipulations. For this type of 
glycosyl donors however, the oxocarbenium ion rearranges rapidly into an oxazoline 
intermediate (Scheme 2.3.c). Even under harsh Lewis acid catalysis, this highly stable 
oxazoline intermediate does not exert strong glycosyl donor properties.  As a result, the 
use of N-acetylated donors is often impractical. On one hand, glycosidation of such 
donors often leads to the formation of relatively unreactive oxazoline intermediate that 
often remains as a major by-product. On the other hand, high nucleophilicity of the lone 
pair of electrons on nitrogen of the acetamido group also presents a complication by 
attracting electrophilic species (such as promoters of glycosylation) that often results in 
decreased reactivity and/or additional by-products.  
A common way to decrease the reactivity of the amino group it is to temporarily 
convert it into an electron-withdrawing amide, carbamate, or imide. The carbonyl 
group(s) effectively withdraw the electron density from the nitrogen atom and renders it 
less reactive. The drawback of this indirect approach is in the necessity to perform a 
number of additional steps that are required for the synthesis of the glycosyl donor and 
the conversion of the temporary substituent into the N-acetamido moiety. These 
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additional synthetic manipulations significantly decrease the over-all efficiency and 
yields. 
The choice of an amine protecting group for C-2 of aminosugars is also 
influenced by the fact that the protecting group at C-2 can directly influence the 
stereochemical outcome of the glycosylation reactions (see Scheme 2.3). Thus, for a 1,2-
trans glycosidic linkage, it would be desirable if the amine function on C-2 would be 
capable of providing anchimeric assistance to the oxocarbenium ion that forms. Overall, 
the ideal amine protecting group should be stable to a wide range of reaction conditions 
while also being able to impart sufficient reactivity, stereoselectivity, and high yield in 
glycosylation reactions. Moreover, it should be readily removed under mild reaction 
conditions. Thus, in order to determine the type of amine protecting group to install on 
our glycosyl donor and acceptor, we surveyed the literature for the most suitable class of 
2-amino-2-deoxy glycoside to use for our purposes.
17
 Following the general theory that 
neighboring group participation promotes efficient formation of 1,2-trans-linked 
glycosides, we narrowed our search to 2-amino substituents that are capable of providing 
anchimeric assistance. Adapting from our published review on the subject,
17
 protecting 
groups of this type that have been successfully employed in glycosylation reactions are 
summarized below.   
2.2. Monosubstituted 2-Amino-2-Deoxy Glycosides: Haloacetamido Derivatives 
Simple amides are generally prepared from the acid chloride or the anhydride. 
Many amides are stable toward mild acidic or basic hydrolysis and are classically 
hydrolyzed by heating in strongly acidic or basic solutions.
23
 Among simple amides, 
hydrolytic stability increases from formyl to acetyl to benzoyl. Lability of the haloacetyl 
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derivatives to mild acid hydrolysis increases with substitution: acetyl < chloroacetyl < 
dichloroacetyl < trichloroacetyl < trifluoroacetyl.
24
  
The use of 2-chloroacetamido-2-deoxy glycopyranosyl donors was introduced by 
Kiso and Anderson in 1985, who reasoned that halogen-substituted 2-acetamides will 
form weaker, and therefore more reactive, oxazoline intermediate (see compound 38, 
Scheme 2.4) by virtue of electron withdrawal.
25
 As a result, glycosyl donors of this type 
would be better electrophiles, and hence, more reactive in glycosidation. To this end, 2-
chloroacetamido derivative 34 was synthesized from 33 using chloroacetyl chloride in the 
presence of 2,6-lutidine in CHCl3 (Scheme 2.4). To demonstrate the effectiveness of 
monochloroacetyl derivatives as glycosyl donors, 34 was then glycosidated with various 
primary and secondary glycosyl acceptors.
24,26
  
Thus, FeCl3-promoted glycosidation of 34 with glycosyl acceptor 35 gave the 
disaccharide 36 in 80% yield. When acetate 34 was treated with FeCl3 in CH2Cl2 in the 
absence of the glycosyl acceptor, the oxazoline derivative 38 was isolated as proof that 
the glycosylation reaction proceeds via an oxazoline intermediate. It was demonstrated 
that the treatment of 36 with zinc and acetic acid in refluxing oxolane reduces the N-
chloroacetyl group (see the synthesis of 37, Scheme 2.4).  
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Scheme 2.4. 2-Chloroacetamido-2-deoxy glucopyranosyl derivatives. 
2-Deoxy-2-dichloroacetamido derivatives were introduced as glycosyl donors to 
provide a solution to one of the biggest issues concerning the use of 2-acetamido 
derivatives as glycosyl donors. Thus, glycosyl donor 2-acetamido-3,4,6-tri-O-acetyl-2-
deoxy-!-D-glucopyranosyl bromide was found to be easily transformed into a relatively 
unreactive 1-acetyl-2-amino-2-deoxy hydrobromide derivative by an N"O acyl 
migration via the oxazoline.
27
 Consequently, it was hypothesized that the powerful 
electron-attracting dichloroacetyl group may have the appropriate structure to address this 
challenge.
28
 For this purpose, glucosamine hydrochloride 39 was reacted with 
dichloroacetic anhydride and sodium dichloroacetate followed by O-benzoylation to 
afford the 2-deoxy-2-dichloroacetamido sugar 40 in 68% yield (Scheme 2.5). 
Bromination of 40 with HBr/HOAc gave the glycosyl donor 41, which was reacted with 
the glycosyl acceptor 42 under Helferich conditions to afford the disaccharide 43 in 47% 
yield.
28,29
 Hydrolysis of the amide group was effected by adding 1N methanolic barium 
methoxide and water to a solution of 43 in methanol.
28
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Scheme 2.5. 2-Deoxy-2-dichloroacetamido glucopyranosyl derivatives. 
 
2-Deoxy-2-trichloroacetamido derivatives have been also investigated, initially 
for its applicability towards the synthesis of nucleosides under acidic conditions.
30
 
Unfortunately, it was found that a stable trichloromethyl oxazoline was the main product 
of this glycosylation method and as a result, further studies were abandoned.  Three 
decades later, Beau and co-workers noted that, as a matter of fact, (2-
trichloromethyl)oxazoline resembles an intramolecular trichloroacetimidate.
31
 Since 
glycosyl trichloroacetimidates are excellent glycosyl donors, this bicyclic derivative 
could serve as a potentially reactive glycosyl donor for the synthesis of 1,2-trans-2-
amino-2-deoxyglycosides.
32
  
To this end, 1,3,4,6-tetra-O-acetyl-2-deoxy-2-trichloroacetamido-!-D-
glucopyranose 44 was prepared from D-glucosamine tetraacetyl derivative 33 as 
illustrated in Scheme 2.6.
30,33
 Anomeric deacetylation of 44 with hydrazine acetate in 
DMF followed by reaction with trichloroacetonitrile in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) afforded the trichloroacetimidate derivative 45 in 
79% yield. The glycosyl donor 45 then was then glycosidated with 46 in the presence of 
TMSOTf to afford 1,2-trans-linked disaccharide 47 in 82% yield. The complete 
stereoselectivity achieved supports the intermediacy of an oxazolinium species. This 
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conclusion was confirmed when treatment of 45 with TMSOTf followed by workup 
furnished oxazoline 48 as the major product (Scheme 2.6). Thus, it seems that the 
electron-withdrawing effect of the trichloromethyl group in the intermediary oxazolinium 
ion greatly increases the electrophilic character of the anomeric carbon, as compared to 
its methyloxazoline counterpart.  
Other classes of glycosyl donors with the 2-deoxy-2-trichloroacetamido moiety 
have been investigated.
31,34-36
 Amongst derivatives investigated, glycosyl donors 49 and 
50 serve as a clear illustration of the versatility of 2-trichloroacetamido derivatives in 
terms of their application to oligosaccharide synthesis. In this connection, Donohoe et al. 
found that 2-(trichloroacetyl)oxazoline derivatives of allosamines and tallosamines are 
also excellent glycosyl donors.
37
  
OAcO
AcO
OAc
OAc
NH2
OAcO
AcO
OAc
OAc
NH
33 CCl3
O
44
Cl3CHCOCl
CH2Cl2, pyridine
OAcO
AcO
OAc
Cl3COHN
45
1. N2H4CH3COOH, DMF
2. Cl3CCN, DBU, DMF
O
NH
CCl3
OAcO
AcO
OAc
SEt
Cl3COHN
49
OAcO
AcO
OAc
N
O
CCl348
OHO
BnO
OBn
OBn
OBn
OAcO
AcO
OAc
Cl3COHN
OO
BnO
OBn
OBn
OBn
OAcO
AcO
OAc
Br
Cl3COHN
50
46
47
HBr/AcOH
TMSOTf
 
Scheme 2.6. 2-Deoxy-2-trichloroacetamido glucopyranosyl derivatives. 
Another advantage to the use of N-trichloroacetyl derivatives is the ease of their 
deprotection. This can be achieved under a variety of reaction conditions, amongst which 
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are tributylstannane-azobisisobutyronitrile (AIBN) in refluxing benzene,
31
 
hydrogenolysis (H2, Et3N, PtO, AcOEt, 55 psi),
38
 or cleavage with NaOH followed by 
reacetylation.
37,39
  
The early application of 2-deoxy-2-trifluoroacetamido (TFA) derivatives was to 
the synthesis of steroid glycosides using glycosyl bromides as donors.
30,40,41
 The 
precursor for this synthesis, derivative 51, was obtained in three steps from D-
glucosamine via sequential treatment with anisaldehyde in 1N NaOH, acetylation with 
acetic anhydride, and hydrolysis of the N,N-anisylidene moiety with 5N HCl.
42,43
 
Reaction of 51 with trifluoroacetic anhydride gave the N-trifluoroacetyl derivative 52 
quantitatively (Scheme 2.7). A variety of glycosyl donors with a suitable anomeric 
leaving group have been prepared. Amongst the reported glycosyl donors bearing the N-
trifluoroacetyl moiety on C-2 are the acetates (such as 52),
44,45
 bromides (53),
30,41,46-51
 
phosphates (54),
52-55
 thioglycosides (55) and their corresponding sulfoxides,
56
 4-
tertbutylthiophenyl glycosides,
57
 phenylselenides,
58
 etc. Very recently, the anomeric 
acetyl moiety was converted into chloride 56 and then into S-benzoxazolyl (SBox) 
glycosyl donor 57 (Scheme 2.7),
59
 The latter derivative showed potent glycosyl donor 
properties; for example, glycosylation of the glycosyl acceptor 58 in the presence of 
AgOTf provided 1,2-trans-linked disaccharide 59 in 89% yield. 
To convert the N-trifluroacetyl moiety back to the free amine, various methods 
have been employed. Amongst these are the use of HCl in MeOH,
60
 NaOH in Acetone-
H2O,
49
 or LiOH
56
 in THF-MeOH. It should be noted that these conditions allow for the 
orthogonal deprotection of the N-trifluoroacetyl group over other amine protecting 
groups.
56
 Glycosyl donors of this class have been employed in the synthesis of chiro-
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inositols,
46
 didemnin B analogues,
61
 C-glycosyl phosphonates,
52
 globotriosylceramide,
62
 
diosgenin derivatives,
50
 bacterial polysaccharide fragments,
63
 and Lipid A
64
 analogues.  
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Scheme 2.7. 2-Deoxy-2-trifluoroacetamido glucopyranosyl derivatives. 
 
2.3. Monosubstituted 2-Amino-2-Deoxy Glycosides: Alkoxycarbamoyl Derivatives 
2-Alkoxycarbamoyl-2-deoxy derivatives have found widespread use as glycosyl 
donors due to their ease of formation and the orthogonality or chemoselectivity of N-
deprotection.
15
 Protection is usually accomplished by condensation of the free amine and 
the appropriate chloroformate in the presence of a mild base.
65
 Conditions for removal, 
however, depend on the carbamate moiety employed, i.e. benzyl carbamate (NHCbz or 
NHZ) is cleaved by catalytic hydrogenolysis; allyl carbamate (NHAlloc) is readily 
cleaved by Pd-catalyzed isomerization; while trichloroethyl carbamate (NHTroc) is 
readily cleaved by acidic hydrolysis or reduction with Zn.
23
 Carbamates such as N-
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methoxycarbonyl,
66-71
 N-(tert-butyl)oxycarbonyl (tBoc),
65
 and N-(p-nitrobenzyl)oxy-
carbonyl (PNZ)
72
 have been used in oligosaccharide synthesis.  
Dating back to the 1930’s,
42,73
 the use of benzylchloroformate (CbzCl) in the 
presence of a suitable base is still the method of choice for installing the N-
benzyloxycarbonyl moiety on the free amine function.
65,74-78
 The tetraacetate 60 can be 
easily prepared from either unprotected glucosamine
73
 or from 2-amino tetraacetate 33.
65
 
The latter approach is preferred if the synthesis of 60 in anomerically pure !-form is 
required (Scheme 2.8). It has been effectively used in the synthesis of glycopeptide
79
 and 
glycolipid
80
 derivatives. Cbz-protected glycosamines can also be obtained by consequent 
reprotection of azido or another carbamate-protected glucosamine.
74,81
  
The first reported glycosylations with 2-N-benzyloxycarbonyl amino sugars 
involved activation of bromides.
82,83
 Unfortunately, the Hg(CN)2-promoted reaction of 
glycosyl bromide 61 with glycosyl acceptors gave the oxazolidinone derivative 62 with 
migration of the benzyl group to the aglycone.
82
 Silver salt-promoted condensation of 
simple alcohols with 2-NHCbz chloride was more successful. Yet, !-glycosides were 
isolated only in moderate yields (42-46%) despite the use of a large excess of alcohol.
84
 
When applied to the synthesis of simple aminosugar-pyrimidine nucleosides, however, 2-
NHCbz chlorides gave the 4-methoxy-pyrimidinone nucleoside in 84% yield.  
Over the years, more potent glycosyl donors bearing the 2-NHCbz moiety have 
been developed including dimethylphosphinothioates,
85
 phosphorodiamidimidothioate,
86
 
trichloroacetimidates,
87
 4-pentenyl glycosides,
86
 and phosphates.
86
 For example, 
glycosylation of glycosyl acceptor 65 with glycosyl donors 63 or 64 in the presence of 
TMSOTf provided the disaccharide 66 in 90 and 81% yield, respectively (Scheme 2.8).
86
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These glycosyl donors were prepared in a few steps using conventional synthetic 
manipulations via stable O-pentenyl moiety as a temporary anomeric substituent. 
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Scheme 2.8. 2-Deoxy-2-Benzyloxycarbamoylglucopyranosides. 
 As mentioned, catalytic hydrogenolysis cleaves the carbobenzyloxy moiety to 
afford the free amine. Reported deprotection conditions include H2/Pd in EtOH,
87
 H2/Pd 
in dioxane/water,
75
 and H2/Pd in MeOH/H2O,
88,89
 along with the chemoselective N-
deprotection reported by Hasegawa
90
 using H2/Pd in the presence of MeOH, HBr, and 
dioxane. The efficacy of these glycosyl donors have been demonstrated in the synthesis 
of nucleosides
91
 inner core of lipopolysaccharides,
92
 heparin derivatives,
88,93-95
 
dibekacin,
96
 Lipid A derivatives,
2
 neoglycoconjugates,
74
 and antibacterial amino 
glycosides,
97
 among others. 
 
 Versatile applications of the allyloxycarbamoyl (Alloc) protective group
98,99
 
prompted Boullanger et al. to investigate its participating properties in 1,2-trans 
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glycosylation reactions.
100
 For this purpose, the glucosyl bromide 68 was prepared in 
74% overall yield from D-glucosamine hydrochloride 39 by sequential treatment with 
allylchloroformate and Et3N at 50 ºC, followed by acetylation (Ac2O, pyridine) and 
bromination with 33% HBr in AcOH (Scheme 2.9).
101
 The reaction of 2-N-
allyloxycabonyl bromide 68 with galactosyl acceptor 65 promoted by Hg(CN)2 gave the 
!-linked disaccharide 69 in 86% yield along with the oxazolidinone derivative 70.
101
 In 
contrast, glycosidation of !-D-acetate 67 with glycosyl acceptor 29 in the presence of 
trimethylsilyl triflate (TMSOTf) provided disaccharide 69 in 82% yield with no side 
product 70 formation.
100
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Scheme 2.9. 2-Allyloxycarbamoyl-2-deoxyglucopyranosides.  
In an attempt to improve the reactivity as well as to expand the scope of 
applications, a variety of 2-allyloxycarbamoyl-2-deoxyglycopyranosyl derivatives have 
been developed over the years; for example, trichloroacetimidates,
102
 and 
thioglycosides.
103
 Derivatives of 2-N-allyloxycarbonyl sugars have been applied to the 
synthesis of peptidoglycan partial structures,
104
 glycopeptide assemblies,
102,105
 1,6-
anhydro derivatives,
106
 neoglycolipid analogues,
107
 N-acetylneuraminic acid 
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derivatives,
103
 and surfactants.
108
 The deprotection of the N-allyloxycarbonyl group is 
achieved using any of the following methods: reductive cleavage,
109
 treatment with 
Ni(CO)4,
110
 basic hydrolysis,
103
 homogeneous palladium catalysis using 
Pd(PPh3)4,
100,104,111-113
 or Pd-catalyzed hydrogenolytic cleavage with formic acid in the 
presence of an allyl acceptor.
114
 The allyl acceptor can be dimedone,
111
 2-ethylhexanoic 
acid,
112
 tributyl tin hydride,
102,113
 dimethyl malonate,
100,107
 or AcOH.
104
   
The use of 2-N-trichloroethoxycarbonyl (Troc) derivatives in aminoglycoside 
synthesis was first introduced by Kusumoto et al. in 1985.
115
 In their report, the N-Troc 
bromide 72 was synthesized from commercially available compound 39 in quantitative 
yield over three steps (Scheme 2.10). Glycosylation of glucosyl acceptor 73 with bromide 
72 gave the disaccharide 74 in good yield and complete !-selectivity. This method was 
used extensively in the synthesis of Escherichia coli Lipid A and analogues thereof, as 
well as in the synthesis of O- and S-linked glycopeptides.
3,116-123
 Another typical 
procedure for the preparation of the NHTroc derivatives is via temporary N,N-
anisylidene protection.
65
 The resulting intermediate 71 can serve as a suitable precursor 
for the preparation of a range of excellent glycosyl donors. 
Schultz and Kunz converted the intermediate !-71 into thioglycoside donor 75, 
thiophilic activation of which with DMTST gave the desired !-linked glycopeptides.
105
 
Trichloroacetimidate 76, obtained from the acetate 71 via conventional two-step 
protocol,
124
 provided high yields in the synthesis of glycopeptides. For example AgOTf-
promoted reaction of 76 with glycosyl acceptor 77 provided 1,2-trans glycoside 78 
(Scheme 2.10a).
125
 Moreover, Mukaiyama and Matsubara showed that tetraacetate !"71 
can be useful in tin(II) trifluoromethanesulfonate-catalyzed glycosylations with alkyl 
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trimethylsilyl ethers.
126,127
 Under these conditions, !-glycosides were typically obtained 
in 80-99% yields. For example, the synthesis of disaccharide 80 was accomplished in 
95% yield from building blocks !"71 and 79 (Scheme 2.10b). 
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Scheme 2.10. 2-Deoxy-2-Trichloroethoxycarbamoylglucopyranosides. 
Over the years, other classes of 2-NHTroc glycosyl donors have been found 
useful in glycoside and oligosaccharide synthesis. These include 
trichloroacetimidates,
104,125,128-152
 fluorides,
130,153,154
 chlorides,
155
 thioglycosides,
131,134,156-
174
 sulfoxides,
70,161
 and more recently, thioimidates,
59
 among others.  
The Troc group has been found to be stable under a wide range of standard 
conditions typically used in carbohydrate synthesis.
156
 Its sensitivity to alcoholysis under 
basic conditions permits convenient transformations into other carbamates. Removal of 
the Troc group to liberate the primary amine is typically accomplished by  reductive 
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elimination using Zn in AcOH,
105,128,130,131,133,139,140,175
 Zn-Cu alloy in 
AcOH,
104,129,136,137,145
 Zn and acidic buffer,
141,176
 Cd-Pb in AcOH,
173,177,178
 or more 
recently, using (Bu3Sn)2
179
 in DMF. The use of Zn-N-methylimidazole,
180
 in particular, 
allows selective deprotection of Troc in the presence of reducible and acid-sensitive 
functionalities. 
2.4. Disubstituted 2-Amino-2-Deoxy Glycosides 
 As mentioned above, the most attractive means for the establishment of a 1,2-
trans-glycosidic linkage would be through the formation of cationic species from a 
derivative of the sugar with participation of the neighboring substituent at C-2 (Scheme 
2.3). The latter substituent should be so chosen that its engagement does not lead to 
products other than the desired 1,2-trans-!-glycoside, i.e. the formation of stable 1,2-
oxazolines or oxazolidinones seen above. In this regard, blocking the amino function with 
two monovalent protecting groups or a bivalent cyclic group seems to be a reasonable 
recourse. Thus, electrophilic activation of the bivalently protected glycosyl donor A 
yields an oxocarbenium ion B which can form an oxazolinium intermediate C (Scheme 
2.11). The reactive intermediate C can only be attacked from the !-face by a nucleophile, 
and more importantly, cannot form a stable oxazoline. Various 2-amino-2-deoxy glycosyl 
donors of this type have been developed over the years. Their preparation, activation, N-
deprotection and model glycosidations will be discussed hereafter.  
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Scheme 2.11. Charge delocalization via bivalently-protected aminosugars. 
  
In 1954, Baker and co-workers prepared 1,3,4,6-tetra-O-acetyl-2-deoxy-2-
phthalimido-!-D-glucopyranose and observed that treatment of this compound with 
HBr/HOAc gave 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranosyl 
bromide.
181
 Six years later, Akiya and Osawa utilized the latter in glycosylations of 
simple alcohols and obtained the desired !-glycosides in high yields.
182
 Hence in 1976, 
Lemieux et al. proposed the use of 2-phthalimido glycopyranosyl halides for the 
development of a generally useful preparation of 2-amino-2-deoxy oligosaccharides.
183
 It 
was anticipated that engagement of the phthalimido group in charge delocalization at the 
anomeric center to form a strongly delocalized intermediate C (Scheme 2.11) will 
strongly influence the formation of a 1,2-trans linkage.  Since then, 2-deoxy-2-
phthalimido-protected glycosyl donors have been extensively studied and arguably 
became the method of choice for the preparation of 1,2-trans-linked glycosides and 
oligosaccharides of 2-amino-2-deoxy sugars.
15
  
 Preparation of 2-deoxy-2-phthalimido glycopyranosyl derivatives is usually 
accomplished by treatment of the corresponding 2-amino-2-deoxy sugar precursor 39 
with phthalic anhydride in the presence of a base. Acetylation of the monosubstituted 
intermediate 81 results in the formation of the per-acetylated derivative 82 that was 
obtained by Kochetkov et al. (conditions A)
184
 or Lemieux et al. (conditions B)
183
 in 69% 
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and 79% yields, respectively (Scheme 2.12). Starting from precursor 82, a range of 
glycosyl donors, including halides, trichloroacetimidates, thioglycosides, and 
thioimidates have been synthesized.  The progress in this area since a comprehensive 
report by Banoub et al. (1992)
15
 will be discussed herein.   
 The chemical synthesis and properties of both the anomeric forms of 3,4,6-tri-O-
acetyl-2-deoxy-2-phthalimido-D-glucopyranosyl halides, for example 83a, as well as 
their 1-chloro and 1-iodo counterparts, have been described by Lemieux and contrary to 
the premise of the anomeric effect, they found that the !-form was more stable.
183
 
Initially, as described in the synthesis of O-specific polysaccharides of Shigella 
flexneri,
185,186
 asialo-GM1 and –GM2,
187
 1,6-anhydromuramyl petides,
92
 and cell-surface 
glycans,
188
 2-phthalimido bromides were more commonly used in glycosylations under 
Koenigs-Knorr or Helferich conditions.  
 A representative example is shown in Scheme 2.12; thus, reaction of the bromide 
donor 83a with glycosyl acceptor 86 resulted in the formation of the trisaccharide 87 in 
72%.
189
 The greater stability of the chloride counterpart, however, started a change in the 
trend and resulted in a number of syntheses employing this building block; for example, 
blood-group antigens,
190
 peptidoglycans,
191
 and disaccharide analogues of 
meonomycin.
192
  
Highly stable 2-phthalimidoglycosyl fluorides also found application in 
aminosugar synthesis.
193
 For example, 2-phthalimidoglucopyranosyl fluoride 83b, 
obtained from 82 by a protecting group sequence followed by treatment with 
dimethylaminosulfur trifluoride (DAST) in THF, was reacted with glycosyl acceptor 
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88.
194
 Amongst the activating conditions developed, Cp2HfCl2-AgClO4 (Suzuki’s 
protocol)
195
 was chosen, providing the disaccharide 89 in 81% yield.
194
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OHO
HO
OH
OH
NH2HCl
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Scheme 2.12. 2-Deoxy-2-phthalimidoglucopyranosides. 
2-Phthalimido thioglycosides have been also widely employed in oligosaccharide 
synthesis. Amongst these: methyl thioglycosides, used in the synthesis of novel sulfated 
GM1b analogues,
196,197
 ganglioside GD2 and GQ1b,
198-200
 and galactosyl globosides;
201
 
ethyl thioglycosides, used in the synthesis of blood group antigens,
202-204
 capsular 
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polysaccharides of bacterial pathogens,
205,206
 glycoprotein
207
 residues, and 
peptidoglycan
208,209
 residues; phenyl thioglycosides, used in the synthesis of blood group 
determinants and antigens,
210-212
 chitin oligosaccharides,
213
 lactosamine
160
 donors, glycan 
residues,
214
 oligosaccharides from respiratory mucins,
215
 selectin ligands,
72,216
 and 
bacteriohopanetetrol
217
 derivatives; p-methylphenyl thioglycosides, used in the synthesis 
of !-Gal epitopes,
218,219
 synthetic aminoglycosides,
220
 and synthetic heparan sulfate
221
 
ligands; and isopropyl thioglycosides, used in the synthesis of immunostimulants
222
 
buffalo milk pentasaccharide derivatives,
223
 and anticancer agents.  
The introduction of the thioalkyl/aryl leaving group is generally accomplished by 
condensation of the appropriate acetate precursor with the corresponding 
thiol,
72,156,222,224,225
 stannane,
188,226
 or silyl ether
227-229
 in the presence of Lewis Acids such 
as BF3OEt2,
72,156,222,224
 TiCl4,
230
 TMSOTf,
227,228
 FeCl3,
225
 ZnI2,
229
 and SnCl4.
188,231
 
Nucleophilic displacement of an anomeric halide with the salt of the thiol is also a viable 
route.
232-234
 Glycosidation of thioglycosides can be achieved with the use of a variety of 
acceptors.
235
 For example, NIS/TfOH-promoted reaction of glycosyl donor 84 with 
glycosyl acceptor 90 afforded the oligosaccharide 91 in 91% yield (Scheme 2.12).
236
 
The use of 2-deoxy-2-phthalimido trichloroacetimidates in aminosugar synthesis 
was introduced by Grundler and Schmidt in 1983.
237
 Thus, the "-imidate 85 was obtained 
by reaction of carbohydrate hemiacetals with trichloroacetonitrile in the presence of a 
base (Scheme 2.12). Typical glycosylations using trichloroacetimidates are performed in 
CH2Cl2 as solvent, using a sub-stoichiometric amount of the promoter, usually 
BF3OEt2
238-242
 or  TMSOTf.
132,243-246
 For example, the synthesis of the disaccharide 93 
from glycosyl donor 85 and glycosyl acceptor 92 was accomplished in 84% yield.
244
 To 
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date, this method has been applied to the synthesis of bacterial antigenic 
polysaccharides,
238,239,244,245
 tumor-associated antigens,
247
 chitosan polysaccharides,
248
 
buffalo milk polysaccharides,
223
 mucin-type
240
 core units,
132
 hyaluronic acid,
241
 and E-
selectin ligands,
242
 among others. 
While the above glycosyl donors have proved to be potent and efficient, other 
glycosyl donors, such as phenylselenides,
249,250
 trifluoroacetimidates,
251,252
 and 
thioimidates,
59
 have also been investigated. Deprotection of the phthaloyl group can be 
achieved with hydrazine hydrate in MeOH or EtOH,
197,253
 alcoholic methylamine,
199,254
 
ethylenediamine in BuOH or EtOH,
194,202,205,207,255,256
 ammonia in MeOH,
257
 sodium 
borohydride,
225,258
 hydrazine acetate,
259
 or hydroxylamine,
260
 forming a free amine.  
The strongly basic conditions described and the high temperature required to 
carry out the cleavage of N-phthaloyl moiety presents the biggest drawback of the 
phthalimido procedure in target synthesis. This excludes its application to the synthesis of 
a broad range of targets, including various families of glycopeptides and glycolipids 
where numerous base-sensitive groups such as esters and !-amino acid residues exist.
16
 
Thus, Fraser-Reid
261
 and Schmidt
262
 reasoned that the presence of electron-withdrawing 
groups on the aromatic ring would enable cleavage under less demanding conditions. It 
was pointed out, however, that the remote withdrawal of electron density should not 
inhibit neighboring group participation.
261
 This lead to the introduction of readily 
available tetrachlorophthalimido (TCP) derivatives as building blocks for aminosugar 
synthesis. Application of the 4,5-dichlorophthalimido moiety to glycoside and 
oligosaccharide synthesis has also been investigated.
263,264
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Scheme 2.13. 2-Deoxy-2-tetrachlorophthalimidoglucopyranosides. 
The TCP derivatives can be readily prepared using Lemieux’s classic procedure 
for the synthesis of 2-phthalimido derivatives.
183
 Thus, starting from precursor 39, the 
tetra-acetyl 2-tetrachlorophthalimido derivative 94 is obtained in 56% yield over three 
steps (Scheme 2.13).
16
 The precursor 94 can then be modified accordingly into potent 
glycosyl donors such as bromides,
50,265,266
 flourides,
264
 pentenyl ethers,
261,267-269
 
trichloroacetimidates,
262,270
 or thioglycosides.
271-273
 Herein, the synthesis and application 
of trichloroacetimidate 95 and O-pentenyl glycoside 99 synthesized via bromide 98, will 
be discussed. Thus, reaction of trichloroacetimidate 95 with glycosyl acceptor 96 in the 
presence of tin(II) triflate afforded trisaccharide 97 in 72% yield.
270
 Glycosylation of 
glycosyl acceptor 100 with O-pentenyl glycoside 99 lead to the corresponding 
disaccharide 101 in a yield of 64% (Scheme 2.13).
261
 
Among other applications, TCP glycosyl donors have been used for the synthesis 
of nodulation factors,
268
 Lipid A derivatives,
269
 saponins,
50
 mucin oligosaccharide 
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chains,
272
 and blood group antigens.
172
 Removal of the TCP group either by ethylene 
diamine,
261,262,267,269
 NaBH4 in isopropanol,
262
 followed by acetylation affords the 
corresponding N-acetyl derivative.  
As mentioned, the relatively harsh conditions required for the removal of the 
phthalimido moiety have limited its use for !-selective coupling.The high temperature 
and strongly basic conditions are incompatible with base-labile groups such as esters and 
"-amino acid residues. Hence, for glycopeptide synthesis, an orthogonal amine protecting 
group that can be easily removed is highly desirable. One such candidate was the N-
dithiasuccinoyl (Dts) function, which was found to be compatible with the Fmoc/Pfp 
protecting group strategy for the effective synthesis of glycopeptides and readily removed 
under mild conditions by thiolysis or other reductive methods.
274-276
 Originally developed 
by Barany and Merrifield,
274
 NDts derivatives had been heavily applied in peptide 
synthesis for many years before it was utilized as an orthogonally removable N-amino-
protecting group of D-glucosamine derivatives.
277
  
Following Barany and Merrifield’s approach,
274
 NDts derivatives can be prepared 
by treating ethoxythiocarbonyl intermediates with anhydrous chlorocarbonylsulfenyl 
chloride. To this end, the ethoxythiocarbonyl glucosamine intermediate 102 was obtained 
by treatment of 39 with S-carbomethyl O-ethyl dithiocarbonate in methanol
277
 or 
bis(ethoxythiocarbonyl) sulfide in aqueous ethanol,
278
 followed by per-acetylation with 
acetic anhydride in pyridine (Scheme 2.14). Upon condensation of the intermediate 102 
with (chlorocarbonyl)sulfenyl chloride, a rapid and clean cyclization occurs to form the 
N-dithiasuccinoyl derivative 103. The latter can then be transformed into a suitable 
glycosyl donor, such as the bromide 104
277,278
 or the trichloroacetimidate 105.
277,279
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Reaction of either glycosyl donor 104 or 105 with the threonine acceptor 106 in the 
presence of AgOTf afforded stereoselectively the !-glycoside 107 in 85 or 71% yield, 
respectively.
277,278
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Scheme 2.14. 2-Deoxy-2-Dithiasuccinoylglucopyranosides. 
 The Dts group can be removed by thiols through an open-chain carbamoyl 
disulfide intermediate,
16
 which reacts further to give the free amine. To date, N-Dts 
derivatives have been successfully transformed into the free amine using !-
mercaptoethanol (BME), N-methyl-mercaptoacetamide (MAc), and dithiothreitol 
(DTT).
277,278
 Moreover, addition of tertiary amines like N,N-diisopropylethylamine was 
also found to greatly accelerate the thiolytic cleavage of the Dts group. 
In 1998, Schmidt et al. introduced the use of N-dimethylmaleoyl (DMM) 
derivatives for the synthesis of 2-amino glycosides.
280
 Aside from its reported ease of 
introduction and cleavage under weakly aqueous basic then acidic conditions, the DMM 
moiety also provides anchimeric assistance to enforce ! linkage. More importantly, its 
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stability to acids and non-nucleophilic bases makes it compatible with a wide array of 
functional group interconversions.
281
 Furthermore, the cyclic DMM group is symmetric – 
a definite advantage for structural assignments by NMR.  
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Scheme 2.15. 2-Deoxy-2-N-dimethylmaleoylglucopyranosides. 
Adopting Lemieux’s classic procedure for the synthesis of 2-phthalimido 
derivatives,
183
 2-NDMM derivatives can be easily synthesized from glucosamine 
hydrochloride 39 in three steps, as shown in Scheme 2.15.
281
 The first step liberates the 
free amine while the next step forms the amide bond upon nucleophilic attack of the 
amine on the carbonyl of the anhydride. Acetylation by acetic anhydride in pyridine 
protects all the hydroxyls and cyclizes the amide into the dimethylmaleoyl moiety to 
afford the tetraacetyl 2-NDMM derivative 108. The anomeric acetate can then be readily 
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removed by treatment with hydrazine acetate to form the hemiacetal 109, which can be 
converted accordingly into glycosyl donors, i.e. fluorides, such as 110, iodides, and more 
commonly, trichloroacetimidates (111).
280,282,283
 
 Glycosyl donors bearing the 2-NDMM moiety have been applied to the synthesis 
of N-glycan derivatives,
282,284
 lacto-N-hexaose analogues,
285,286
 glycopeptides,
287,288
 
glucosamine-glycerophospholipids,
289
 and human milk
290
 oligosaccharides. For example, 
TMSOTf-promoted glycosidation of trichloroacetimidate 111 with glycosyl acceptor 112 
afforded chitodisaccharide 113 in 91% yield.
281
 The cleavage of the DMM moiety in 108 
is outlined in Scheme 2.15b.
281
 Thus, base hydrolysis leads to ring-opened intermediate 
A, which, in the presence of an acid, is in equilibrium with butenolide B. Protonation of 
the basic nitrogen atom of the amide acetal moiety leads to generation of DMMA and the 
amine hydrochloride 51, which can then be transformed into the 2-acetamido derivative 
by N-acetylation.  
Boons and co-workers developed the 2,5-dimethylpyrrole group, which was 
found to be compatible with many reaction conditions employed in carbohydrate 
chemistry.
280
 It was installed by the reaction of D-glucosamine 39 with 2,5-hexanedione 
in the presence of Et3N in methanol to afford the intermediate 114, which was then 
conventionally converted into the trichloroacetimidate derivative 115 (Scheme 2.16). 
Glycosylation of the acceptor 116 with glycosyl donor 115 in the presence of TMSOTf 
was entirely stereoselective affording the disaccharide 117 in 78% yield. Since the 
dimethylpyrrole moiety is not capable of anchimeric assistance, the high 1,2-trans 
diastereoselectivity of this glycosylation was attributed to a hindered access to the bottom 
face of the ring resulting from its steric bulk. It was also demonstrated that the 
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dimethylpyrrole moiety in 117 can be converted into the natural 2’-acetamido derivative 
118 by treatment with hydroxylamine followed by acetylation. Importantly, the 
dimethylpyrrole moiety was found to be stable toward conditions for the 2-phthalimido 
group removal. 
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Scheme 2.16. 2-Deoxy-2,5-dimethylpyroleglucopyranosides. 
 
In summary, it should be noted that the discovery of new methods and strategies 
for stereoselective glycoside synthesis and convergent oligosaccharide assembly is 
critical for the area of glycosciences. However, as evident from above, a universal 
approach for the synthesis 2-amino-2-deoxy sugars has not yet been developed despite 
recent progress in the field. While a variety of excellent participating moieties are 
available for the synthesis of 1,2-trans glycosides, the N-phthaloyl moiety is arguably the 
most commonly employed. However, in recent years, new excellent participating groups 
(especially NTroc) that can be removed under mild reaction conditions have been rapidly 
emerging. Amongst the amides, the trifluoroacetyl moiety (TFA) also looks promising. 
Indeed, these compounds deliver excellent properties to the glycosyl donor, yet 
cumbersomeness of their preparation often results in lengthy synthetic sequences. In 
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addition, it should be noted that virtually all leaving groups that have been employed in 
glycosidations with neutral sugars have also been employed in the synthesis of the 
glycosides of 2-amino-2-deoxy sugars. Amongst these leaving groups, the 
trichloroacetimidoyl, alkyl/arylthio, acetyl, or halogeno moieties are the most commonly 
used. While anomeric halides or acetates offer the most reliable glycosyl donors for the 
preparation of glycosides of simple alcohols, there is arguably a lack of an efficient, 
universal method for the synthesis of complex oligosaccharides. Moreover, we noticed 
that in contrast to the enormous effort expended on the development of suitable amine 
protecting groups, the development of potent glycosylating agents of 2-amino-2-doxy 
sugars have been sorely neglected.  
2.5. Chemoselective Synthesis of Oligosaccharides of 2-Deoxy-2-Aminosugars 
In response to the observations above, we decided to initiate studies on improving 
current methods for the introduction of 2-deoxy-2-N-substituted-!-D-glucopyranosyl 
residues into complex oligosaccharides. We assumed that this goal could be achieved by 
applying novel thioimidoyl glycosidation methodology, the development of which has 
been the primary focus of our research program. Amongst thioimidates investigated, our 
laboratory has already reported that 1-S-benzoxazolyl (SBox) derivatives make excellent 
glycosyl donors due to their accessibility, stability, and high stereoselectivity and yields 
in glycosylations achieved under mild activation conditions.
291,292
 However, application 
of this particular methodology to 2-amino-2-deoxy glycosides is yet to be explored. 
Indeed, the difference in valencies between oxygen and nitrogen precludes the 
interchangeability of glycosidation methods between neutral sugars and aminosugars. 
Details from our recently published report are reported herein.
59
 Furthermore, while the 
Bongat, Aileen, 2008, UMSL, p. 115 
 
  
majority of oligosaccharides  are synthesized in an expeditious selective or 
chemoselective fashion
293
 nowadays, persistent attempts to apply these methods to 2-
aminosugars have yet to emerge. As a result, the ultimate goal of our study was to 
develop an efficient strategy for the synthesis of oligosaccharides containing multiple 
sequential residues of 2-amino-2-deoxysugars. It is our belief that the discovery outlined 
hereafter provides the first essential step towards this meritorious aim.  
With these intentions in mind, we employed acetate precursors containing an N-
protecting group from each class surveyed above – trifluoroacetamide (TFA) from the 
amides, trichloroethoxycarbamoyl (Troc) from the carbamates, and pthalimido (Phth) 
from the imide – and subsequently, synthesized four novel N-substituted SBox glycosides 
119-122 (Table 2.1). It should be noted that the 2-acetamido donor 122 was mainly 
intended for comparative studies. As reported previously, there are two methods by 
which the SBox glycosides are synthesized.
291,292
 The first involves reaction between the 
glycosyl acetates and 2-mercaptobenzoxazole (HSBox) in the presence of a Lewis acid. 
The second method involves conversion of the acetate precursor into a glycosyl halide 
followed by nucleophilic displacement of the halide with 2-benzoxazolethione potassium 
salt (KSBox) in the presence of 18-crown-6.   
Thus, 2-pthalimido tetra-acetate precursor 82 (Scheme 2.12)
183,184
 can be 
transformed into the SBox glycoside 119 either by the reaction between 82 and HSBox or 
by conversion of 82 into the corresponding bromide 83a
183
 followed by displacement of 
the bromide using KSBox. The latter was accomplished in 82% yield and complete 
anomeric !-stereoselectivity (entry 1, Table 2.1). The former, on the other hand, can be 
accomplished with a variety of Lewis acids. The best method, however, was the reaction 
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between 82 and HSBox in the presence of BF3·Et2O which gave the ! anomer of 119 in 
85% yield (entry 2, Table 2.1).  
Table 2.1. Synthesis of 2-amino-2-deoxy SBox glycosides. 
Entry Starting Material Conditions Yield 
Stereo-
selectivity 
Product 
1 
HBr/HOAc, 
CH2Cl2, 1h then 
KSBox,18C-6, 
Acetone, 16h 
82% ! only 
2 
HSBox, BF3·Et2O, 
3ÅMS, DCM, 16 h 
85% ! only 
3 
HSBox, AlCl3, 
3ÅMS, DCM, 1.5h 
95% 1:10 ":! 
4 
HSBox, ZrCl4, 
3ÅMS, DCM, 16h 
75% 1:16 ":! 
5 
OAcO
AcO
NPhth
OAc
82
OAc
 
HSBox, TMSOTf, 
3ÅMS, DCM, 1.5h 
85% 1:8 ":! 
OAcO
AcO
NPhth
OAc
119
S
N
O
 
6 
OAcO
AcO
NHTroc
OAc
71
OAc
 
HBr/HOAc, DCM, 
1.5h then KSBox, 
18C-6, Acetone, 
1.5h 
73% ! only 
OAcO
AcO
NHTroc
OAc
120
S
N
O
 
7 
OAcO
AcO
NHTFA
OAc
52
OAc
 
DCMME, ZnCl2, 
CHCl3, 1h then 
KSBox, 18C-6, 
Acetone, 1h 
71% ! only 
OAcO
AcO
NHTFA
OAc
121
S
N
O
 
8 
OAcO
AcO
NHAc
OAc
118
OAc
 
TiCl4, CHCl3, 1h, rt 
then KSBox, 18C-
6, Acetone, 1h 
78% ! only 
OAcO
AcO
NHAc
OAc
122
S
N
O
 
 
 The 2-Troc precursor 71 (Scheme 2.10)
65,115
 was converted to SBox glycoside 
120 via bromide 72
115
 followed by nucleophilic displacement of the bromine using 
KSBox (entry 6, Table 2.1). The nucleophilic displacement step was accomplished in 1.5 
hours and gave 120 in 73% yield and complete !-selectivity. Despite reports stating that 
71 can be transformed into a thioglycoside via reaction between 71 and a thiol in the 
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presence of a Lewis acid,
65
 we found that this method of less efficiency in our particular 
case. Likewise, we found that transformation of 52 (Scheme 2.7)
42,43
 into SBox glycoside 
122 was best accomplished using the same two-step route. To this end, 52 was converted 
to the corresponding chloride 56 using an adapted method from a published procedure by 
Pavliak and Kovac.
294
 Nucleophilic displacement of the chlorine using KSBox gave 122 
in 71% yield and complete !-selectivity. Finally, commercially available 2-acetamido-2-
deoxy-1,3,4,6-tetra-O-acetyl-!-D-glucopyranose 118 was first transformed into the 
corresponding chloride using an adapted method from a published procedure by Hesek et 
al.
295
 Again, the nucleophilic displacement of the chlorine using KSBox in the presence 
of 18-crown-6 gave 122 in 78 % yield and complete !- selectivity. 
Having obtained SBox glycosides 119-122, which were found to be stable 
crystalline or amorphous solids, we turned our attention to investigating their glycosyl 
donor properties in reactions with common glycosyl acceptors 58, 116, 123, and 124.
296-
298
 Based on previous reports from our group, SBox derivatives of neutral sugars can be 
activated with mildly electrophilic promoters such as silver trifluoromethanesulfonate 
(AgOTf), methyl trifluoromethanesulfonate (MeOTf), copper trifluoromethanesulfonate 
(Cu(OTf)2), or the combination of N-iodosuccinimide and trifluoromethanesulfonic acid 
(NIS/TfOH).
292,299
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Table 2.2. MeOTf-promoted synthesis of 1,2-trans-linked disaccharides 125-128.  
Entry Acceptor Donor Product 
Reaction 
time 
Reaction 
yield 
1 119 2 h 92% 
2 120 15 min 92% 
3 
OBnO
BnO
HO
OMe
OBn
123  
121 
125 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
OBnO
BnO
O
OMe
OBn
OAcO
AcO
R
AcO
 1.5 h 80% 
4 119 1h 87% 
5 120 1h 88% 
6 
OBnO
HO
BnO
OMe
OBn
58  
121 
OBnO
O
BnO
OMe
OBn
OAcO
AcO
R
OAc
126 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA  
1h 84% 
7 119 30 min 84% 
8 120 15 min 89% 
9 
OHO
BnO
BnO
OMe
OBn
124  
121 
127 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
       d: R=NHAc
OO
BnO
BnO
OMe
OBn
OAcO
AcO
R
OAc
 3 h 78% 
10 119 2 h 92% 
11 120 15 min 88% 
12 121 1h 89% 
13 
OBnO
BnO
BnO
OMe
OH
116  
122 
OBnO
BnO
BnO
OMe
O
OAcO
AcO
R
OAc
128 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
       d: R=NHAc  
16 h
 
79%* 
* based on recovered acceptor. 
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Table 2.3. AgOTf-promoted synthesis of 1,2-trans-linked disaccharides 125-128.  
Entry Acceptor Donor Product 
Reaction 
time 
Reaction 
yield 
1 119 15 min 90% 
2 120 15 min 88% 
3 
OBnO
BnO
HO
OMe
OBn
123  
121 
125 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
OBnO
BnO
O
OMe
OBn
OAcO
AcO
R
AcO
 15 min 84% 
4 119 15 min 85% 
5 120 15 min 90% 
6 
OBnO
HO
BnO
OMe
OBn
58  
121 
OBnO
O
BnO
OMe
OBn
OAcO
AcO
R
OAc
126 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA  
15 min 89% 
7 119 15 min 86% 
8 120 15 min 88% 
9 
OHO
BnO
BnO
OMe
OBn
124  
121 
127 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
       d: R=NHAc
OO
BnO
BnO
OMe
OBn
OAcO
AcO
R
OAc
 45 min 86% 
10 119 15 min 90% 
11 120 15 min 91% 
12 121 15 min 93% 
13 
OBnO
BnO
BnO
OMe
OH
116  
122 
OBnO
BnO
BnO
OMe
O
OAcO
AcO
R
OAc
128 a: R=NPhth
       b: R=NHTroc
       c: R=NHTFA
       d: R=NHAc  
16 h
 
87%* 
* based on recovered acceptor. 
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In this instance, we found that glycosidations of 2-N-substituted SBox glycosides 
are best activated with either AgOTf or MeOTf.  The corresponding MeOTf-promoted 
and AgOTf-promoted glycosidations between glycosyl donors 119-122 and glycosyl 
acceptors 58, 116, 123, and 124 are summarized in Tables 2.2 and 2.3, respectively.  
As shown above, MeOTf-promoted glycosidations of glycosyl donors 119-121 
proceeded fairly quickly (30 minutes to 3 hours) and gave the corresponding 
disaccharides in high yields ranging from 78% to 92% (entry 1-12, Table 2.2). Moreover, 
in line with our expectations, the disaccharides were obtained with complete 1,2-trans 
selectivity. In contrast, glycosidation of 2-acetamido derivative 122 (entry 13, Table 2.2) 
was sluggish and incomplete even in prolonged experiments (16-48 h). As anticipated, 
the reaction was negatively affected by the formation 1,2-oxazoline intermediate which 
was relatively unreactive under the reaction conditions applied. 
On the other hand, the AgOTf-promoted glycosidations of glycosyl donors 119-
121 proceeded even faster than the analogous MeOTf-promoted reactions and were 
generally complete after 15 minutes. The corresponding disaccharides 125-128 were 
obtained in yields ranging from 84% to 93% and complete 1,2-trans selectivity (entry 1-
12, Table 2.3). Again, glycosidation of 2-acetamido derivative 122 was sluggish and 
incomplete even in prolonged experiments (16-48 h).  
At this point, it should be noted that while AgOTf – promoted glycosidations of 
119-121 were complete in less than 15 minutes, significantly different results have been 
recorded in MeOTf-promoted glycosylations. Accordingly, we observed that under 
essentially the same reaction conditions, glycosidation of 2-NPhth (119) and 2-NHTFA 
(121) typically required at least 1-2 h whereas NHTroc glycosyl donor (120) could be 
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glycosidated in a matter of minutes (<5-15 min). Thus, we anticipated that this 
observation could give rise to a complementary glycosylation approach for 
chemoselective glycosidation of 2-aminosugars similar to that discovered by Fraser-
Reid
300
 and explored by others
296,301,302
 for the neutral sugars.  
The chemoselective approach and its variations make use of only one class of 
leaving group for both the glycosyl donor and glycosyl acceptor. This leaving group is 
either activated (armed) or deactivated (disarmed), respectively, by the influence of the 
protecting groups. Thus, depending on the type of protecting groups installed in both 
reaction components, a direct coupling can be achieved wherein the armed glycosyl 
donor is chemoselectively activated over the disarmed derivative (bearing the same type 
of LG) in the presence of a mild promoter (Scheme 2.17). The disaccharide obtained can 
then be used for subsequent direct glycosylation in the presence of a more powerful 
promoter capable of activating the disarmed leaving group. In some applications, the 
same promoter used in step 1 could be used for step 2 provided that the reactions are 
performed at elevated temperatures. 
Chemoselective strategies have become valuable techniques for expeditious 
oligosaccharide synthesis. These strategies allow efficient oligosaccharide assembly 
without the necessity of performing additional synthetic steps between the glycosylation 
steps. The classic armed–disarmed approach, developed by Fraser-Reid, has created a 
solid basis for extensive studies and applications and all chemoselective strategies 
devised thus far are related to (or derived from) this elegant concept. The effect of 
protecting groups on leaving-group ability has been known for long time, but it was 
Fraser-Reid and co-workers who explored this phenomenon and developed it into a new 
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strategy for chemoselective oligosaccharide synthesis.
303,304
 This concept utilizes the fact 
that the protective groups present on the sugar molecule dictate its reactivity. It was 
discovered that armed glycosides, sugar molecules that are protected with an ether moiety 
at C-2, can be readily activated by mild promoters. On the other hand, disarmed 
glycosides that are protected by an ester group at C-2 require stronger promoters. This 
allows for direct coupling according to which a benzylated (electronically activated, 
armed) glycosyl donor is chemoselectively activated over the acylated (electronically 
deactivated, disarmed) derivative bearing the same type of LG in the presence of a mild 
promoter (Scheme 2.17).  
O
Mild activator
HO
Armed Disarmed
HO
Powerful activator
O
R1
LG:
!-
!!!
!+
O
R2
LG:
!+
?
!-
R1
O
R2
O
O
R1
O
R2
O
O
O
O
R1
O
R2
O
O O
O
(IDCP)
(NIS/TfOH)
A
A
Armed
Disarmed
R1 = OCH2Ph
R2 = OCOCH3
Disarmed
 
Scheme 2.17. Armed-disarmed approach. 
The key factor for the armed–disarmed activation to take place is the availability 
of a suitable promoter that differentiates between the armed and disarmed building 
blocks.  Consequently, we believe that the difference in reaction rates we observed during 
MeOTf- and AgOTf-promoted reactions of 2-amino-2-deoxy SBox glycosides makes 
these promoters suitable for the development of a chemoselective strategy for 
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aminosugars. Moreover, while a significant disparity in reaction rates between NPhth- 
and NHTroc-protected derivatives have been previously reported,
131,156
 no systematic 
studies have yet become available. The possibility of chemoselective activation of 
NTroc-protected donor over NPhth-protected acceptor for convergent oligosaccharide 
synthesis has only been used once by Baasov’s group in sequential one-pot 
oligosaccharide synthesis employing tolyl thioglycosides.
305
 Another relevant report 
explores the chemoselective activation of 2-NPhth-protected glycosyl donor over 2-azido 
acceptor. Unfortunately, only a modest yield of 31 % was achieved.
205
 
To explore this opportunity, we needed to transform glycosyl donor 119 into a 
suitable glycosyl acceptor. Thus, deacetylation of 119 under Zemplen conditions was 
completed in 4h and gave precursor 129a in essentially quantitative yields (Scheme 2.18). 
A sequential tritylation-acetylation sequence was then performed on 129a to obtain 129b 
in quantitative yield. Finally, removal of the trityl protecting moiety on C-6 of 129b gave   
the glycosyl acceptor 130 in 62% yield after these three steps. We would like to note that 
the SBox moiety remained stable during the basic (deacetylation step) and acidic 
(detritylation step) conditions employed for the conversion of glycosyl donor 119 into 
glycosyl acceptor 130.   
Consequently, glycosyl acceptor 130 was then glycosylated with glycosyl donor 
120, as illustrated in Scheme 2.18. We determined that this coupling is best accomplished 
at reduced temperature (5ºC); under these reaction conditions, the disaccharide 131 was 
obtained in complete !-stereoselectivity and a high yield of 82%. Finally, to reiterate the 
potency of SBox 2-aminoglycosides as glycosyl donors, subsequent AgOTf-promoted 
glycosidation of disaccharide 131 with glycosyl acceptor 125 at room temperature gave 
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trisaccharide 132 in 73% yield, also with complete !"selectivity. In a similar fashion, we 
believe that based on the significant difference in the glycosylation rates, 2-TFA or 2-
acetamido-protected glycosyl acceptors could also be glycosidated with NTroc glycosyl 
donor 120. 
OAcO
AcO
NPhth
OH
S
N
O
OAcO
AcO
NPhth
O
OAcO
AcO
TrocHN
OAc
O
OBnO
BnO
BnO
OMe
OAcO
AcO
PhthN
O
OAcO
AcO
TrocHN
OAc
130
S
N
O
131
132
OAcO
AcO
NHTroc
OAc
S
N
O
120
OAcO
AcO
NPhth
OAc
S
N
O
119
0.1 N NaOCH3 in CH3OH
4h, rt, quantitative
OHO
HO
NPhth
OH
S
N
O
129a
Trityl chloride, DMAP,
pyridine, 55°C, 24 h,
then Ac2O, 1h, quantitative
OAcO
AcO
NPhth
OTr
S
N
O
129b
TFA, wet CH2Cl2,
2h, rt, 62% yield
OBnO
BnO
BnO
OMe
OH
125
MeOTF,
82% yield
AgOTf,
73% yield
 
Scheme 2.18. SBox glycosides of aminosugars in chemoselective strategies. 
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2.6. Summary and Conclusions 
In summary, we investigated the application of the SBox glycosyl donors to the 
stereoselective and high yielding synthesis of 1,2-trans glycosides of 2-amino-2-
deoxysugars. In addition, we discovered that 2-NTroc-protected SBox glycosides can be 
chemoselectively activated over 2-NPhth SBox glycosyl acceptor. This two-step 
sequential activation leads to the formation of trans-trans-linked oligosaccharides. It 
should be noted that our results differ significantly from Fraser-Reid’s classic armed-
disarmed approach that was developed for neutral sugars, according to which a cis 
linkage should be introduced first. It is to be expected that the strategy developed would 
significantly complement Baasov’s previously reported approach. Since the SBox 
glycosides can be selectively activated over the S-alkyl/aryl moiety, a longer 
oligosaccharide sequences could be obtained by the application of chemoselective and 
selective activation protocols. 
2.7. Experimental Section 
2.7.a. General 
Column chromatography was performed on silica gel 60 (EM Science, 70-230 
mesh), reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The 
compounds were detected by examination under UV light and by charring with 10% 
sulfuric acid in methanol. Solvents were removed under reduced pressure at < 40 
o
C. 
CH2Cl2, ClCH2CH2Cl, CH3CN, CHCl3, and toluene were distilled from CaH2 directly 
prior to application. Methanol was dried by refluxing with magnesium methoxide, 
distilled and stored under argon. Pyridine was dried by refluxing with CaH2 and then 
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distilled and stored over molecular sieves (3 Å). Acetone was dried by refluxing with 
K2CO3 and stored over 3 Å molecular sieves. Anhydrous DMF (EM Science) was used as 
is. Molecular sieves (3 Å), used for reactions, were crushed and activated in vacuo at 390 
°C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to 
application. AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in 
vacuo for 2-3 h directly prior to application. Optical rotations were measured at ‘Jasco P-
1020’ polarimeter. Unless noted otherwise, 1H-n.m.r. spectra were recorded in CDCl3 at 
300 MHz (Bruker Avance), 13C-NMR spectra and two-dimensional experiments were 
recorded in CDCl3 at 75 MHz (Bruker Avance) or at 125 MHz (Bruker ARX-500). 
HRMS determinations were made with the use of JEOL MStation (JMS-700) Mass 
Spectrometer. 
2.7.b. Preparation of the SBox Glycosides 
Method A. Typical procedure for the preparation from glycosyl halides: Crown 
ether (18-crown-6, 0.2 mmol) and salt (KSBox, 3.0 mmol) were added to a stirred 
solution of a glycosyl halide (1.0 mmol) in dry acetone (10 mL) under argon. The 
reaction mixture was stirred for 1-16 h at rt. Upon completion, the mixture was diluted 
with CH2Cl2 (30 mL) and washed with 1% aq. NaOH (15 mL) and water (3 x 10 mL). 
The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to afford the corresponding SBox glycoside. 
Method B. Typical procedure for the preparation from glycosyl acetates: The 
solution of a glycosyl acetate (0.128 mmol), 2-mercaptobenzoxazole (0.256 mmol) and 
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activated molecular sieves 3Å (100 mg) in CH2Cl2 (1.0 mL) was stirred under argon for 
30 min at rt. The Lewis acid (BF3OEt2, AlCl3, ZrCl4, or TMSOTf, 0.256 mmol) was then 
added dropwise and the reaction mixture was kept for 45 min at rt. After that, another 
portion of 2-mercaptobenzoxazole (0.256 mmol) and Lewis acid (0.256 mmol) were 
added and the reaction mixture was kept for 1.5-16 h at rt. Upon completion, the mixture 
was diluted with CH2Cl2 (10 mL), the solid was filtered-off and the residue was washed 
with CH2Cl2 (2 x 10 mL). The combined filtrate (30 mL) was washed with 1% aq. NaOH 
(15 mL) and water (3 x 10 mL). The organic layer was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate-hexane gradient elution) to afford the corresponding SBox glycoside. 
3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-!-D-glucopyranosyl chloride 
(56). This chlorination method was adopted and modified from a procedure previously 
reported by Pavliak and Kovac.
294
 To a mixture of 1,3,4,6-tetra-O-acetyl-2-deoxy-2-
trifluoroacetamido-"-D-glucopyranose (4.43 g, 10 mmol) and zinc chloride (~300 mg) in 
alcohol-free chloroform (15 mL) was added !,!-2,2-dichloromethyl methyl ether 
(DCMME, 15 mL). The mixture was stirred at 50ºC for an hour, wherein TLC showed 
complete conversion of the starting material into a faster moving product. After 
concentration of the mixture and co-evaporation with toluene, the residue was purified by 
column chromatography on silica gel (ethyl acetate – toluene gradient elution) to afford 4 
in white foam (3.74 g, 89 %). Rf = 0.53 (hexanes-ethyl acetate, 3/2, v/v); [!]D
25
 32.8º (c = 
1.0, CHCl3); 
1
H-n.m.r.: #, 2.04, 2.05, 2.10 (3s, 9H, COCH3), 4.14 (dd, 1H, J5,6a = 3.0 Hz, 
J6a,6b = 13.6 Hz, H-6a), 4.30-4.35 (m, 2H, H-5, 6b), 4.50-4.56 (m, 1H, H-2), 5.23 (dd, 1H, 
J4,5 = 9.7 Hz, H-4), 5.43 (dd, 1H, J3,4 = 10.1 Hz, H-3), 6.23 (d, 1H, J1,2 = 3.8 Hz, H-1), 
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7.07 (d, 1H, NH) ppm, 
13
C-n.m.r.: !, 20.54, 20.63, 20.82, 54.17, 61.17, 66.95, 69.97, 
71.22, 92.02, 115.57, 157.57, 169.32, 170.70, 171.71 ppm; HR-FAB MS [M+H]
+
 calcd 
for C14H18ClF3NO8 420.0673, found 420.0668.  
Benzoxazolyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-"-D-
glucopyranoside (119) obtained by Method B as an amorphous solid in 85% yield: Rf = 
0.53 (toluene-ethyl acetate, 3/2, v/v); [#]
D
25
 145.4o (c = 1.0, CHCl3); 
1H-n.m.r.: !, 1.89, 
2.06, 2.07 (3s, 9H, 3 x COCH3), 4.23-4.12 (m, 2H, J5,6b = 2.1 Hz, J6a,6b = 12.4 Hz, H-6b, 
H-5), 4.36 (dd, 1 H, J5,6a = 4.6 Hz, H-6a), 4.68 (dd, 1H, J2,3 = 10.5 Hz, H-2), 5.29 (dd, 1H, 
J4,5 = 9.7 Hz, H-4), 5.98 (dd, 1H, J3,4 = 9.6 Hz, H-3), 6.52 (d, 1H, J1,2 = 10.9 Hz, H-1), 
7.86-7.26 (m, 8H, aromatic) ppm, 13C-n.m.r.: !, 20.6, 20.8, 20.9, 53.6, 62.0, 68.6, 71.5, 
76.6, 77.4, 81.3, 110.3, 119.3, 124.1 (x 2), 124.7 (x 2), 129.2 (x 2), 131.6, 134.7, 141.8, 
152.1, 160.0, 169.7, 167.4, 170.2, 170.6 ppm; HR-FAB MS [M+H]+ calcd for 
C27H25N2O10S 569.1230, found 569.1219. 
Benzoxazolyl 3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-1-thio-
"-D-glucopyranoside (120) was obtained as a white amorphous solid in 73% yield. Rf = 
0.55 (toluene-ethyl acetate, 3/2, v/v); [#]
D
25
 19.3o (c = 1.0, CHCl3);  
1H-n.m.r.: !, 1.96, 
2.00, 2.01 (3s, 9H, 3 x COCH3), 3.86-3.91 (m, 1H, H-5), 4.05-4.12 (m, 2H, H-2, 6b), 4.22 
(dd, 1H, J5,6a = 4.8 Hz, J6a,6b = 12.5 Hz, H-6a), 4.63 (s, 2H, CH2CCl3), 5.12 (dd, 1H, J3,4 = 
9.7 Hz, H-4), 5.28 (dd, 1H, J2,3 = 9.8 Hz, H-3), 5.68 (d, 1H, J1,2 = 10.7 Hz, H-1), 5.69 (d, 
1H, NH), 7.20-7.53 (m, 4H, aromatic) ppm; 13C-n.m.r.: !, 20.8, 20.8, 20.9, 55.9, 62.0, 
68.2, 73.5, 74.7, 76.9, 84.8, 95.4, 110.4, 118.9, 124.8, 128.8, 141.5, 152.1, 154.5, 161.9, 
Bongat, Aileen, 2008, UMSL, p. 129 
 
  
169.6, 170.9, 171.1 ppm, HR-FAB MS [M+H]+ calcd for C22H24Cl3N2O10S 613.0217, 
found 613.0217. 
Benzoxazolyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-1-thio-!-D-
glucopyranoside (121) was obtained as an off-white amorphous solid in 70 % yield. Rf = 
0.51 (toluene-ethyl acetate, 1/1, v/v); ["]D
25
 21.3
o
 (c = 1.0, CHCl3);  
1
H-n.m.r.: #, 2.01, 
2.03, 2.09 (3s, 9H, 3 x COCH3), 3.95-4.00 (m, 1H, H-5), 4.15 (dd, 1H, J5,6b = 2.2 Hz, 
J6a,6b = 12.6 Hz, H-6b), 4.27 (dd, 1H, J5,6a = 4.9 Hz, H-6a), 4.50 (dd, 1H, J2,3 = 10.2 Hz, 
H-2), 5.19 (dd, 1H, J4,5 = 9.8 Hz, H-4), 5.46 (dd, 1H, J3,4 = 9.8 Hz, H-3), 5.76 (d, 1H, J1,2 
= 10.7 Hz, H-1), 7.21-7.56 (m, 4H, aromatic), 7.73 (d, 1H, NH) ppm,  
13
C-n.m.r.: #, 20.6, 
20.8, 20.9, 62.1, 68.0, 73.8, 77.2, 84.0, 110.6, 113.8, 117.6, 118.7, 125.0, 125.0, 141.2, 
152.2, 157.8, 161.8, 169.5, 170.9, 171.8 ppm, HR-FAB MS [M+H]
+
 calcd for 
C21H22F3N2 O9S 535.0998, found 535.1000. 
Benzoxazolyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-!-D-
glucopyranoside (122)  was obtained as a white crystalline solid in 70 % yield. Rf = 0.53 
(acetone-toluene, 1/1, v/v); ["]D
25
 4.3
o
 (c = 1.0, CHCl3);  
1
H-n.m.r.: #, 1.92, 2.02, 2.06, 
2.07 (4s, 12H, COCH3), 3.89-3.94 (m, 1H, H-5), 4.14 (dd, 1H, J5,6b = 2.2 Hz, J6a,6b = 12.6 
Hz, H-6b), 4.27 (dd, 1H, J5,6a = 4.8 Hz, H-6a), 4.45 (dd, 1H, J2,3 = 10.0 Hz, H-2), 5.19 
(dd, 1H, J4,5 = 9.6 Hz, H-4), 5.26 (dd, 1H, J3,4 = 9.7 Hz, H-3), 5.68 (d, 1H, J1,2 = 10.7 Hz, 
H-1), 6.02 (d, 1H, NH), 7.27-7.61 (m, 4H, aromatic) ppm,  
13
C-n.m.r.: #,  20.81, 20.88 (x 
2), 23.34, 53.56, 62.06, 68.05, 73.96, 77.43, 85.20, 110.46, 118.81, 124.74, 124.84, 
141.59, 152.14, 162.50, 169.44, 170.52, 170.88, 171.48 ppm, HR-FAB MS [M+H]
+
 calcd 
for C21H24N2 O9SNa 503.1100, found 503.1093. 
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Benzoxazolyl 3,4-di-O-acetyl-2-deoxy-2-phthalimido-1-thio-!-D-
glucopyranoside (130). To a suspension of the SBox glycoside 1 (0.57 g, 1.0 mmol) in 
methanol (10 mL) was added a 0.1 N solution of NaOCH3 in methanol to pH 7.5. The 
reaction mixture was kept for 4 h at rt, then Dowex (H
+
) was added until neutral pH. The 
resin was filtered off and washed with methanol (5 x 15 mL). The combined filtrate was 
concentrated in vacuo and dried. A crude residue containing benzoxazolyl 2-deoxy-2-
phthalimido-1-thio-!-D-glucopyranoside (44 mg, 1.0 mmol), was dissolved in dry 
pyridine (5 mL) and 4-Dimethylaminopyridine (0.24 g, 2 mmol) along with 
triphenylmethyl chloride (1.1 g, 4 mmol) was added. The reaction mixture was refluxed 
at 55
o
C for 24 h, then cooled to rt and acetic anhydride (0.95 mL, 10 mmol) was added. 
The reaction mixture was stirred at rt for 1 h and then quenched with methanol (10 mL). 
Volatile solvents were evaporated in vacuo, the residue was diluted with CH2Cl2 (100 
mL), and the organic layer was washed with water (20 mL), saturated aq. NaHCO3 (20 
mL), water (20 mL), 1M HCl (2 x 20 mL), and water (3 x 20 mL). The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The crude intermediate was 
then dissolved in CH2Cl2 containing trifluoroacetic acid, and water (1/94/5, v/v/v). The 
reaction mixture was kept for 2 h at rt, then diluted with CH2Cl2 (100 mL) and washed 
with water (20 mL), sat. NaHCO3 (20 mL), and water (3 x 20 mL). The organic phase 
was separated, dried over MgSO4, and concentrated in vacuo. The residue was purified 
by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to allow 
13 as an amorphous solid in 62% yield. Rf = 0.56 (toluene-ethyl acetate, 2/3, v/v); ["]D
25
 
43.0
o
 (c = 1.0, CHCl3);  
1
H-n.m.r.: #, 1.90, 2.10 (2s, 6H, 2 x COCH3), 3.68 (dd, 1H, J5,6a 
= 5.1 Hz, J6a,6b = 12.5 Hz, H-6a),  3.84 (dd, 1H, H-6b), 3.95-4.01 (m, 1H, H-5), 4.66 (dd, 
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1H, J2,3 = 10.5 Hz, H-2), 5.23 (dd, 1H, J4,5 = 9.7 Hz, H-4), 6.01 (dd, 1H, J3,4 = 10.0 Hz, 
H-3), 6.50 (d, 1H, J1,2 = 10.7 Hz, H-1), 7.26-7.86 (m, 8H, aromatic) ppm,  
13
C-n.m.r.: !, 
20.69, 20.93, 53.83, 61.71, 69.18, 71.47, 77.47, 79.18, 81.24, 110.35 (x 2), 119.46 (x 2), 
124.11 (x 4), 124.87 (x 2), 134.78 (x 2), 141.82, 152.10, 170.32, 170.37 ppm, HR-FAB 
MS [M+H]
+
 calcd for C25H23N2O9S 527.1124, found 527.1119. 
2.7.c. Preparation of the di- and trisaccharides 
Method A. Typical AgOTf-promoted glycosylation procedure (activation of the 
SBox glycosides): A mixture the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 
mmol), and freshly activated molecular sieves (3Å, 200 mg) in ClCH2CH2Cl (2 mL) was 
stirred under argon for 1.5 h. Freshly conditioned AgOTf (0.22 mmol) was added and the 
reaction mixture was stirred for 1-2 h at rt. The mixture was diluted with CH2Cl2, filtered 
to remove the solids, and the residue was washed with CH2Cl2. The combined filtrate (30 
mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3 x 10 mL). The organic 
phase was separated, dried over MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to afford a di- or an oligosaccharide derivative. 
Method B. Typical MeOTf-promoted glycosylation procedure (activation of SBox 
glycosides). A mixture the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), 
and freshly activated molecular sieves (3Å, 200 mg) in ClCH2CH2Cl (2 mL) was stirred 
for 2 h under argon. MeOTf (0.33 mmol) was added and the reaction mixture was stirred 
for 1-2 h at room temperature. Triethylamine (0.5 mL) was added to neutralize the 
reaction and the mixture was diluted with CH2Cl2 (30 mL), the solids were filtered off, 
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and the residue was washed with CH2Cl2. The combined filtrate was washed with water 
(4 x 10 mL) then the organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
hexane gradient elution) to yield the corresponding di- or oligosaccharide. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranosyl)-
(1"2)-2,4,6-tri-O-benzyl-#-D-glucopyranoside (126a) was obtained from 119 and 123 
as an amorphous solid in 92% yield. Rf = 0.50 (toluene-ethyl acetate, 3/2, v/v); [#]D
25
 
57.8º (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.74, 1.96, 2.05 (3s, 9H, 3 x COCH3), 3.33 (s, 3H, 
OCH3), 3.48-3.65 (m, 5H, H-2, 4, 5, 6a, 6b), 3.77 (dd, 1H, J3,4 = 9.3 Hz, H-3), 3.80-3.84 
(m, 1H, H-5’), 4.15-4.18 (m, 2H, H-6a’, 6b’), 4.30 (dd, 2H, 
2
J = 10.7 Hz, CH2Ph), 4.31 
(s, 2H, CH2Ph), 4.41-4.44 (m, 1H, H-2’), 4.46 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.94 (d, 
1H, J1,2 = 3.3 Hz, H-1), 5.08 (dd, 1H, J4,5 = 9.6 Hz, H-4’), 5.56 (d, 1H, J1’,2’ = 8.5 Hz, H-
1’), 5.66 (dd, 1H, J3’,4’ = 9.2 Hz, H-3’), 6.73-7.40 (m, 19H, aromatic) ppm,  
13
C-n.m.r.: $, 
20.6, 20.8, 21.0, 54.8, 56.3, 62.6, 68.5, 69.0, 70.1, 71.0, 72.2, 73.6, 74.8, 75.1, 77.8, 80.5, 
83.1, 99.3, 100.0, 123.5, 126.1 (x 2), 126.7, 127.7, 127.9, 128.0 (x 4), 128.1 (x 6), 128.3 
(x 2), 128.5 (x 2), 131.0, 134.2 (x 2), 138.1 (x 2), 138.7, 169.7, 170.3, 170.8 ppm, HR-
FAB MS [M+H]
+
 calcd for C48H51NO15Na 904.3156, found 904.3130. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-!-D-
glucopyranosyl)-(1"2)-3,4,6-tri-O-benzyl-#-D-glucopyranoside (126b) was obtained 
from 120 and 123 as an amorphous solid in 92% yield. Rf = 0.49 (toluene-ethyl acetate, 
3/2, v/v); [#]D
25
 43.3° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.90, 1.94, 2.01 (3s, 9H, 3 x 
COCH3), 3.32 (s, 3H, OCH3), 3.56-3.70 (m, 7H, H-2, 2’, 4, 5, 5’, 6a, 6b), 3.89 (dd, 1H, 
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J3,4 = 9.3 Hz, H-3), 4.07-4.16 (m, 2H, H-6a’, 6b’), 4.24 (dd, 2H, 
2
J = 12.2 Hz, CH2CCl3), 
4.49 (dd, 2H, 
2
J = 12.1 Hz, CH2Ph), 4.50 (dd, 2H, 
2
J = 10.8 Hz, CH2Ph), 4.71-4.79 (m, 
4H, H-1’, NH, CH2Ph), 4.85 (d, 1H, J1,2 = 3.6 Hz, H-1), 4.94 (dd, 1H, J4’,5’ = 9.7 Hz, H-
4’), 5.14 (dd, 1H, J3’,4’ = 9.9 Hz, H-3’), 6.95-7.29 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: !, 
20.8 (x 2), 21.0, 29.9, 55.4, 56.5, 62.4, 68.5, 68.9, 70.2, 72.1 (x 2), 73.7, 75.2, 75.3, 77.4, 
78.2, 81.3, 81.4, 95.5, 99.5, 101.9, 127.1, 127.8, 127.9, 128.0, 128.1 (x 4), 128.5 (x 2), 
128.6 (x 2), 128.7 (x 2), 138.1, 138.2, 139.1, 154.0, 169.7, 170.5, 170.8 ppm, HR-FAB 
MS [M+H]
+
 calcd for C43H50Cl3NO15Na 948.2144, found 948.2172. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-"-D-
glucopyranosyl)-(1#2)-3,4,6-tri-O-benzyl-$-D-glucopyranoside (126c) was obtained 
from 121 and 123 as an amorphous solid in 84% yield. Rf = 0.45 (toluene-ethyl acetate, 
1/1, v/v); [$]D
25
 8.6º (c = 1.0, CHCl3);  
1
H-n.m.r.: !, 1.95, 2.02, 2.08 (3s, 9H, 3 x COCH3), 
3.37 (s, 3H, OCH3), 3.60-3.75 (m, 6H, H-2, 4, 5, 5’, 6a, 6b), 3.93 (dd, 1H, J3,4 = 9.2 Hz, 
H-3), 4.06 (dd, 1H, J2’,3’ = 8.8 Hz, H-2’), 4.14-4.24 (m, 2H, H-6a’, 6b’), 4.52 (dd, 2H, 
2
J 
= 10.6 Hz, CH2Ph), 4.54 (dd, 2H, 
2
J = 11.7 Hz, CH2Ph), 4.74 (dd, 2H, 
2
J = 10.6 Hz, 
CH2Ph), 4.88 (d, 1H, J1’,2’ = 7.9 Hz, H-1’), 4.90 (d, 1H, J1,2 = 3.2 Hz, H-1), 5.06 (dd, 1H, 
J4’,5’ = 9.6 Hz, H-4’), 5.20 (dd, 1H, J3’,4’ = 9.9 Hz, H-3’), 6.33 (d, 1H, NH), 6.98-7.32 (m, 
15H, aromatic) ppm,  
13
C-n.m.r.: !, 20.5, 20.8, 21.0, 55.2, 55.4, 62.2, 68.5, 70.1, 72.1, 
72.3, 73.7, 75.1, 75.2, 77.4, 78.3, 81.0 (x 2), 99.5, 101.2, 113.6, 117.4, 127.0 (x 2), 127.7, 
127.9, 128.1 (x 2), 128.5 (x 4), 128.6 (x 2), 128.7 (x 2), 138.0, 138.1, 138.7, 157.4, 169.5, 
170.8, 171.0 ppm, HR-FAB MS [M+H]
+
 calcd for C42H48F3NO14Na 870.2925, found 
870.2911. 
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Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranosyl)-
(1"3)-2,4,6-tri-O-benzyl-#-D-glucopyranoside (127a) was obtained from 119 and 58 
as a colorless syrup in 87% yield. Rf = 0.55 (toluene-ethyl acetate, 3/2, v/v); [#]D
25
 +2.0º 
(c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.88, 1.98, 2.02 (3s, 9H, 3 x COCH3), 3.07 (s, 3H, 
OCH3), 3.19 (dd, 1H, J2,3 = 9.6 Hz, H-2), 3.45-3.60 (m, 4H, H-4, 5, 6a, 6b), 3.76-3.86 (m, 
1H, H-5’), 4.02 (dd, 1H, J5’,6a’ = 1.8 Hz, J6a’,6b’ = 12.2 Hz, H-6a’), 4.09 (d, 1H, J1,2 = 3.6 
Hz, H-1), 4.25-4.39 (m, 3H, H-2, 3, 6b’), 4.22 (dd, 2H, 
2
J = 12.6 Hz, CH2Ph), 4.43 (dd, 
2H, 
2
J = 12.3 Hz, CH2Ph), 4.71 (dd, 2H, 
2
J = 10.9 Hz, CH2Ph), 5.19 (dd, 1H, J4’,5’ = 9.6 
Hz, H-4’), 5.81 (d, 1H, J1’,2’ = 8.4 Hz, H-1’), 5.97 (dd, 1H, J3’,4’ = 9.1 Hz, H-3’), 7.05-
7.85 (m, 19H, aromatic) ppm,  
13
C-n.m.r.: $, 20.6, 20.9 (x 2), 55.0, 55.5, 62.1, 68.6, 69.3, 
69.6, 70.7, 71.5, 73.6, 74.1, 74.8, 76.0, 78.4, 81.0, 97.7, 98.2, 123.7, 127.6, 127.9, 128.1 
(x 4), 128.2, 128.3 (x 2), 128.4 (x 4), 128.5 (x 4), 128.6 (x 2), 131.7, 134.5, 138.0, 138.4, 
138.9, 167.7, 169.8, 170.3, 170.9 ppm, HR-FAB MS [M+H]
+
 calcd for C48H51NO15Na 
904.3156, found 904.3193. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-!-D-
glucopyranosyl)-(1"3)-2,4,6-tri-O-benzyl-#-D-glucopyranoside (127b) was obtained 
from 120 and 58 as a colorless syrup in 90% yield. Rf = 0.52 (toluene-ethyl acetate, 3/2, 
v/v); [#]D
25
 +9.1° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.89, 1.91, 1.93 (3s, 9H, 3 x COCH3), 
3.24 (s, 3H, OCH3), 3.46-3.65 (m, 6H, H-2, 5, 5’, 6a, 6b, 6b’), 3.76 (dd, 1H, J2’,3’ = 9.7 
Hz, H-2’), 3.93 (dd, 1H, J3,4 = 12.3 Hz, H-3), 4.12-4.20 (m, 2H, H-4, 6a’), 4.46 (dd, 2H, 
2
J = 12.1 Hz, CH2Ph), 4.59 (d, 2H, CH2CCl3), 4.61 (dd, 2H, 
2
J = 10.6 Hz, CH2Ph), 4.61 – 
4.78 (m, 4H, H-1, 1’, 3’, NH), 4.74 (dd, 2H, 
2
J = 8.6 Hz, CH2Ph),  4.98 (dd, 1H, J4’5’ = 
9.6 Hz, H-4’), 7.10-7.37 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: $, 20.8 (x 2), 20.9, 55.3, 
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56.6, 62.3, 68.6, 70.0, 71.9, 72.9, 73.2, 73.8, 74.9, 75.1, 75.5, 77.5, 80.1, 81.5, 95.8, 97.2, 
101.7, 127.8, 128.0, 128.2 (x 2), 128.4 (x 6), 128.6 (x 2), 128.8 (x 2), 129.2, 137.8, 138.1, 
138.7, 154.6, 169.6, 170.7, 171.0 ppm, HR-FAB MS [M+H]
+
 calcd for C43H50Cl3NO15Na 
948.2144, found 948.2186. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-!-D-
glucopyranosyl)-(1"3)-2,4,6-tri-O-benzyl-#-D-glucopyranoside (127c) was obtained 
from 3 and 7 as a colorless syrup in 89% yield. Rf = 0.46 (ethyl acetate-hexane, 3/2, v/v); 
[#]D
25
 14.3° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.91, 1.92, 1.96 (3s, 9H, 9 x COCH3), 3.20 (s, 
3H, 3 x OCH3), 3.41-3.61 (m, 6H, H-2, 5’, 6a, 6a’, 6b, 6b’), 3.96 (dd, 1H, J5,6a = 2.1 Hz, 
J6a,6b = 12.3 Hz, H-6a), 4.10 (dd, 1H, J2’,3’ = 9.2 Hz, H-2’), 4.18 (dd, 1H, J3,4 = 9.1 Hz, H-
3), 4.20 (dd, 1H, H-6a’), 4.44 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.53 (s, 2H, CH2Ph), 4.57 
(d, 1H, J1,2 = 3.4 Hz, H-1), 4.60 (dd, 2H, 
2
J = 11.0 Hz, CH2Ph), 4.90 (dd, 1H, J3’,4’ = 10.6 
Hz, H-3’), 4.95 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 5.05 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 6.09 (d, 
1H, NH), 7.10-7.38 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: $, 20.77, 21.00, 21.05, 55.19, 
55.42, 62.31, 68.42, 68.68, 70.19, 72.32, 72.66, 72.85, 73.96, 75.30, 75.73, 77.65, 79.95, 
81.53, 97.38, 101.10, 127.77 (x 2), 127.99, 128.17, 128.42 (x 2), 128.54 (x 2), 128.56 (x 
2), 128.83 (x 2), 128.86, 129.30 (x 2), 138.06, 138.25, 138.86, 157.67, 169.70, 171.14, 
171.32 ppm, HR-FAB MS [M+H]
+
 calcd for C42H48F3NO14Na 870.2925, found 
870.2941. 
 Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranosyl)-
(1"4)-2,3,6-tri-O-benzyl-#-D-glucopyranoside (128a) was obtained from 119 and 124 
as an amorphous solid in 86% yield. Rf = 0.56 (toluene-ethyl acetate, 3/2, v/v); [#]D
25
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11.3º (c = 1.0, CHCl3);  
1
H-n.m.r.: !, 1.84, 2.00 (x 2) (3s, 9H, 3 x COCH3), 3.28 (s, 3H, 
OCH3), 3.34-3.39 (m, 1H, H-5’), 3.45-3.50 (m, 3H, H-2, 6a, 6b), 3.55-3.60 (m, 1H, H-5), 
3.82 (dd, 1H, J5’,6b’ = 2.0 Hz, J6a’,6b’ = 10.5 Hz, H-6b’), 3.90 (dd, 1H, J3,4 = 9.1 Hz, H-4), 
4.00 (dd, 1H, J4,5 = 9.30 Hz, H-3), 4.10 (dd, 1H, J5’,6a’ = 3.7 Hz, H-6a’), 4.28 (dd, 1H, 
J2’,3’ = 8.4 Hz, H-2’), 4.36 (s, 2H, CH2Ph), 4.52 (d, 1H, J1,2 = 3.6 Hz, H-1), 4.64 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.98 (dd, 2H, 
2
J = 11.8 Hz, CH2Ph), 5.13 (dd, 1H, J4’,5’ = 9.6 Hz, 
H-4’), 5.65 (d, 1H, J1’,2’ = 8.4 Hz, H-1’), 5.71 (dd, 1H, J3’,4’ = 9.2 Hz, H-3’), 7.26-7.82 
(m, 19H, aromatic) ppm,  
13
C-n.m.r.: !, 20.6, 20.8, 20.9, 55.4, 55.5, 61.7, 68.4, 68.8, 69.5, 
71.0, 71.8, 73.0, 73.6, 74.8, 75.7, 77.4, 79.6, 80.4, 97.5, 98.3, 123.8, 127.0 ( x 2), 127.3, 
127.5 x2), 127.6, 128.0, 128.2 (x 2), 128.4 (x 8), 128.5 (x 2), 131.6, 134.5, 138.4, 138.5, 
139.7, 169.6, 170.4, 170.9 ppm, HR-FAB MS [M+H]
+
 calcd for C48H51NO15Na 
904.3156, found 904.3141. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-"-D-
glucopyranosyl)-(1#4)-2,3,6-tri-O-benzyl-$-D-glucopyranoside (128b) was obtained 
from 120 and 124 as an amorphous solid in 89% yield. Rf = 0.55 (toluene-ethyl acetate, 
3/2, v/v); [$]D
25
 -26.3° (c = 1.0, CHCl3);  
1
H-n.m.r.: !, 1.93, 1.98, 2.02 (3s, 9H, 3 x 
COCH3), 3.35 (s, 3H, OCH3), 3.36-3.72 (m, 6H, H-2, 2’, 4, 5’, 6a, 6b’), 3.79-3.81 (m, 
4H, H-3, 5, 6b, CH2
a
CCl3), 4.11-4.23 (m, 2H, H-6a’, CH2
b
CCl3), 4.58 (d, 1H, J1,2 = 4.0 
Hz, H-1), 4.60 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.59 – 5.03 (m, 8H, H-1’, 3’, 4’, NH, 2 x 
CH2Ph), 7.14-7.54 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: !, 20.8 (x 3), 55.5, 56.4, 62.0, 
67.4, 68.82, 69.3, 71.4, 72.5, 73.7, 73.9, 74.6, 75.4, 77.4, 77.5, 78.8, 80.4, 95.8, 98.6, 
100.8, 127.3 (x 3), 128.0, 128.2 (x 2), 128.3 (x 2), 128.5 (x 2), 129.3 (x 2), 129.4, 129.7, 
Bongat, Aileen, 2008, UMSL, p. 137 
 
  
137.6, 138.4, 139.8, 154.0, 169.6, 170.5, 170.8 ppm, HR-FAB MS [M+H]
+
 calcd for 
C43H50Cl3NO15Na 948.2144, found 948.2167. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-!-D-
glucopyranosyl)-(1"4)-2,3,6-tri-O-benzyl-#-D-glucopyranoside (128c) was obtained 
from 121 and 124 as an amorphous solid in 86% yield. Rf = 0.48 (toluene-ethyl acetate, 
3/2, v/v); [#]D
25
 - 45.4° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.94, 1.99, 2.03 (3s, 9H, 3 x 
COCH3), 3.36 (s, 3H, OCH3), 3.36-3.39 (m, 1H, J5’,6a’ = 4.2 Hz, H-5’), 3.44-3.62 (m, 4H, 
H-2, 5, 6a, 6b), 3.81-3.93 (m, 4H, H-2’, 3, 4, 6b’), 4.14 (dd, 1H, J6a’,6b’ = 12.4 Hz, H-6a’), 
4.28 (d, 1H, J1’,2’ = 8.3 Hz, H-1’), 4.57 (d, 1H, J1,2 = 3.2 Hz, H-1), 4.59 (dd, 2H, 
2
J = 12.1 
Hz, CH2Ph), 4.65 (dd, 2H, 
2
J = 12.3 Hz, CH2Ph), 4.81 (dd, 1H, J3’,4’ = 9.9 Hz, H-3’), 4.86 
(dd, 2H, 
2
J = 10.9 Hz, CH2Ph), 4.99 (dd, 1H, J4’,5’ = 9.7 Hz, H-4’), 5.82 (d, 1H, NH), 7.25 
–7.49 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: $, 20.5, 20.7, 20.8, 55.1, 55.6, 61.9, 67.7, 
67.8, 68.2, 69.3, 71.6, 72.0, 72.2, 73.6, 73.9, 75.3, 77.4, 78.9, 80.0, 98.5, 99.6, 115.7, 
127.4 (x 3), 129.0, 128.3 (x 2), 128.5 (x 2), 129.1 (x 2), 129.3 (x 3), 137.5, 138.3, 139.6, 
157.2, 169.4, 170.8, 170.9 ppm, HR-FAB MS [M+H]
+
 calcd for C42H48F3NO14Na 
870.2925, found 870.2907. 
Methyl O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-!-D-glucopyranosyl)-
(1"4)-2,3,6-tri-O-benzyl-#-D-glucopyranoside (128d) was obtained from 122 and 124 
as an amorphous solid in 95% yield. Rf = 0.46 (ethyl acetate-hexane, 3/2, v/v); [#]D
25
 
14.3° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.91, 1.92, 1.96 (3s, 9H, 3 x COCH3), 3.20 (s, 3H, 3 
x OCH3), 3.41-3.61 (m, 6H, H-2, 4, 5, 5’, 6b, 6b’), 3.96 (dd, 1H, J5,6a = 2.1 Hz, J6a,6b = 
12.3 Hz, H-6a), 4.10 (dd, 1H, J2’,3’ = 9.2 Hz, H-2’), 4.18 (dd, 1H, J3,4 = 9.1 Hz, H-3), 4.20 
Bongat, Aileen, 2008, UMSL, p. 138 
 
  
(dd, 1H, H-6a’), 4.44 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.53 (s, 2H, CH2Ph), 4.57 (d, 1H, 
J1,2 = 3.4 Hz, H-1), 4.60 (dd, 2H, 
2
J = 11.0 Hz, CH2Ph), 4.90 (dd, 1H, J3’,4’ = 10.6 Hz, H-
3’), 4.95 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 5.05 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 6.09 (d, 1H, 
NH), 7.10-7.38 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: !, 20.77, 21.00, 21.05, 55.19, 55.42, 
62.31, 68.42, 68.68, 70.19, 72.32, 72.66, 72.85, 73.96, 75.30, 75.73, 77.65, 79.95, 81.53, 
97.38, 101.10, 127.77 (x 2), 127.99, 128.17, 128.42 (x 2), 128.54 (x 2), 128.56 (x 2), 
128.83 (x 2), 128.86, 129.30 (x 2), 138.06, 138.25, 138.86, 157.67, 169.70, 171.14, 
171.32 ppm, HR-FAB MS [M+H]
+
 calcd for C42H48F3NO14Na 870.2925, found 
870.2941. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-"-D-glucopyranosyl)-
(1#6)-2,3,4-tri-O-benzyl-$-D-glucopyranoside (129a) was obtained from 119 and 125 
as an amorphous solid in 92% yield. Rf = 0.53 (toluene-ethyl acetate, 3/2, v/v); [$]D
25
 
14.3
o
 (c = 1.0, CHCl3);  
1
H-n.m.r.: !, 1.82, 1.99, 2.05 (3s, 9H, 3 x COCH3), 3.13 (s, 3H, 
OCH3), 3.20 (dd, 1H, J4,5 = 8.9 Hz, H-4), 3.35 (dd, 1H, J2,3, = 9.7 Hz, H-2), 3.59-3.65 (m, 
2H, H-5, 6b), 3.80 (dd, 1H, J3,4 = 9.3 Hz, H-3), 3.81-3.86 (m, 1H, H-5’), 4.03-4.16 (m, 
3H, H-6a, 6b’, CH2
a
Ph),  4.26-4.40 (m, 4H, H-1, 2’, 6a’, CH2
b
Ph),  4.61 (dd, 2H, 
2
J = 
12.1 Hz, CH2Ph), 4.72 (dd, 2H, 
2
J = 10.8 Hz, CH2Ph), 5.14 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 
5.40 (d, 1H, J1’,2’ = 8.5 Hz, H-1’), 5.76 (dd, 1H, J3’,4’ = 9.1 Hz, H-3’), 6.97-7.51 (m, 19H, 
aromatic) ppm,  
13
C-n.m.r.: !, 20.6, 20.8, 20.9, 54.6, 55.1, 60.5, 62.2, 68.9, 69.1, 69.3, 
70.9, 72.1, 73.5, 74.9, 75.8, 77.7, 79.8, 82.0, 98.1, 98.5, 123.6 (x 2), 127.7, 127.8, 127.9 
(x 2), 128.1 (x 3), 128.2 (x 2), 128.5 (x 4), 128.6 (x 2), 131.8 (x 2), 134.3 (x 2), 137.9, 
138.2, 138.8, 167.8, 169.6, 170.3, 170.9 ppm, HR-FAB MS [M+H]
+
 calcd for 
C48H51NO15Na 904.3156, found 904.3157. 
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Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-!-D-
glucopyranosyl)-(1"6)-2,3,4-tri-O-benzyl-#-D-glucopyranoside (129b) was obtained 
from 120 and 125 as an amorphous solid in 91% yield. Rf = 0.46 (ethyl acetate-hexanes, 
3/2, v/v); [#]D
25
 22.89° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 1.93, 1.95, 1.97 (3s, 9H, 3 x 
COCH3), 3.29 (s, 3H, OCH3), 3.36-3.43 (m, 2H, H-2, 4), 3.51-3.69 (m, 4H, J5’,6a’ = 4.2 
Hz, H-2, 5, 5’, 6a), 3.91 (dd, 1H, J3,4 = 9.1 Hz, H-3), 3.98-4.06 (m, 2H, H-6b, 6b’), 4.15 
(dd, 1H, J6a’,6b’ = 12.1 Hz, H-6a’), 4.32 (d, 1H, J1’,2’ = 8.7 Hz, H-1’), 4.45 (s, 2H, 
CH2CCl3), 4.52 (d, 1H, J1,2 = 3.5 Hz, H-1), 4.65 (dd, 2H, 
2
J = 11.4 Hz, CH2Ph), 4.65 (dd, 
2H, 
2
J = 12.8 Hz, CH2Ph), 4.79 (d, 1H, NH), 4.82 (dd, 2H, 
2
J = 10.8 Hz), 4.95 (dd, 1H, 
J4’,5’ = 9.6 Hz, H-4’), 5.12 (dd, 1H, J3’,4’ = 9.4 Hz, H-3’), 7.19-7.30 (m, 15H, aromatic) 
ppm,  
13
C-n.m.r.: $, 20.8 (x 2), 20.9, 55.5, 56.2, 62.2, 68.2, 68.8, 69.7, 72.0, 72.1, 73.6, 
74.6, 74.7, 76.0, 77.4, 79.9, 82.3, 95.4, 98.3, 101.0, 127.9, 128.1 (x 2), 128.2 (x 4), 128.4 
(x 2), 128.6 (x 2), 128.7 (x 2), 128.8 (x 2), 138.2, 138.8, 138.9, 154.0, 169.6, 170.8, 170.9 
ppm, HR-FAB MS [M+H]
+
 calcd for C43H50Cl3NO15Na 950.2126, found 950.2116. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-!-D-
glucopyranosyl)-(1"6)-2,3,4-tri-O-benzyl-#-D-glucopyranoside (129c) was obtained 
from 121 and 125 as an amorphous solid in 93% yield. Rf = 0.48 (toluene-ethyl acetate, 
1/1, v/v); [#]D
25
 3.51° (c = 1.0, CHCl3);  
1
H-n.m.r.: $, 2.02, 2.04, 2.06 (3s, 9H, 3 x 
COCH3), 3.34 (s, 3H, OCH3), 3.35 (dd, 1H, J4,5 = 9.3 Hz, H-4), 3.49 (dd, 1H, J2,3 = 9.5 
Hz, H-2), 3.57 (dd, 1H, J5,6a = 5.1 Hz, J6a,6b = 10.5 Hz, H-6a), 3.63-3.68 (m, 1H, J5’,6a’ = 
4.3 Hz, H-5’), 3.74-3.79 (m, 1H, H-5), 3.99 (dd, 1H, J3,4 = 9.2 Hz, H-3), 3.97-4.16 (m, 
3H, H-2’, 6b, 6b’), 4.25 (dd, 1H, J6a’,6b’ = 12.2 Hz, H-6a’), 4.34 (d, 1H, J1’,2’ = 8.3 Hz, H-
1’), 4.44 (dd, 2H, 
2
J = 8.3 Hz, CH2Ph), 4.55 (d, 1H, J1,2 = 1.6 Hz, H-1), 4.70 (dd, 2H, 
2
J
 
= 
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12.1 Hz, CH2Ph), 4.71 (dd, 2H, 
2
J = 12.1 Hz, CH2Ph), 5.08 (dd, 1H, J4’,5’ = 9.5 Hz, H-4’), 
5.20 (dd, 1H, J3’4’ = 10.1 Hz, H-3’), 6.42 (d, 1H, NH), 7.25-7.39 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: !, 20.6, 20.8, 20.9, 54.9, 55.3, 68.4, 68.6, 69.5, 71.9, 72.2, 73.6, 74.7, 75.8, 
77.4, 80.1, 82.2, 98.1, 100.5, 127.8 (x 2), 128.0 (x 2), 128.1 (x 6), 128.4 (x 2), 128.6 (x 
2), 128.7 (x 4), 138.3, 138.5, 138.9, 169.5, 170.9, 171.3 ppm, HR-FAB MS [M+H]
+
 calcd 
for C42H48F3NO14Na 870.2925, found 870.2911. 
Methyl O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-"-D-glucopyranosyl)-
(1#6)-2,3,4-tri-O-benzyl-$-D-glucopyranoside (129d) was obtained from 122 and 125 
as an amorphous solid in 93% yield. Rf = 0.56 (acetone - toluene, 1/1, v/v); [$]D
25
 - 20.1° 
(c = 1.0, CHCl3);  
1
H-n.m.r.: !, 1.74, 1.94 (x 3) (4s, 12H, 3 x COCH3), 3.29 (s, 3H, 
OCH3), 3.40 (dd, 1H, J4,5 = 9.3 Hz, H-4), 3.44 (dd, 1H, J2,3 = 9.7 Hz, H-2), 3.58-3.82 (m, 
4H, H-2’, 5, 5’, 6b), 3.91 (dd, 1H, J3,4 = 9.2 Hz, H-3), 3.97-4.05 (m, 2H, H-6a, 6b’), 4.14 
(dd, 1H, J5’,6a’ = 4.9 Hz, J6a’,6b’ = 12.4 Hz, H-6a’), 4.52 (d, 1H, J1,2 = 3.0 Hz, H-1), 4.61 
(d, 1H, J1’,2’ = 8.1 Hz, H-1’), 4.63 (dd, 2H, 
2
J = 10.5 Hz, CH2Ph), 4.64 (dd, 2H, 
2
J = 12.2 
Hz, CH2Ph), 4.81 (dd, 2H, 
2
J = 10.8 Hz, CH2Ph), 4.97 (dd, 1H, J4’,5’ = 9.7 Hz, H-4’), 5.20 
(dd, 1H, J3’,4’ = 10.4 Hz, H-3’), 5.36 (d, 1H, NH), 7.18-7.29 (m, 15H, aromatic) ppm,  
13
C-n.m.r.: !, 20.80, 2.86 (x 3), 23.46, 54.85, 55.36, 62.34, 67.83, 68.81, 69.65, 72.03, 
72.45, 73.52, 74.77, 75.88, 77.57, 79.92, 82.17, 98.22, 100.73, 127.77, 127.92 (x 2), 
128.05, 128.11 (x 2), 128.32 (x 2), 128.55 (x 2), 128.63 (x 2), 128.67 (x 2), 138.27, 
138.48, 138.91, 169.55, 170.12, 170.86, 171.00 ppm, HR-FAB MS [M+H]
+
 calcd for 
C42H51NO14Na 816.3207, found 816.3209. 
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Benzoxazolyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-!-D-
glucopyranosyl)-(1"6)-3,4-di-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranoside 
(131) was obtained by Method B from 120 and 130 as an amorphous solid in 82% yield: 
Rf = 0.57 (toluene-ethyl acetate, 2/3, v/v); [#]D
25 61.2o (c = 1.0, CHCl3);  
1H-n.m.r.: $, 1.87, 
1.93, 1.96, 2.07, 2.09 (5s, 15H, 5 x COCH3), 3.54-3.61 (m, 1H, H-5’), 3.78-3.96 (m, 3H, 
H-2’, 6a, 6b), 4.07-4.26 (m, 3H, H-5, 6a’, 6b’), 4.54 (dd, 1H, J2,3 = 10.6 Hz, H-2), 4.79 
(d, 1H, J1’,2’ = 8.5 Hz, H-1’),  4.84-4.92 (m, 3H, H-3’, CH2CCl3), 4.97-5.10 (m, 2H, H-4, 
4’), 5.90 (dd, 1H, J3,4 = 9.7 Hz, H-3), 6.41 (d, 1H, J1,2 = 10.9 Hz, H-1), 6.84 (d, 1H, NH), 
7.26-7.88 (m, 8H, aromatic) ppm,  13C-n.m.r.: $, 20.59, 20.75, 20.79, 20.85, 20.98, 29.91, 
53.56, 55.90, 62.11, 67.93, 68.86, 69.02, 71.16, 72.04, 72.56, 74.77, 77.43, 79.75, 81.67, 
95.94, 101.71, 110.47 (x 2), 119.51 (x 2), 124.14 (x 2), 124.87, 125.28, 134.78, 141.29, 
151.98, 155.40, 160.84, 166.57, 169.64, 169.90, 170.09, 170.23, 170.95 ppm, HR-FAB 
MS [M+H]+ calcd for C40H40Cl3N3O18SNa 1012.0972, found 1012.0935. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-trichloroethoxycarbamoyl-!-D-
glucopyranosyl)-(1"6)-O-(3,4-di-O-acetyl-2-deoxy-2-phthalimido-!-D-
glucopyranosyl)-(1"6)-2,3,4-tri-O-benzyl-#-D-glucopyranoside (132) was obtained 
by Method A from 125 and 131 as an amorphous solid in 73% yield: Rf = 0.56 (toluene-
ethyl acetate, 2/3, v/v); [#]
D
25 7.3o (c = 1.0, CHCl3);  
1H-n.m.r.: $, 1.76, 1.94, 1.95, 1.97, 
2.03 (5s, 15H, 5 x COCH3), 3.18 (s, 3H, OCH3), 3.27 (dd, 1H, J4A,5A = 9.4 Hz, H-4A), 
3.36 (dd, 1H, J2A,3A = 9.6 Hz, H-2A), 3.55-3.82 (m, 7H, H-2C, 3A, 5A, 5B, 5C, 6B, 6C’), 
3.93 (dd, 1H, J5B,6B’ = 1.9 Hz, J6B,6B’ = 10.9 Hz, H-6B’), 4.00-4.10 (m, 3H, H-6A’, 6C, 
CH2
aPh), 4.20-4.36 (m, 3H, H-2B, 6A, CH2
bPh), 4.50-4.71 (m, 4H, H-1A, 1C, CH2CCl3), 
4.61 (d, 2H, 2J = 15.8 Hz, CH2Ph), 4.70 (dd, 2H, 
2
J = 10.9 Hz, CH2Ph), 4.93-5.02 (m, 2H, 
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H-4B, 4C), 5.10 (dd,1 H, J3C,4C = 9.9 Hz, H-3C), 5.38 (d, 1H, J1B,2B = 8.5 Hz, H-1B), 5.56 
(d, 1H, NH), 5.68 (dd, 1H, J3B,4B = 10.7 Hz, H-3B), 6.84-6.90 (m, 15H, aromatic)  ppm; 
13C-n.m.r.: !, 20.63, 20.83, 20.87, 20.92, 20.98, 29.92, 54.65, 55.30, 56.35, 62.14, 68.41, 
68.97, 69.37, 69.61, 69.78, 70.89, 72.06, 72.68, 73.17, 73.80, 74.84, 75.79, 77.44, 79.61, 
81.97, 95.72, 98.11, 98.51, 101.75, 123.71 (x 2), 127.71 (x 2), 127.83 (x 2), 127.89 (x 2), 
128.10 (x 3), 128.31 (x 2), 128.47 (x 2), 128.50 (x 3), 128.67 (x 2), 131.30, 134.35 (x 2), 
137.94, 138.33, 138.96, 154.55, 169.66, 170.02, 170.31, 170.71, 170.91 ppm; HR-FAB 
MS [M+H]+ calcd for C40H40Cl3N3O18SNa 1323.3098, found 1325.3164. 
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3.1. Introduction 
As mentioned in Chapter 1, disaccharide analogues usually provide more 
appreciable antagonism towards LPS due to their structural similarity with native Lipid 
A. To this end, various structure-activity studies have been performed on bacterial Lipid 
A and its derivatives.
1
 However, recent findings on the structure and binding site of the 
LPS receptors has led Jerala to propose that the structural motif of a possible LPS 
antagonist can be condensed to the arrangement of anionic groups and a large 
hydrophobic moiety.
2
 Apparently, this arrangement provides a more likely complement 
to the cationic residues and the large hydrophobic binding site of the LPS receptors.  
Since Lipid IVA – the biosynthetic precursor of E. coli Lipid A (16, see Chapter 
1) – is known to antagonize LPS, we built our targeted design for the disaccharide 
analogues on the relative structural simplicity of this molecule.
3-6
 To this end, we 
maintained the di-glucosamine !-(1!6)-linked disaccharide core and the four identical 
hydrophobic chains.  Moreover, since previous research showed a distinct ambivalence 
towards the type of hydrocarbon chain necessary for antagonistic activity,
7
 we decided to 
try all three types namely: the simple alkyl chain (26, Figure 4.1), the !-hydroxyacyl 
chain (24, Figure 4.1), and the acyl chain (25, Figure 4.1). We believe that these 
structures exhibit the hydrophobic character recommended by Jerala.
2
  
With the hydrophobic moiety in place, we turned our attention to finding a 
suitable anionic group to install on C-6’ of the disaccharide. Previous research by Fukase 
et al. introduced the novel idea of employing acidic amino acid on C-6 of their 
monosaccharide analogues.
8
 They reasoned that acidic amino acids provide a natural 
complement to the basic amino acid residues present in the binding sites of LPS 
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receptors. In our case, we believe that the tendency of amino acids to assume a 
zwitterionic character under physiological conditions converts acidic amino acids into a 
suitable anionic group. Thus, our targeted designs for the disaccharide analogues, 
mentioned earlier in Chapter 1, are reiterated below (Figure 4.1). 
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Figure 3.1. Targeted design for the disaccharide analogues. 
 
The first part of Chapter 2 mentions the retrosynthetic scheme for the synthesis of 
our disaccharide analogues. As illustrated below (Scheme 4.1), our plan is to synthesize 
the beta-(1!6)-linked disaccharide from a differently protected glycosyl donor and 
acceptor. Once the disaccharide is formed, it will be selectively deprotected and 
functionalized into our target compounds. To this end, we set out to synthesize various 
differently protected glycosyl donors and acceptors that would allow a more efficient 
construction of the disaccharide core. 
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Scheme 3.1. Retrosynthetic scheme the synthesis of Lipid A analogs. P = Protecting Group;     
PG = Participating Group; LG = Leaving Group; R = Alkyl Group 
3.2. Synthesis of the Differently Protected Glycosyl Donors 
 Aside from the 2-deoxy-2-N-substituted SBox glycosides we synthesized earlier 
(Chapter 2), we also decided to prepare other 2-deoxy-2-N-substituted SBox donors for 
comparison. These donors will feature the appropriate protecting group pattern necessary 
to reduce the number of linear steps involved in the construction of the disaccharide 
analogues. The synthesis of the glycosyl donors began with the conversion of tetra-
acetate precursor 82 into the corresponding thioglycoside 133. Thioglycosides are known 
to be stable towards a wide range of reaction conditions and more importantly, it can be 
easily hydrolyzed into the corresponding hemiacetal. Thus, the reaction between 82 and 
ethanethiol, in the presence of BF3·Et2O and CH2Cl2 under reflux,  gave 133 in 70% yield 
after 4 hours (Scheme 3.2).
9
 Deacetylation of 133 under Zemplen conditions followed by 
protection of the 4,6-diol in 134 as a benzylidene acetal gave 135 in 71 % yield. Our 
choice of protecting the C-4 and C-6 hydroxyls as a benzylidene acetal was a result of 
two main considerations – this protecting group can be easily deprotected under mildly 
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acidic conditions or opened regioselectively into a C-4 or C-6 hydroxyl. As illustrated in 
Scheme 3.2, conversion of 134 to 135 was accomplished using benzaldehyde dimethyl 
acetal and catalytic camphorsulfonic acid in acetonitrile. This procedure was adapted 
from a published account which used a different acid source and solvent (p-
tolueneseulfonic acid in DMF).
10
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Scheme 3.2. Synthesis of glycosyl donors. 
After a quantitative acetylation of the C-3 hydroxyl, the thioglycoside moiety in 
136 was converted into the more potent thioimidate moiety in two steps. The first step 
involved the conversion of the thioglycoside into a glycosyl bromide while the second 
consists of a nucleophilic displacement of the bromide 2-benzoxazolethione potassium 
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salt (KSBox) in the presence of 18-crown-6. Herein, we observed the formation of the N-
linked isomer 141a as the major product. Unfortunately for our purposes, this isomer is 
known to be unreactive during glycosidation reactions.
11
 Thus, the known thioglycoside 
136
12
 was converted into the S-benzoxazolyl glycoside 140a in 27% yield. 
As a result of our unsuccessful attempts discussed above, we decided to protect 
the 4,6-diol in 134 as a p-methoxybenzylidene acetal instead. Our decision was based on 
a well-accepted convention that benzylidene acetals deactivate the sugar ring towards 
substitution reactions.
13
 To this end, the reaction between 134 and p-anisaldehyde 
dimethyl acetal, in the presence of catalytic CSA and CH3CN, gave the known 
thioglycoside 137
14
 in 85% yield after 2 hours (see Scheme 3.2 above).  Following the 
acetylation of the C-3 hydroxyl in 137 as an acetate, the thioglycoside 139
15
 was 
converted into the corresponding thioimidate using the same reaction sequence described 
for 136. Unfortunately, we obtained an even lower yield of the corresponding S-
benzoxazolyl glycoside 140b (12% yield) that was forming alongside the unreactive N-
linked isomer 141b (27% yield).   
We would like to note, at this point, that our unsuccessful synthesis of glycosyl 
donors 140a and 140b has discouraged us to pursue it further. Consequently, simplified 
glycosyl donor 119 (see Table 2.1 in Chapter 2) was our donor of choice henceforth. 
3.3. Synthesis of the Differently Protected Glycosyl Acceptors 
 As illustrated in Scheme 3.1, we also needed a differently protected glycosyl 
acceptor to synthesize the !-(1!6)-linked disaccharide. Our initial considerations in 
designing the glycosyl acceptor included: 1) the C-2 and C-3 protecting group moieties 
on the glycosyl acceptor should be compatible with the C-2 and C-3 protecting groups on 
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the glycosyl donors in that we should be able simultaneously deprotect all four positions 
in one step;  2) the C-4 protecting group should remain stable throughout the subsequent 
steps but it should be  easily removable during the final, global deprotection step; and 
most importantly, 3) we should be able to chemoselectively activate the anomeric moiety 
on the glycosyl donor over the anomeric moiety on the glycosyl acceptor.  
 Thus, starting from precursor 139, cleavage of the p-methoxybenzylidene acetal 
using NaBH(OAc)3 and (CH3)3SiCl in CH3CN gave 69% of glycosyl acceptor 142 (see 
Scheme 3.3a).
14
 Our initial attempts to glycosylate this acceptor, however, were 
unsuccessful. We realized that the presence of trace amounts of NaBH(OAc)3 were 
negatively affecting the outcome of the glycosylation. After our repeated attempts to 
purify 142 by column chromatography proved futile, we decided to convert the C-6 
hydroxyl into a silyl ether. We reasoned that the difference in Rf between 142 and 143 
would give us a better chance of removing the impurities from the previous step. After 
removal of the silyl protecting group, the glycosyl acceptor 142 was obtained in a 
disappointing yield of 39%. This is very likely due to the marginal stability of p-
methoxybenzylidene acetals in the acidic medium. 
 At this point, we have also realized that the lithium aluminum hydride-aluminum 
chloride method to regioselectively open benzylidene acetals to a C-6 hydroxyl
16
 will 
lead to the undesired opening of the imide protecting group in 136. Since there are 
currently no reported methods to effect this transformation, we resolved to form the 4,6-
diol instead by simple acid hydrolysis of the benzylidene acetal in the presence of 
trifluoroacetic acid (TFA). Accordingly, acceptor 144
17
 was obtained from 136
12
 in 90% 
yield after 30 minutes (Scheme 3.3b).  
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Scheme 3.3 Synthesis of glycosyl acceptors. 
 We were still quite concerned, however, about the possible ramifications of 
leaving the C-4 hydroxyl unprotected during the subsequent steps. Obviously, the 
formation of unwanted products will make the elaboration of the disaccharide into our 
target compound too complicated. In order to address this dilemma, we decided to 
synthesize our acceptor via the levoglucosan route. Levoglucosan (or 1,6-
anhydroglucopyranoses) has enjoyed a long and interesting history in the preparation of 
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biologically important and structurally diverse natural products
18-25
 and modified
26-28
 
sugars.  Its [3.2.l] bicyclic framework has been known to elicit a remarkable range of 
stereo- and regioselectivities during transformations. Moreover, since the pyranose ring is 
locked in the 
l
C4 conformation, substituents adapt axial orientations as opposed to the 
equatorial orientations encountered with the conventional 
4
C1 counterparts. In addition to 
these topological properties, the presence of an internal acetal reduces the number of 
protecting groups that are required. Accordingly, we decided to take advantage of the 
attractive properties of this molecule for the synthesis of our glycosyl acceptor. 
   The synthesis began with the transformation of D-glucose 145 into levoglucosan 
146 in 28% yield (Scheme 3.3c). Thus, as described by Fraser-Reid et al.,
29
 the primary 
hydroxyl group of 145 was selectively tosylated under carefully controlled conditions. 
This was followed, in situ, by the intramolecular displacement of the C-6 tosylate by the 
anomeric hydroxyl group on treatment of the reaction mixture with aqueous sodium 
hydroxide. After 146 was obtained, the C-2 and C-4 hydroxyl was selectively tosylated 
using tosyl chloride in pyridine to give 147 in essentially quantitative yields.
30
 
Intramolecular displacement of the C-4 tosylate was then achieved by treatment of 147 
with sodium methoxide in methanol to form the 1,6:3,4-dianhydrogalactopyranose 148 in 
quantitative yields.
31
 Remarkably, this particular configuration allows selective 
introduction of a nucleophile onto C-4. Thus, selective opening of the 3,4-oxirane ring in 
148 with benzyl alcohol,  in the presence of BF3Et2O and toluene, was achieved after 
stirring overnight to give 149
31,32
 in 86% yield.   
To introduce the amino moiety, we decided to take advantage of the chemistry of 
Cerny epoxides.
33
 To this end, precursor 149 was quantitatively transformed into the 
Bongat, Aileen, 2008, UMSL, p. 172 
 
 
Cerny expoxide 150 via intramolecular displacement of the C-2 tosylate, in the presence 
of NaOCH3 in MeOH.
34,35 Selective opening of the 2,3-oxirane with sodium azide then 
proceeded smoothly to give 151 in 92% yield.36 After acetylation of the 151,37 the 1,6-
anhydride bond was then selectively opened using (CH3)3SiSPh and ZnI2 to give glycosyl 
acceptor 153 as a separable mixture of anomers.38  
3.4. Formation of the Disaccharide Core 
 With the glycosyl donors and acceptors in hand, we then proceeded to determine 
the best building blocks to construct our disaccharide core. Glycosidations with the 
glycosyl acceptors 142, 144, 153a, and 153b (Scheme 3.4) were all performed in the 
presence of AgOTf, and 3Å molecular sieves (MS) in dichloroethane (DCE) to afford the 
corresponding disaccharides with complete !-stereoselectivity. Glycosylations with 
glycosyl acceptors 153a and 153b proceeded much slower which, in connection with the 
low-yielding synthesis of these acceptors (mentioned earlier), made us abandon this 
route. The moderate yield achieved in glycosylation of 142 made us believe that the best 
glycosyl donor and glycosyl acceptor for our purposes were 119 and 144, respectively. 
The resulting disaccharide 157 was obtained in 93% yield. Moreover, it should be noted 
that the deactivating effect of the C-2 phthalimido moiety on C-4, along with the 
increased steric hindrance around the C-4 hydroxyl has allowed us to regioselectively 
form the !-(1!6) linked product, without any traces of the !-(1!4)-linked by-products.  
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Scheme 3.4. Glycosidation reactions with triacetate glycosyl donor 119. 
3.5. Synthesis of the (R)-3-Hydroxy Hexadecanoic Acid 
 In line with the synthetic effort towards preparing Lipid A analogues that possess 
minimal (if not completely absent) endotoxic properties and beneficial immunostimulant 
activities, several methods have been developed for the synthesis of (R)-3-hydroxy fatty 
acids. Indeed, synthesis of the latter has been achieved by both chemical
39-43
 and 
enzymatic
44-46
 means, giving a wide range of  truly practical methods for large scale 
preparations. Along with the progress in developing scalable methods to synthesize 3-
hydroxy fatty acid, various methods to determine the enantiomeric purity have also been 
developed to date. These include NMR analysis of Mosher MTPA ester derivatives
39,45
 
chiral NMR shift studies
42,43
 and HPLC Chiralpak® AS analysis
47
 of p-bromophenacyl 
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esters. Deriving from these methods, the synthesis of (R)-3-benzyloxyhexadecanoic acid 
164 is described below (see Scheme 3.2.).  
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Scheme 3.5. Synthesis of (R)-3-benzyloxyhexadecanoic acid. 
 The synthesis began with the acylation of commercially available Meldrum’s acid 
159 (2,2-dimethyl-1,3-dioxane-4,6-dione) with myristoyl chloride 158 by the Yonemitsu 
procedure.
48,49
 The crude myristylated Meldrum’s acid 160, formed in 75% yield in the 
presence of pyridine in CH2Cl2, was subjected to acetal removal followed by 
decarboxylation. This was accomplished in boiling methanol for 2 hours to afford the 
desired methyl 3-oxohexadecanoate 161
50
 in 70% yield.
42,48
 It should be noted that a 
simple filtration on a pad of silica gel was sufficient to purify compound 161 for the 
subsequent step. The introduction of the stereocenter at the !-carbon in enantiomerically 
pure form was then achieved via Noyori’s catalytic hydrogenation.
51
 Thus, following a 
procedure developed by Taber et al.,
52
 the asymmetric hydrogenation of 161 in methanol 
using catalytic dichloro[(R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl]ruthenium 
(II) or (RuCl2[(R)-BINAP]) gave methyl (R)-3-hydroxyhexadecanoate 162
50
 in 92% 
yield after 16 hours. This reduction was performed in the presence of 0.1 mol % HCl 
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using a standard Parr apparatus at 60 psig hydrogen, as described by King and co-
workers.
53
 Noyori’s asymmetric hydrogenation was particularly convenient since the 
BINAP-Ru(II) catalyst is commercially available in both enantiomeric forms, has very 
high catalytic efficiency, and gives products of predictable absolute configuration.
54
  
The enantiomeric excess of 162 was then identified by 
1
H NMR of the mixture in 
the presence of  tris[3-(heptafluoro-1-hydroxybutylidene]-(+)-camphoratoeuropium (III) 
[Eu(hfc)3] in CDCl3.
55,56
  The singlet around 3.61 ppm associated with C(O)CH3 was 
separated into two singlets – 3.88 and 3.92 ppm for the (R) and (S) forms, respectively –  
and made it possible to identify 6% of the (S) form.  Then, benzylation of the !-hydroxyl 
using benzyl 2,2,2-trichloroacetimidate in CH2Cl2, in the presence of catalytic 
trifluoromethanesulfonic acid, gave 163 in 93% yield.
38
 Finally, base hydrolysis of the 
methyl ester using 2M aqueous NaOH in tetrahydrofuran (THF)
57
 afforded (R)-3-
benzyloxyhexadecanoic acid 164
38
 in 81% yield, or 36 % overall yield from the starting 
material 158.  
3.6. Synthesis of the Disaccharide Template 
 After obtaining disaccharide 157, we then turned our attention to selectively 
functionalizing key positions (see Scheme 3.6). Thus, deacetylation of 157 in the 
presence of NaOCH3 in methanol gave 165 in quantitative yield after 2 hours. The 4,6-
diol in intermediate 165 was then selectively protected as a benzylidene acetal using 
benzaldehyde dimethyl acetal in the presence of CSA and CH3CN. Compound 166 was 
subsequently obtained in quantitative yield after 2 hours.  
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Scheme 3.6. Synthesis of the disaccharide template. 
 
Deprotection of the phthalimido moieties was then performed in the presence of ethylene 
diamine in butanol, and gave intermediate 167 in 86% yield. The (R)-3-hydroxy fatty 
acids were then installed simultaneously via a-chloroenamines and gave 168 in a 
disappointing yield of 13%. Finally, the disaccharide template 169 was obtained in 89% 
yield after stirring 168 in the presence of CF3COOH and wet CH2Cl2 for 30 mins. 
Unfortunately, our attempts to install the butoxycarbonyl-protected glutamic acid moiety 
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on C-6’ proved unsuccessful. Despite our best intentions, we were unable to synthesize 
our target disaccharide analogues. Regardless, our efforts toward this end are still 
ongoing. 
3.7. Summary and Conclusions 
 As shown above, we have revisited classic reactions in carbohydrate chemistry in 
our effort to optimize conditions for the synthesis of the disaccharide core. In particular, 
the levoglucosan route had shown the remarkable versatility of carbohydrate synthons. 
Based on the disappointing yields we obtained from the synthesis of glycosyl donors 161 
and 162, we have also proved the verity of our initial claim that the unique chemistry of 
aminosugars precludes any illusion that methods developed for neutral sugars will be 
equally effective for aminosugars. Thus, considering the prevalence of this motif in 
biologically important substrates, the necessity of improving the array of glycosylating 
agents for aminosugars is of particular importance.   
 
3.8. Experimental Section 
3.8.a. General (see Section 2.7, page 125) 
3.8.b. Preparation of the Glycosyl Donors 
Typical procedure for preparation of SBox glycosides from thioglycosides: The 
solution of the thioglycosides 136 and 139 (0.13 mmol) and activated molecular sieves 
3Å (70 mg) in CH2Cl2 (2 mL) was stirred under argon for 1 h. A freshly prepared 
solution of Br2 in CH2Cl2 (1.2 mL, 1/165, v/v) was then added and the reaction mixture 
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was kept for 5 min at rt. After that, CH2Cl2 was removed under reduced pressure at rt. 
The crude residue was then treated with KSBox (0.51 mmol) in dry acetonitrile (1 mL) 
under argon for 2 h at rt. Upon completion, the mixture was diluted with toluene, the 
solid was removed by filtration and the residue was washed with toluene. The combined 
filtrate (30 mL) was washed with 1% aq. NaOH (15 mL) and water (3x10 mL), the 
organic layer was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (acetone-toluene gradient elution) 
to afford the SBox glycosides 140a and 140b. 
Benzoxazolyl 3-O-acetyl-2-deoxy-4,6-O-benzylidene-2-phthalimido-1-thio-!-
D-glucopyranoside (140a) was obtained as an amorphous solid in 27% yield. Rf = 0.69 
(hexanes-ethyl acetate, 1/1, v/v); 
1
H-n.m.r.: ", 1.84 (s, 3H, CH3CO), 3.77 (dd 1H, J6a,6b = 
10.2 Hz, H-6a), 3.81 (dd, 1H, J4,5 = 9.4 Hz, H-4), 3.90-3.95 (m, 1H, H-5), 4.40 (dd, 1H, 
J5,6b = 4.9 Hz, J6a,6b = 10.5 Hz, H-6b), 4.58 (dd, 1H, J2,3 = 10.5 Hz, H-2), 5.50 (s, 1H, 
CHPh), 5.98 (dd, 1H, J3,4 = 9.4 Hz, H-3), 6.49  (d, 1H, J1,2 = 10.7 Hz, H-1), 7.17-7.78 (m, 
13H, aromatic) ppm, 
13
C-n.m.r.: ", 20.7, 54.2, 68.6, 70.5, 71.0, 79.0, 81.8, 102.0, 110.3, 
119.4, 124.0, 124.7, 124.8, 126.5, 126.6, 128.5, 129.2, 129.4, 129.9, 134.7, 137.0, 141.7, 
152.0, 159.9, 170.3 ppm; HR-FAB MS [M+H]
+
 calcd for C30H24N2O8SNa 595.1151, 
found 595.1149. 
Benzoxazolyl 3-O-acetyl-2-deoxy-4,6-O-p-methoxybenzylidene-2-
phthalimido-1-thio-!-D-glucopyranoside (140b) was obtained as an amorphous solid 
in 12% yield. 
1
H-n.m.r.: ", 2.25 (s, 3H, CH3CO), 3.65-3.79 (m, 5H, H-4, H-6a, OCH3), 
4.20 (dd, 1H, J5,6b = 4.9 Hz, J6a,6b = 10.4 Hz, H-6b), 4.30 (dd, 1H, J5,6a = 5.0 Hz, J4,5 = 9.7 
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Hz, H-5), 4.97 (dd, 1H, J2,3 = 11.5 Hz, H-2), 5.43 (s, 1H, PMPCH), 6.48 (dd, 1H, J3,4 = 
9.4 Hz, H-3), 6.59 (d, 1H, J1,2 = 5.7 Hz, H-1), 6.79 (d, 2H, J = 8.7 Hz, PMP), 7.03-7.77 
(m, 13H, aromatic), ppm. 
3.8.c. Preparation of Disaccharides 
Typical AgOTf-promoted glycosylation procedure (activation of the SBox 
glycosides): A mixture the glycosyl donor 119 (0.11 mmol), glycosyl acceptors 142, 144, 
153a, or 153b  (0.10 mmol), and freshly activated molecular sieves (3Å, 200 mg) in 
ClCH2CH2Cl (2 mL) was stirred under argon for 1.5 h. Freshly conditioned AgOTf (0.22 
mmol) was added and the reaction mixture was stirred for 1-2 h at rt. The mixture was 
diluted with CH2Cl2, filtered to remove the solids, and the residue was washed with 
CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL) and 
water (3 x 10 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to afford the disaccharide. 
Phenyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-!-D-glucopyranosyl)-
(1"6)-3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-1-thio-#-D-glucopyranoside (156) 
was obtained as an amorphous solid in 91% yield.  1H-n.m.r.: 2.01, 2.04, 2.17, 2.20 (s, 
12H, 4 x CH3CO), 3.61 (t, 1H, J4,5 = 9.5 Hz, H-4), 3.89-4.05 (m, 3H, H-2, H-5’, H-6a’), 
4.14 (dd, 1H, 3J5’,6b’ = 1.0 Hz, 
2
J6a’,6b’ = 10.8 Hz, H-6b’), 4.20 (d, 1H, 
2
J = 10.7 Hz, 
PhCH2
a), 4.27-4.33 (m, 1H, H-6a), 4.33 (d, 1H, 2J = 10.7 Hz, PhCH2
b), 4.40-4.49 (m, 2H, 
H-5, H-6b), 4.58 (dd, 1H, J2’,3’ = 10.5 Hz, H-2’), 5.31 (t, 1H, J4’,5’ = 9.6 Hz, H-4’), 5.36-
5.46 (m, 1H, H-3), 5.60 (d, 1H, J1’,2’ = 8.5 Hz, H-1’), 5.65 (d, 1H, J1,2 = 5.5 Hz, H-1), 
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5.95 (dd, 1H, J3’,4’ = 9.2 Hz, H-3’), 7.06-7.14 (m, 2H, aromatic), 7.27-7.49 (m, 6H, 
aromatic), 7.60 (dd, 2H, 
3
J = 1.4 Hz, 
3
J = 7.6 Hz, aromatic), 7.72-7.80 (m, 2H, aromatic), 
7.82-7.92 (m, 2H, aromatic) ppm,  
13
C-n.m.r.: !, 20.4, 20.58, 20.64, 20.7, 54.4, 62.0, 
62.1, 67.6, 69.0, 70.6, 72.1, 73.0, 74.3, 76.1, 86.9, 98.0, 123.5, 127.5, 127.6, 127.9, 128.2, 
128.3, 129.0, 129.1, 131.1, 131.8, 133.3, 134.3, 137.0, 167.6 (" 2), 169.3, 169.4, 170.1, 
170.6 ppm.  
Ethyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-#-D-glucopyranosyl)-
(1$6)-3-O-acetyl-2-deoxy-2-phthalimido-1-thio-#-D-glucopyranoside (157) was 
obtained as an amorphous solid in 93% yield.  
1
H-n.m.r.: !, 0.96 (t, 3H, 
3
J = 7.3 Hz, 
CH3CH2S), 1.75 (s, 3H, CH3CO), 1.78 (s, 3H, CH3CO), 1.95 (s, 3H, CH3CO), 2.04 (s, 
3H, CH3CO), 2.20-2.48 (m, 2H, CH3CH2S), 3.13 (d, 1H, 3J = 6.4 Hz, OH), 3.29-3.44 (m, 
1H, H-4), 3.63 - 3.77 (m, 2H, H-5, H-6a), 3.85 (m, 1H, H-5’), 4.04 (t, 1H, 
3
J2,3 = 10.4 Hz, 
H-2), 4.08-4.19 (m, 2H, H-6b, H-6a’), 4.22-4.35 (m, 2H, H-6b’, H-2’), 5.12 (dd, 1H, 
3
J4,5 
= 9.6 Hz, H-4’), 5.37 (d, 1H, 
3
J1,2 = 10.5 Hz, H-1), 5.46 (d, 1H, 
3
J1’,2’ = 8.5 Hz, H-1’), 
5.56 (dd, 1H, 
3
J3,4 = 9.5 Hz, H-3), 5.73 (dd, 1H, 
3
J3’,4’ = 9.9 Hz, H-3’), 7.62-7.80 (m, 8 H, 
aromatic) ppm,  
13
C-n.m.r.: !, 14, 20.2, 20.4, 20.4, 20.5 (x 4), 23.7, 53.5, 54.3, 61.6, 68.6, 
69.1, 69.9, 70.6, 71.7, 73.9, 78.7, 80.1, 98.2, 123.4, 130.8, 131.1, 131.2, 131.3, 134.0, 
134.1, 134.3, 167.1, 167.5 (x 2), 169.3, 169.9, 170.5, 170.9 (x 4) ppm.  
3.8.c. Preparation of Disaccharide Template 
Ethyl O-(4,6-benzylidene-2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-
benzyloxyhexadecanoyl]-2-deoxy)-(1$6)-3-O-acetyl-2-[(R)-3-benzyloxy-
hexadecan]amido-3-O-[(R)-3-benzyloxy-hexadecanoyl]-2-deoxy-1-thio-#-D-
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glucopyranoside (168). To a stirred solution of 164 (6.0 mmol) in CH2Cl2 (30 mL) was 
added oxalyl chloride (6.0 mmol) and the reaction was stirred at 0°C under Argon. 
Catalytic amounts of DMF (0.006 mmol) were then added and the reaction was allowed 
to warm up to room temperature. After a TLC of the reaction showed complete 
conversion of the carboxylic acid to a higher running spot, the reaction mixture was 
evaporated to dryness under reduced pressure. The crude residue was then redissolved in 
CH2Cl2 (ca. 15 mL) and added to a stirred solution of the sugar (1 mmol) and DMAP (1 
mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred for 16 hours, diluted with 
CH2Cl2 (30 mL), and washed with the following: 0.5 N aq. KHSO4 (2 x 20 mL), saturated 
aq. NaHCO3 (20 mL), and brine (20 mL). The organic phase was separated, dried with 
anhydrous MgSO4, and concentrated to dryness under reduced pressure. The residue was 
purified by column chromatography on silica gel (acetone - toluene gradient elution) to 
afford 168 as an amorphous solid in 13% yield. Rf = 0.38 (CH2Cl2-methanol, 9/1, v/v); 
1
H-n.m.r.: !, 0.76 - 0.87 (m, 12H, 4 ! CH3 lipid), 1.08-1.13 (m, 3H, CH3CH2S), 1.13-1.30 
(m, 88H, 44 ! CH2 lipid), 1.32-1.58 (m, 8H, 4 ! CH2CHOBn), 2.19-2.30 (m, 4H, 2 ! 
CH2CO), 2.31-2.45 (m, 2H, 2 ! CH2
a
CO), 2.50-2.63 (m, 4H, 2 ! CH2
b
CO, CH3CH2S), 
3.07-3.15 (m, 1H, H-5’), 3.29-3.36 (m, 2H, H-4’, H-5), 3.45-3.52 (m, 1H, H-6a’), 3.61-
3.74 (m, 6H, H-4, H-6a, 2 ! CHOBn, PhCH2), 3.78-3.90 (m, 3H, H-6b’, PhCH2), 3.91-
4.01 (m, 3H, H-2, H-2’, PhCH2
a
), 4.26 - 4.33 (m, 2H, H-6b, PhCH2
b
), 4.39-4.51 (m, 2H, 
PhCH2), 4.67 (dd, 1H, 
3
J3’,4’= 8.9 Hz, H-3’), 5.12 (dd, 1H, 
3
J3,4 = 10.0 Hz, H-3), 5.35 (s, 
1H, PhCH), 6.13 (d, 1H, 
3
J1’,2’ = 9.0 Hz, H-1’), 6.30 (d, 1H, 
3
J1,2 = 9.0 Hz, H-1), 7.14 - 
7.32 (m, 25H, aromatic) ppm, 
13
C-n.m.r.: !, 14.1 (x 4), 14.9, 22.7 (x 4), 23.2, 25.1, 29.3, 
29.7, 31.9, 33.9, 34.1, 34.4, 39.59, 39.62, 41.3, 41.5 (x 48), 51.8, 54.2, 66.5, 68.5, 69.0, 
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69.3, 69.7, 71.0, 71.7, 75.4, 75.7, 76.3 (x 14),  78.4, 78.6, 83.8, 101.3, 102.2, 126.0, 
127.4, 127.5, 127.6, 127.7, 127.8, 128.1, 128.2, 128.3, 128.37, 128.42, 128.5, 128.6, 
128.7, 128.79, 128.84, 128.9, 129.0, 136.7, 138.2, 138.3, 138.4, 138.6, 171.1, 171.4, 
171.7, 172.1 (x 4) ppm. HR-FAB MS [M+H]
+
 calcd for C113H176N2O16SNa 1872.2638, 
found 1872.2593. 
Ethyl O-(2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-benzyloxy-
hexadecanoyl]-2-deoxy)-(1!6)-3-O-acetyl-2-[(R)-3-benzyloxy-hexadecan]amido-3-
O-[(R)-3-benzyloxy-hexadecanoyl]-2-deoxy-1-thio-"-D-glucopyranoside (169). To a 
solution of 168 (1 mmol) in wet CH2Cl2 (10 mL CH2Cl2, 0.1 mL H2O) was added 
CF3COOH dropwise, simultaneously monitoring the reaction progress by TLC upon each 
addition. Once TLC showed complete conversion of the starting material (ca. after 30 
min), the reaction was diluted with CH2Cl2 (50 mL) and washed with the following: 
saturated aq. NaHCO3 (3 x 20 mL), brine (20 mL). The organic phase was separated, 
dried with anhydrous MgSO4, and concentrated to dryness under reduced pressure. The 
residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford 169 as an amorphous solid in 89% yield. Rf = 0.43 (CH2Cl2-methanol, 
9/1, v/v). 
1
H-n.m.r.: #, 0.76 - 0.87 (m, 12H, 4 ! CH3 lipid), 1.08-1.13 (m, 3H, CH3CH2S), 
1.13-1.30 (m, 88H, 44 ! CH2 lipid), 1.32-1.58 (m, 8H, 4 ! CH2CHOBn), 2.19-2.30 (m, 
4H, 2 ! CH2CO), 2.31-2.45 (m, 2H, 2 ! CH2
a
CO), 2.50-2.63 (m, 4H, 2 ! CH2
b
CO, 
CH3CH2S), 3.07-3.15 (m, 1H, H-5’), 3.29-3.36 (m, 2H, H-4’, H-5), 3.45-3.52 (m, 1H, H-
6a’), 3.61-3.74 (m, 6H, H-4, H-6a, 2 ! CHOBn, PhCH2), 3.78-3.90 (m, 3H, H-6b’, 
PhCH2), 3.91-4.01 (m, 3H, H-2, H-2’, PhCH2
a
), 4.26 - 4.33 (m, 2H, H-6b, PhCH2
b
), 4.39-
4.51 (m, 2H, PhCH2), 4.67 (dd, 1H, 
3
J3’,4’= 8.9 Hz, H-3’), 5.12 (dd, 1H, 
3
J3,4 = 10.0 Hz, 
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H-3), 5.35 (s, 1H, PhCH), 6.13 (d, 1H, 
3
J1’,2’ = 9.0 Hz, H-1’), 6.30 (d, 1H, 
3
J1,2 = 9.0 Hz, 
H-1), 7.14 - 7.32 (m, 25H, aromatic) ppm, 
13
C-n.m.r.: !, 14.1 (x 4), 14.9, 22.7 (x 4), 23.2, 
25.1, 29.3, 29.7, 31.9, 33.9, 34.1, 34.4, 39.59, 39.62, 41.3, 41.5 (x 48), 51.8, 54.2, 66.5, 
68.5, 69.0, 69.3, 69.7, 71.0, 71.7, 75.4, 75.7, 76.3 (x 14),  78.4, 78.6, 83.8, 101.3, 102.2, 
126.0, 127.4, 127.5, 127.6, 127.7, 127.8, 128.1, 128.2, 128.3, 128.37, 128.42, 128.5, 
128.6, 128.7, 128.79, 128.84, 128.9, 129.0, 136.7, 138.2, 138.3, 138.4, 138.6, 171.1, 
171.4, 171.7, 172.1 (x 4) ppm. HR-FAB MS [M+H]
+
 calcd for C106H172N2O16SNa 
1784.2325, found 1784.2288. 
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4.1. Introduction 
As mentioned in Chapter 1, the main goal of this dissertation is to design Lipid A 
analogues that will bind with high affinity to CD14.  Consequently, since there are scarce 
examples of Lipid A analogs that lack the disaccharide core yet still maintain potent 
antagonistic activity, we felt the necessity to focus our efforts toward designing potent 
monosaccharide antagonists.  
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Figure 4.1. Targeted design for monosaccharide Lipid A analogues. 
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Our first consideration in designing our monosaccharide targets was the 
observation by Peri
1
 and colleagues that compounds structurally unrelated to Lipid A can 
still exhibit potent antagonistic activity; for example, flavolipin and Vitamin D.
2,3
 
Following their findings, our natural course of action should have been to develop other 
glucose-derived ammonium species containing hydrophobic alkyl chains, in place of the 
natural ester- and amide-linked acyl chains. Instead, we found ourselves interested in 
pursuing a structural lead that: 1) preserves the native glucosamine residue and the ester- 
and amide-linked (R)-3-hydroxy fatty acid chains, 2) lacks any unstable phosphate 
residue, and 3) contains a cationic residue on C-6. Basically, we wanted to explore the 
ramifications of Peri’s idea on a structure that is analogous to Lipid X (1, see Figure 1.5 
in Chapter 1). In addition, Fukase et al.’s approach of utilizing amino acids to provide the 
cationic character also seems quite fitting to include in our design.
4,5
 Therefore, our goal 
is to synthesize compounds 27-32 (Figure 4.1) and evaluate these molecules for possible 
antagonism towards LPS-induced proinflammatory activity. 
As seen above, compounds 27-32 all contain a glucosamine residue and amide- 
(C-2) and ester-linked (C-3) (R)-3-hydroxy fatty acids. The basic difference between the 
analogs we designed is the type of amino acid installed on C-6. Target 27, which has a C-
6 hydroxyl is synthesized as a negative control – in essence, we expect that this 
compound will not induce nor antagonize an LPS-induced release of pro-inflammatory 
cytokines in vitro. Monosaccharide analogs 28-30, on the other hand, are designed to 
contain ester linked amino acid moieities namely Glycine, Alanine, and Serine, 
respectively. We expect that following the natural tendency of amino acids to adopt a 
zwitterionic form under physiological conditions, the free amine on these moieties will be 
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protonated (NH3
+
) and provide a cationic character to our analogs. Finally, for analogs 31 
and 32, we chose to install a proline moiety on C-6 since its heterocyclic motif closely 
resembles the C-6 moiety on Peri’s most promising monosaccharide antagonist. In 
contrast to Peri’s design, we reasoned that an ester-linked proline moiety will be more 
stable in the conditions required for the biological assays. Moreover, in order to observe 
the effect of a fully cationic character, we also decided to form an ammonium species by 
methylating proline as per Peri’s published procedure. To eliminate any intramolecular 
destabilization of the salt by proton exchange, the anomeric hydroxyl on analog 32 was 
protected as a methyl glycoside.  
4.2. Synthesis of the Differently Protected Glucosamine Core 
 In order to synthesize our monosaccharide analogs, we first needed to obtain a 
differently protected glucosamine building block. Henceforth referred to as the 
glucosamine core, this precursor should contain a protecting group pattern that will allow 
us to selectively deprotect and functionalize key positions of the molecule into the 
desired configuration. Consequently, the synthesis of the glucosamine core began with 
the conversion of 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-!,"-D-glucopyranose 
(82) into thioglycoside 133 (Scheme 3.1). As described earlier, deacetylation of 
thioglycoside 133 under Zemplen conditions, followed by protection of the 4,6-diol in 
134 as a benzylidene acetal gave 132 in 71 % yield.  
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Scheme 4.1. Synthesis of the glucosamine core. 
4.3. Derivatization of the Amino Acids 
 As mentioned earlier, our plan is to install amino acids on the C-6 hydroxyl of the 
glucosamine core anticipating that these moieties will provide the cationic character to 
our analogs. Since amino acids contain multiple functionalities, we needed to obtain 
derivatives where the carboxylic function is free and the rest of the functionalities are 
masked. To this end, we found that N-(benzyloxycarbonyl)glycine and N-
(benzyloxycarbonyl-L-alanine are commercially available. In contrast, N-(benzyloxy-
carbonyl)-(S)-proline 171 and 2-(benzyloxy-carbonyl-amino)-3-(benzyloxycarbonyloxy)-
propanoic acid 173 had to be synthesized. To this end, compound 171
6
 was synthesized 
from L-proline 170 by reaction with benzyl chloroformate in 2M aqueous sodium 
hydroxide at 0-5°C, in 96% yield (Scheme 4.2.).
7
 On the other hand, reaction of 
commercially available N-(benzyloxycarbonyl)-L-serine 172 with benzyl chloroformate, 
in pyridine at room temperature, gave compound 173 in 71% yield.
8
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Scheme 4.2. Derivatization of L-serine and L-proline. 
4.4. Synthesis of the 2,3-Lipidated Monosaccharide Template 
 The synthesis of the monosaccharide template, suitable for the introduction of 
amino acid residues, began with the removal of the phthalimido protecting group in 
compound 135. Thus, treatment of 135 with ethylene diamine in refluxing 1-butanol 
overnight gave intermediate 174 in 90% yield (see Scheme 4.3).
9
 Selective N-acylation of 
intermediate 174 with (R)-3-benzyloxy-hexadecanoic acid 164 was then achieved via 
dicyclohexylcarbodiimide (DCC)-mediated coupling, in the presence of 4-
dimethylaminopyridine (DMAP) in CH2Cl2.  
 Consequently, we found that the optimum formation of the “activated” ester, O-
acylisourea, can be achieved after leaving 164 to stir overnight in the presence of DCC 
and DMAP in CH2Cl2. Addition of a solution of 174 to this pre-activated reagent gave 
175 in 66% yield after 1 hour. It should be noted that our attempts to perform O- and N-
acylation in one step proved to be extremely inefficient. Thus, while N-acylation was 
achieved in 30 minutes to an hour, attempts to O-acylate by adding more reagents were 
extremely futile. 
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Scheme 4.3. Synthesis of monosaccharide template via DCC-mediated coupling.  
 
Between the weak reactivity of the C-3 hydroxyl of amino sugars and the 
competing rearrangement of O-acylisourea to the more stable N-acylurea, it became more 
effective to perform the reaction in two steps with chromatographic separation in 
between. Then, following the same overnight pre-activation procedure of 164, as 
established for the synthesis of 175, O-acylation of intermediate 175 gave 176 in 94% 
yield. Finally, the monosaccharide template 177, suitably configured for subsequent 
conjugation with amino acid building blocks, was obtained in 84% yield by treatment of 
176 with trifluoroacetic acid in wet CH2Cl2.   
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Scheme 4.4. Synthesis of monosaccharide template via acyl chloride. 
The inefficiency of performing N- and O-acylation simultaneously via DCC-
mediated coupling in the presence of DMAP, along with the inherent difficulty of 
separating the byproduct N,N'-dicyclohexylurea from the product, led us to explore other 
avenues by which the fatty acids can be more effectively installed. To this end, we found 
that in situ conversion of 164 into an acyl chloride provides a more efficient reaction 
intermediate with which to perform the N- and O-acylation concomitantly. Formation of 
the acyl chloride was quickly achieved by reacting 164 with oxalyl chloride, in the 
presence of catalytic DMF and CH2Cl2.
10
 After evaporating the excess reagent off, the 
acyl chloride was redissolved in CH2Cl2 and added to a solution of 174 and DMAP in 
CH2Cl2 to give 176 in 82% yield. Finally, the desired monosaccharide template 177 was 
obtained as described above in Scheme 4.4. 
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4.5. Synthesis of the Monosaccharide Amino Acid Conjugates 
 To provide a basis for comparison (anticipated negative control) and to determine 
any residual toxicity of the monosaccharide template, we conducted the synthesis of 
analogue 24. Thus hydrolysis of the thioglycoside
11
 in 177 was performed in the presence 
of NIS in wet CH2Cl2. This step was immediately followed by removal of the benzyl 
protecting groups via catalytic hydrogenolysis in the presence of Pd(OH)2 on charcoal 
(Pearlman's catalyst),
12
 to give 27 in 70% yield over two steps (Scheme 4.5a).  
On the other hand, attempts to install the amino acid moiety on C-6 of 177 via 
DCC-mediated coupling were ineffective in our hands. Instead, we found that 
commercially available N-(benzyloxy-carbonyl)glycine can be converted to an acyl 
chloride by reacting the corresponding carboxylic acid with 1-chloro-N,N,2-trimethyl-1-
propen-1-amine
13
 using a procedure described by Schmidt et al.
14
 The solution of the 
amino acid chloride in THF was then added to a stirred solution of 177 and DMAP in 
THF and subsequently, compound 178 was formed in 85% yield after 1 hour (Scheme 
4.5b). While hydrolysis of the thioglycoside in 178 proceeded quantitatively in the 
presence of NIS and wet CH2Cl2, deprotection of the benzyloxycarbonyl (CBz) and 
benzyl protecting groups proved to be quite tricky. Thus, we found that after the CBz 
moiety has been removed, the resulting free amine poisons Pearlman’s catalyst and 
makes it very unreactive.
15,16
 This problem was solved by adding a fresh batch of  
catalyst and 0.1 mol % of AcOH.
15
 As a result, analogue 28 was obtained in 88% yield 
after stirring the reaction mixture under H2 for 2 days.   
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Scheme 4.5. Synthesis of monosaccharide analogues 27-29. 
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 Similarly, acylation of 177 with N-(benzyloxycarbonyl)-L-alanine was 
accomplished using 1-chloro-N,N,2-trimethyl-1-propen-1-amine
13
 to give 179 in 70% 
yield (Scheme 4.5). After performing the same thioglycoside hydrolysis and deprotection 
sequence described for analogue 28, the monosaccharide analogue 29 was obtained in 
80% yield.  
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Scheme 4.6. Synthesis of monosaccharide analogues 30 and 31. 
While the amino acid chloride method by Schmidt and colleagues
14
 has worked 
well in synthesis of 178 and 179,  it was practically ineffective in converting derivatives 
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171 and 173 (see Scheme 4.2) into the corresponding acid chloride. In this case, in situ 
formation of the !-chloroenamine via reaction of 171 or 173 with oxalyl chloride and 
catalytic DMF provided a more effective solution to this problem.
17
 After the 
corresponding acid chlorides of 171 and 173 were formed, the excess reagents were 
evaporated off and the crude residue was redissolved in CH2Cl2. These solutions were 
then added to a stirred solution 177 and DMAP in CH2Cl2 to give 181 and 180 in 61% 
and 67% yield, respectively (Scheme 4.6). Moreover, while hydrolysis of thioglycosides 
178, 179 and 181 took 16 hours to complete (NIS, wet CH2Cl2), the same reaction set-up 
with 180 was complete in 2 hours.   
With regards to the final step, the cleavage of the CBz and benzyl groups by 
catalytic hydrogenolysis, we found that the amino acid moiety in 180 is more acid labile 
than that of 178 and 179 and tends to hydrolyse in a slightly acidic medium.  Fortunately, 
the addition of water to the solvent mixture of MeOH:CH2Cl2 (1:1) proved to be effective 
in this case. Thus, catalytic hydrogenation with Pearlman’s catalyst was performed in a 
solvent mixture of MeOH:CH2Cl2:H2O (2:2:0.2) for 2 days to give 30 in 78% yield.
15
 
Similarly, since the proline moiety on 181 remains a secondary amine after CBz 
deprotection and is thereby not as poisonous to the catalyst, the hydrogenation conditions 
used the synthesis of 30 was also effective in the synthesis of analog 31 and gave the later 
in 65% yield.  
 At this point, since proline closely resembles the C-6 moiety on Peri’s most 
promising monosaccharide analog
1
 (see 12, Figure 1.6), we found ourselves interested in 
synthesizing the ammonium counterpart of 32. Subsequently, we realized that the close 
proximity of a hemiacetal to the ammonium moiety may be lead to the collapse of the salt 
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via proton exchange. Thus, following Peri’s lead, we decided to protect the anomeric 
hydroxyl as a methyl glycoside. The synthesis of compound 32 began with the three-step 
conversion of 82 to 182 in 99% yield (Scheme 4.7), as described by Kochetkov et al.
18
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Scheme 4.7. Synthesis of analogue 32. 
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Cleavage of the phthalimido group in 182 was then performed using ethylene diamine in 
butanol to give compound 183 in 92% yield.
9
 However, despite the in situ conversion of 
the fatty acid 164 to the corresponding acyl chloride, a two step acylation sequence also 
proved to be necessary in this case. Hence, as described earlier, fatty acid 164 was 
converted into an acyl chloride using oxalyl chloride and catalytic DMF and then added 
to a stirred solution of 183 and DMAP in CH2Cl2 to give 184 in 60% yield.
10
 After 
repeating the same acylation sequence on 184, bis-acylated compound 185 was obtained 
in 85% yield. Removal of the benzylidene acetal was accomplished through the slow 
addition of TFA to a stirred solution of 185 in wet CH2Cl2 to give 186 in 90% yield.  
 With compound 186 in hand, the proline moiety was installed as described for the 
synthesis of 181 (see Scheme 4.6) and gave 187 in 84% yield (Scheme 4.7). Following a 
the deprotection of the CBz and benzyl groups via catalytic hydrogenolysis, and reaction 
with methyl iodide in the presence of sodium carbonate, the ammonium analogue 32 was 
finally obtained in 60% yield.   
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4.6. Summary and Conclusions 
The compounds synthesized above represents an innovative approach to the 
targeted design of monosaccharide Lipid A analogues. Expanding on Peri’s hypothesis 
that a cationic moiety is responsible for the surprising anti-endotoxic activity of 12, we 
designed and synthesized analogs that possess the configuration of Lipid X and contain 
an amino acid moiety on C-6. We were convinced that the observed tendency of amino 
acids to adopt a charge at physiological pH will furnish the cationic character to our 
compounds. Moreover, should any of these compounds show antagonistic activity 
towards LPS-induced proinflammatory activity and be possibly considered as a drug 
candidate, clearance from the body after administration should not be an issue due to the 
fact that all of the components in our design are native to the human body. 
On the other hand, the syntheses described herein illustrate novel applications of 
well-established reactions. Thus, we showed the usefulness of the in situ conversion of 
carboxylic acids to acid chlorides – using oxalyl chloride or commercially available !-
chloroenamines – in esterification and amidation reactions involving sugar substrates. We 
have also demonstrated ways by which to circumvent problems associated with the 
presence of free amines during catalytic hydrogenolysis. Finally, we have provided an 
interesting insight on the determination of the enantiomeric purity of methyl (R)-3-
hydroxyhexadecanoate using chiral shift reagents. While the latter approach has been 
previously described, the relevant details are initially presented herein. 
The compounds synthesized herein are currently being evaluated for antagonistic 
activity by our collaborators.  
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4.7. Experimental Section 
4.7.a. General. See Section 2.7,  page 125. 
4.7.b. Preparation of the Amino Acid Derivatives 
2-(Benzyloxycarbonylamino)-3-(benzyloxycarbonyloxy)propanoic acid (173).  
The preparation of 173 was adapted from a published procedure by Ramesh and 
colleagues.
8
 Thus, N-benzyloxycarbonyl-L-serine (172, 1 mmol) was dissolved in freshly 
distilled CH2Cl2 (5 mL) and the solution was cooled to 0°C. After stirring for 5 minutes, 
pyridine (2.5 mmol, 0.2 mL) was added dropwise. The solution was allowed to stir for 
another 5 minutes and then 1.1 mmol of benzylchloroformate was added over a period of 
30 minutes. The reaction was allowed to warm up to room tempearature and stirred for 2 
hours. Once a TLC of the reaction mixture showed no changes between starting material 
and product ratios, the crude reaction mixture was diluted with CH2Cl2 (50 mL). The 
CH2Cl2 extract was then washed twice with citric acid solution (20 mL), once with water 
(20 mL) and finally with brine (20 mL). The organic phase was separated, dried over 
anhydrous MgSO4, and concentrated to dryness under reduced pressure. The crude 
residue was purified by column chromatography on silica gel (ethyl acetate – hexane 
gradient elution) to afford 173 as a colorless oil (0.27 g, 71 %). HR-FAB MS [M+H]
+
 
calcd for C18H19NO5Na 352.1163, found 352.1159.  
4.7.c. General Acylation Protocols 
 Method A. Typical procedure for DCC-mediated acylation: The carboxylic acid 
(4 mmol), 4-dimethylaminopyridine (4 mmol) and N,N'-Dicyclohexyl-Carbodiimide (4 
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mmol) was stirred in CH2Cl2 (10 mL) overnight under argon for 16h at room 
temperature. Subsequently, this reaction mixture was added to solution of the 
monosaccharide derivatives (1 mmol) in CH2Cl2 (10 mL). The resulting mixture was 
stirred under Argon for 1 hour at room temperature then diluted with CH2Cl2 (50 mL) 
and washed with the following: 5% aq. oxalic acid (2 x 20mL), saturated aq. NaHCO3 (2 
x 20mL), brine (20 mL).  The organic phase was separated, dried over anhydrous MgSO4, 
and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel (ethyl acetate - toluene gradient elution) to afford the 
acylated product.  
Method B. Typical procedure for acylation using oxalyl chloride: To a stirred 
solution of the carboxylic acid (2 mmol) in CH2Cl2 (10 mL) was added oxalyl chloride (2 
mmol) and the reaction mixture was stirred for 5 minutes at 0°C under Argon. A catalytic 
amount of DMF (0.002 mmol) was then added and the reaction was allowed to warm to rt 
and kept for an additional 55 minutes. The volatile components were then evaporated to 
dryness under reduced pressure. The crude residue was redissolved in CH2Cl2 (ca. 5 mL) 
and added to a stirred solution of the monosaccharide derivative (1 mmol) and DMAP (1 
mmol) in CH2Cl2 (10 mL). After stirring the reaction mixture under Argon for 1 hour, the 
reaction was diluted with CH2Cl2 (30 mL) and washed with the following: 0.5 N aq. 
KHSO4 (2 x 15 mL), saturated aq. NaHCO3 (15 mL), and brine (15 mL). The organic 
phase was separated, dried with anhydrous MgSO4, and concentrated to dryness. The 
residue was purified by column chromatography on silica gel (ethyl acetate - toluene 
gradient elution) to afford the acylated product. 
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 Method C. Typical procedure for acylation via !-chloroenamines: To a stirred 
solution of the amino acid (2 mmol) in CH2Cl2 (10 mL) was added 1-chloro-N,N,2-
trimethyl-1-propen-1-amine (2.2 mmol) and the reaction was stirred at 0°C under Argon 
for 30 minutes. The reaction was then warmed up to room temperature and added to a 
stirred solution of the monosaccharide derivative (1 mmol) and DMAP (1 mmol) in 
CH2Cl2 (10 mL). The resulting reaction mixture was stirred at rt for 1 hour, under Argon. 
After that, it was diluted with CH2Cl2 (30 mL) and washed with the following: 0.5 N aq. 
KHSO4 (2 x 15 mL), saturated aq. NaHCO3 (15 mL), and brine (15 mL). The organic 
phase was separated, dried with anhydrous MgSO4, and concentrated to dryness under 
reduced pressure. The residue was purified by column chromatography on silica gel 
(ethyl acetate - toluene gradient elution) to afford the amino acid ester.   
Ethyl 4,6-benzylidene-2-[(R)-3-benzyloxy-hexadecan]amido-2-deoxy-1-thio-
!-D-glucopyranoside (175) was obtained by Method A as an amorphous solid in 66% 
yield.  
1
H-n.m.r.: ",  0.80 (t, 3H, J = 6.4 Hz, CH3 lipid), 1.12 (t, 3H, J = 7.5 Hz, 
CH3CH2S), 1.17 (s, 12H, 11 ! CH2 lipid), 1.43-1.69 (m, 2H, CH2CHOBn), 2.37 (dd, 1H, 
3
J = 7.0 Hz, 
2
J = 15.3 Hz, CH2
a
CO), 2.43-2.60 (m, 3H, CH2
b
CO, CH3CH2S), 3.25-3.37 
(m, 1H, H-4), 3.47 (dd, 1H, J5,6a = 9.0 Hz, H-5), 3.60-3.82 (m, 3H, H-2, H-6a, CHOBn), 
4.23 (dd, 1H, J4,5 = 9.5 Hz, H-4), 4.32 (dd, 1H, J6a,6b = 9.6 Hz, H-6b), 4.46 (d, 1H, 
2
J = 
11.3 Hz, PhCH2
a
), 4.55 (d, 1H, 
2
J = 11.3 Hz, PhCH2
b
), 5.45 (s, 1H, PhCH), 6.69 (d, 1H, 
J1,2 = 6.6 Hz, H-1), 7.22- 7.32 (m, 8H, aromatic), 7.38-7.43 (m, 2H, aromatic) ppm, 
13
C-
n.m.r.: ", 14.1, 14.8, 22.7, 23.9, 24.9, 25.1, 25.6, 29.3, 29.5, 29.6, 29.6, 31.9, 33.5, 33.9, 
40.9, 49.1, 56.2, 68.5, 70.4, 71.1, 73.5, 81.4, 83.8, 101.8, 126.3, 127.6, 127.9, 128.2, 
128.6, 129.1, 137.0, 138.0, 172.7 ppm;  
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Ethyl 4,6-benzylidene-2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-
benzyloxy-hexadecanoyl]-2-deoxy-1-thio-!-D-glucopyranoside (146) was obtained as 
an amorphous solid from 175 by Method A in 94% yield and from 174 by Method B in 
82% yield. Rf = 0.35 (hexanes-ethyl acetate, 4/1, v/v); (c = 1.0, CHCl3); 
1
H-n.m.r.: ", 
0.80 (t, 6H, 
3
J = 6.4 Hz, 2 ! CH3 lipid), 1.15-1.21 (m, 44H, 22 ! CH2 lipid), 1.31-1.54 
(m, 4 H, 2 ! CH2CHOBn), 2.26 (d, 2H, 
3
J = 5.5 Hz, CH2CO), 2.37 (dd, 1H, 
3
J = 5.6 Hz, 
2
J = 15.0 Hz, CH2
a
CO), 2.60 (dd, 1H, 
3
J = 6.3 Hz, 
2
J = 15.0 Hz, CH2
b
CO), 3.22 (s, 3H, 
OCH3), 3.34-3.43 (m, 1H, H-5), 3.57 (dd, 1H, J4,5 = 9.4 Hz, H-4), 3.63-3.77 (m, 3H, H-
6a, 2 ! CHOBn), 3.98 (dd, 1H, J2,3 = 9.1 Hz, H-2), 4.14 (d, 1H, 
3
J = 8.3 Hz, NH), 4.22 
(dd, 1H, J5,6b = 4.8 Hz, J6a,6b = 10.5 Hz, H-6b), 4.30 (d, 1H, 
2
J = 11.9 Hz, PhCH2
a
), 4.41 
(d, 2H, 
2
J = 12.2 Hz, PhCH2
a
’, PhCH2
b
’), 4.49 (d, 1H, 
2
J = 11.9 Hz, PhCH2
b
), 5.25 (dd, 
1H, J3,4 = 9.4 Hz, H-3), 5.33 (s, 1H, PhCH), 6.42 (d, 1H, J1,2 = 9.1 Hz, H-1), 7.15-7.32 
(m, 15H, aromatic) ppm, 
13
C-n.m.r.: ", 14.1 (x 2), 14.6, 22.6 (x 2),  23.8, 25.0, 25.1, 29.5 
(x 2), 29.6 (x 4), 31.9, 33.9, 34.4, 39.6, 41.2 (x 24),  52.7, 68.5, 70.6, 71.0, 72.6, 73.0, 
75.4, 76.4 (x 5), 78.7, 85.0, 101.2, 126.0, 127.3, 127.5, 127.6, 127.7, 128.1, 128.2, 128.4, 
128.5, 128.6, 136.7, 138.4 (x 2), 171.3 (x 2) ppm;  
Ethyl 6-O-[N-(benzyloxycarbonyl)glycine]-2-[(R)-3-benzyloxy-hexadecan]-
amido-3-O-[(R)-3-benzyloxy-hexadecanoyl]-2-deoxy-1-thio-!-D-glucopyranoside 
(178) was obtained as an amorphous solid from 177 by Method C in 85% yield. Rf = 0.60 
(toluene-acetone, 4/1, v/v); 
1
H-n.m.r.: ", 0.81 (t, 6 H, J = 6.2 Hz, 2 ! CH3 lipid), 1.08-
1.13 (m, 3H, CH3CH2S), 1.14-1.27 (m, 44H, 22 ! CH2 lipid), 1.37-1.59 (m, 4H, 2 ! 
CH2CHOBn), 2.29 (d, 2H, J = 5.1 Hz, CH2CO), 2.37-2.45 (m, 1H, CH2
a
CO), 2.46-2.64 
(m, 3H, CH2
b
CO, CH3CH2S), 2.89 (d, 1H, J = 3.2 Hz, OH), 3.25-3.49 (m, 2H, H-4, H-5), 
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3.65-3.75 (m, 1H, CHOBn), 3.76-3.84 (m, 1H, CHOBn), 3.85- 4.03 (m, 3H, H-2, CH2 
Gly), 4.18-4.28 (m, 2H, H-6a, H-6b), 4.38-4.49 (m, 3H, PhCH2
a
, PhCH2), 4.56 (d, 1H, J 
= 11.7 Hz, PhCH2
b
), 4.80 (dd, 1H, J3,4 = 8.9 Hz, H-3), 6.32 (d, 1H, J1,2 = 8.5 Hz, H-1), 
7.12-7.42 (m, 15H, aromatic) ppm.  
Ethyl 6-O-[N-(benzyloxycarbonyl)-L-alanine]-2-[(R)-3-benzyloxyhexadecan]-
amido-3-O-[(R)-3-benzyloxy-hexadecanoyl]-2-deoxy-1-thio-!-D-glucopyranoside 
(179) was obtained as an amorphous solid from 177 by Method C in 70% yield. Rf = 0.37 
(toluene-acetone, 4/1, v/v); (c = 1.0, CHCl3); 
1
H-n.m.r.: ", 0.77-0.85 (m, 6H, 2 ! CH3 
lipid), 1.07-1.14 (m, 3H, CH3CH2S), 1.14-1.24 (m, 44H, 22 ! CH2 lipid), 1.26 (d, 3H, 
3
J 
= 7.0 Hz, CH3 Ala), 1.31-1.61 (m, 4H, 2 ! CH2CHOBn), 2.25-2.33 (m, 2H, CH2CO), 
2.40 (dd, 1H, 
3
J = 4.8 Hz, 
2
J = 14.8 Hz, CH2
a
CO), 2.46-2.68 (m, 3H, CH3CH2S, 
CH2
b
CO), 3.27-3.39 (m, 1H, H-4), 3.65-3.83 (m, 2H, PhCH2), 3.85-4.04 (m, 1H, H-2), 
4.25-4.35 (m, 2H, H-5, PhCH2
a
), 4.40-4.46 (m, 2H, 2 ! CHOBn), 4.52-4.66 (m, 2H, CH 
Ala, PhCH2
b
), 4.77-4.84 (m, 1H, H-3), 5.01-5.04 (m, 3H, PhCH2, H-6a), 5.23 (dd, 1 H, 
3
J5,6 = 1.8 Hz, 
2
J6a,6b = 4.4 Hz, H-6b), 5.72-5.78 (m, 1H, NH), 6.34 (d, 1 H, 
3
J1,2 = 9.2 Hz, 
H-1), 7.21-7.32 (m, 15H, aromatic) ppm, 
13
C-n.m.r.: ", 14.1 (x 2), 14.8, 18.9, 22.7 (x 2), 
24.0, 25.1, 29.4, 29.6, 29.65, 29.69, 31.9, 33.8, 34.0, 35.7, 36.9 (x 24), 46.8, 49.7, 52.1, 
64.3, 66.7, 67.0, 69.1, 71.0 (x 2), 75.9 (x 8), 84.4, 127.6, 127.7, 127.8, 127.9 (x 2), 128.0, 
128.1, 128.2, 128.4, 128.5 (x 2), 128.6, 136.1, 136.5, 138.3, 155.5, 171.3, 172.2, 172.9 
ppm;  
Ethyl 6-O-[2-(benzyloxycarbonylamino)-3-(benzyloxycarbonyloxy)]pro-
panoyl-2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-benzyloxy-hexadecanoyl]-
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2-deoxy-1-thio-!-D-glucopyranoside (180) was obtained as an amorphous solid from 
177 by Method B in 60% yield. 
1
H-n.m.r.: ", 0.81 (t, 6H, 
3
J = 6.6 Hz, 2 ! CH3 lipid), 1.10 
(t, 3H, 
3
J = 7.4 Hz, CH3CH2S), 1.14-1.32 (m, 44H, 22 ! CH2 lipid), 1.35-1.61 (m, 4H, 2 
! CH2CHOBn), 2.26-2.33 (m, 2H, CH2CO), 2.37-2.45 (m, 1H, CH2
a
CO), 2.49-2.60 (m, 
3H, CH3CH2S, CH2
b
CO), 3.18-3.24 (m, 1H, H-5), 3.50 (dd, 1H, 
3
J3,4 = 
3
J4,5 = 9.5 Hz, H-
4), 3.58-3.84 (m, 8H, H-6a, H-6b, CH2 Ser, 2 ! CHOBn, PhCH2), 3.84-4.00 (m, 2H, H-2, 
PhCH2
a
), 4.08 (d, 1H, 
2
J = 10.4 Hz, PhCH2
b
), 4.35-4.40 (m, 1H, CH Ser), 4.41-4.45 (m, 
2H, PhCH2), 4.83 (dd, 1H, 
3
J2,3 = 
3
J3,4 = 9.5 Hz, H-3), 5.01-5.10 (m, 2H, PhCH2), 5.74-
5.83 (m, 1H, NH), 6.41 (d, 
3
J1,2 = 9.4 Hz, 1H, H-1), 7.20-7.39 (m, 20H, aromatic) ppm, 
13
C-n.m.r.: ", 14.1 (x 2), 14.7, 22.6 (x 2), 23.9, 25.1, 29.3, 29.58, 29.61, 29.63, 29.65, 
29.67, 31.9, 33.9, 39.6, 41.2 (x 24), 52.2, 52.7, 62.5, 67.1 (x 2), 67.4, 69.5, 71.0, 71.0, 
75.9, 76.5, 77.1, 79.3 (x 7), 84.3, 127.6, 127.7, 127.8, 128.0, 127.98, 128.06, 128.1, 
128.2, 128.4, 128.50, 128.52, 128.6, 135.1, 136.1, 137.8, 138.3, 156.2, 170.4, 171.0, 
171.4, 172.2 ppm; HR-FAB MS [M+H]
+
 calcd for C54H89NO8SNa 934.6207, found 
934.6237. 
Ethyl 6-O-[N-benzyloxycarbonyl-L-proline]-2-[(R)-3-benzyloxyhexa-decan]-
amido-3-O-[(R)-3-benzyloxy-hexadecanoyl]-2-deoxy-1-thio-!-D-glucopyranoside 
(181) was obtained as an amorphous solid from 177 by Method B in 60% yield. Rf = 0.64 
(toluene-acetone, 4/1, v/v); 
1
H-n.m.r.: ", 0.78-0.85 (m, 6H, 2 ! CH3 lipid), 1.12 (t, 3H, 
3
J 
= 7.5 Hz, CH3CH2S), 1.15-1.29 (m, 44H, 22 ! CH2 lipid), 1.34-1.56 (m, 4H, 2 ! 
CH2CHOBn), 1.56-1.64 (m, 2H, CH2CH2N), 2.02 (m, 2H, 
3
J = 6.6 Hz, CH2CHN), 2.24-
2.34 (m, 2H, CH2CO), 2.37-2.47 (m, 1H, CH2
a
CO), 2.47-2.66 (m, 3H, CH3CH2S, 
CH2
b
CO), 2.88 (d, 1 H, 
3
J = 3.6 Hz, OH), 3.15-3.26 (m, 1H, H-5), 3.47 (dd, 1 H, 
3
J3,4 = 
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9.5 Hz, 
3
J4,5 = 3.3 Hz, H-4), 3.55-3.83 (m, 6H, H-6a, H-6b, 2 ! CHOBn, CHN, PhCH2
a
), 
3.84-3.99 (m, 3H, H-2, CH2N), 4.00-4.08 (m, 1H, PhCH2
b
), 4.38-4.49 (m, 3H, PhCH2
a
’, 
PhCH2), 4.52 - 4.61 (m, 1H, PhCH2
b
’), 4.73 - 4.86 (m, 1H, H-3), 6.35 (d, 1 H, 
3
J1,2 = 9.2 
Hz, H-1), 7.14 - 7.39 (m, 15H, aromatic) ppm, 
13
C-n.m.r.: !, 14.1 (x 2), 14.8, 18.9, 22.7 
(x 2), 24.0, 25.1, 29.4, 29.6, 29.65, 29.69, 31.9, 33.8, 34.0, 35.7, 36.9 (x 24), 46.8, 49.7, 
52.1, 64.3, 66.7, 67.0, 69.1, 71.0 (x 2), 75.9 (x 8), 84.4, 127.6, 127.7, 127.8, 127.9 (x 2), 
128.0, 128.1, 128.2, 128.4, 128.5 (x 2), 128.6, 136.1, 136.5, 138.3, 155.5, 171.3, 172.2, 
172.9 ppm; HR-FAB MS [M+H]
+
 calcd for C67H102N2O11Na 1165.7102, found 
1165.7144. 
Methyl 4,6-benzylidene-2-[(R)-3-benzyloxy-hexadecan]amido-2-deoxy-"-D-
glucopyranoside (184) was obtained from 183 by Method B as an amorphous solid in 
60% yield.  Rf = 0.59 (toluene-acetone, 7/3, v/v); [#]D
25
 32.8º (c = 1.0, CHCl3); 
1
H-n.m.r.: 
!,  0.81 (t, 3H, 
3
J = 6.3 Hz, CH3 lipid), 1.09-1.30 (m, 22H, 11 ! CH2 lipid), 1.30-1.67 (m, 
2H, CH2CHOBn), 2.36 (dd, 1H, 
3
J = 7.0 Hz, 
2
J = 15.1 Hz, CH2
a
CO), 2.48 (dd, 1H, 
3
J = 
3.6 Hz, 
2
J = 15.1 Hz, CH2
b
CO), 3.26 (s, 3H, OCH3), 3.31-3.40 (m, 1H, H-5), 3.40-3.53 
(m, 2H, H-2, H-4), 3.64-3.81 (m, 2H, H-6a, CHOBn), 3.91 (dd, 1H, 
3
J3,4 = 9.1 Hz, H-3), 
4.25 (dd, 1H, 
3
J5,6b = 4.8 Hz, 
2
J6a,6b = 10.3 Hz, H-6b), 4.34 (d, 1H, 
3
J = 8.3 Hz, NH), 4.45 
(d, 1H, 
2
J = 11.3 Hz, PhCH2
a
), 4.52 (d, 1H, 
2
J = 11.3 Hz, PhCH2
b
), 5.47 (s, 1H, PhCH), 
6.72 (d, 1H, 
3
J1,2 = 5.8 Hz, H-1), 7.05 - 7.35 (m, 8H, aromatic), 7.35 - 7.48 (m, 2H, 
aromatic) ppm, 
13
C-n.m.r.: !, 14.1, 22.7, 25.2, 29.3, 29.5, 29.58, 29.61, 29.64, 31.9, 33.6, 
41.1, 56.8, 58.6, 66.2, 68.6, 71.2, 71.7, 81.5, 101.7, 101.8, 126.3, 127.7, 127.9, 128.2, 
128.5, 129.1, 137.1, 138.0, 173.2  ppm; HR-FAB MS [M+H]
+
 calcd for C37H56NO7 
626.4057, found 626.4058.  
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Methyl 4,6-benzylidene-2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-
benzyloxy-hexadecanoyl]-2-deoxy-!-D-glucopyranoside (185) was obtained as an 
amorphous solid from 154 by Method B in 85% yield. 
1
H-n.m.r.: ", 0.80 (t, 6H, 
3
J = 6.4 
Hz, 2 ! CH3 lipid), 1.15-1.21 (m, 44H, 22 ! CH2 lipid), 1.31-1.54 (m, 4 H, 2 ! 
CH2CHOBn), 2.26 (d, 2H, 
3
J = 5.5 Hz, CH2CO), 2.37 (dd, 1H, 
3
J = 5.6 Hz, 
2
J = 15.0 Hz, 
CH2
a
CO), 2.60 (dd, 1H, 
3
J = 6.3 Hz, 
2
J = 15.0 Hz, CH2
b
CO), 3.22 (s, 3H, OCH3), 3.34-
3.43 (m, 1H, H-5), 3.57 (dd, 1H, 
3
J4,5 = 9.4 Hz, H-4), 3.63-3.77 (m, 3H, H-6a, 2 ! 
CHOBn), 3.98 (dd, 1H, 
3
J2,3 = 9.1 Hz, H-2), 4.14 (d, 1H, 
3
J = 8.3 Hz, NH), 4.22 (dd, 1H, 
3
J = 4.8 Hz, 
2
J = 10.5 Hz, H-6b), 4.30 (d, 1H, 
2
J = 11.9 Hz, PhCH2
a
), 4.41 (d, 2H, 
2
J = 
12.2 Hz, PhCH2
a
, PhCH2
b
), 4.49 (d, 1H, 
2
J = 11.9 Hz, PhCH2
b
), 5.25 (dd, 1H, 
3
J3,4 = 9.4 
Hz, H-3), 5.33 (s, 1H, PhCH), 6.42 (d, 1H, 
3
J = 9.1 Hz, H-1), 7.15 - 7.32 (m, 15H, 
aromatic) ppm, 
13
C-n.m.r.: ", 14.0, 22.6, 25.1, 25.1, 29.3, 29.56, 29.59, 31.8, 34.1, 34.3, 
39.5, 41.7, 53.9, 56.7, 66.0, 68.5, 70.9, 71.1, 71.7, 75.4, 76.2, 78.9, 101.1, 102.6, 125.9, 
127.3, 127.49, 127.52, 128.0, 128.1, 128.3, 128.7, 128.8, 136.8, 138.39, 138.42, 171.4, 
171.5  ppm;  
3.8.b. Deprotection Protocols 
Method A. Typical procedure for benzylidene deprotection: To a solution of 
starting material (1 mmol) in wet CH2Cl2 (CH2Cl2/H2O, 100/1, v/v) was added 
CF3COOH dropwise, simultaneously monitoring the progress of the reaction by TLC 
upon each addition. Once TLC showed complete conversion of the starting material (ca. 
after 30 min) after the addition of ca. 0.20 mL TFA, the reaction was diluted with CH2Cl2 
(50 mL) and washed with 20 mL portions of the following: thrice with saturated aq. 
NaHCO3, brine. The organic phase was separated, dried over anhydrous MgSO4, and 
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concentrated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel (ethyl acetate - toluene gradient elution) to afford the 4,6-
diol derivative.  
Method B. Typical procedure for thioglycoside hydrolysis: To a solution of the 
sugar (0.1 mmol) in CH2Cl2 (5 mL) was added N-iodosuccinimide (0.2 mmol) and H2O 
(2 mmol) and the reaction was stirred at rt from a period of 2 hours to 16 hours. After 
that, the reaction mixture was diluted with CH2Cl2 (25 mL) and washed with the 
following: 0.1 N aq. Na2S2O3 (2 x 10 mL), saturated aq. NaHCO3 (10 mL), brine (10 
mL). The organic phase was separated, dried over MgSO4, and concentrated to dryness 
under reduced pressure to afford the corresponding hemiacetal. 
Method C. Typical procedure for catalytic hydrogenolysis under neutral, 
anhydrous conditions: To a solution of the sugar (0.1 mmol) in MeOH: CH2Cl2 (4 mL, 
1/1, v/v) was added Pearlman’s catalyst (Pd(OH)2, 0.02 mmol) and the reaction mixture 
was stirred under Argon for 30 minutes at room temperature. The argon was removed 
under vacuum and the reaction mixture was flushed repeatedly flushed with hydrogen 
under atmospheric pressure and stirred for 16 hours to 2 days at rt. After that, the reaction 
mixture was diluted with a solution of CH2Cl2:MeOH:H2O (4.2 mL; 1/1/0.1, v/v), stirred 
for 30 minutes, and filtered over a pad of Florisil®. After washing the pad of florisil 
repeatedly with the CH2Cl2:MeOH:H2O solvent system (20 mL), the combined filtrates 
were concentrated under reduced pressure to afford 24. 
Method D. Typical procedure for catalytic hydrogenolysis under neutral, hydrous 
conditions: To a solution of the sugar (0.1 mmol) in MeOH:CH2Cl2:H2O (4.2 mL, 
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1/1/0.1, v/v) was added Pearlman’s catalyst (Pd(OH)2, 0.02 mmol) and the reaction 
mixture was stirred for 30 minutes under Argon at room temperature. The argon was 
removed under vacuum and the reaction mixture was flushed repeatedly flushed with 
hydrogen under atmospheric pressure and stirred for 16 hours to 2 days at rt. After that, 
the reaction mixture was diluted with a solution of CH2Cl2:MeOH:H2O (4.2 mL; 1/1/0.1, 
v/v), stirred for 30 minutes, and filtered over a pad of Florisil®. After washing the pad of 
florisil repeatedly with the CH2Cl2:MeOH:H2O solvent system (20 mL), the combined 
filtrates were concentrated under reduced pressure to afford 25 and 26.  
Method E. Typical procedure for catalytic hydrogenolysis under slightly acidic 
conditions: To a solution of the sugar (0.1 mmol) in MeOH:CH2Cl2 (4 mL, 1/1, v/v) was 
added Pearlman’s catalyst (Pd(OH)2, 0.02 mmol) and CH3COOH (10 µL).  the reaction 
mixture was stirred for 30 minutes under Argon at room temperature. The argon was 
removed under vacuum and the reaction mixture was flushed repeatedly flushed with 
hydrogen under atmospheric pressure and stirred for 16 hours at rt. After that, the 
reaction mixture was reaction mixture was neutralized with Et3N, diluted with a solution 
of CH2Cl2:MeOH:H2O (4.2 mL; 1/1/0.1, v/v), stirred for 30 minutes, and filtered over a 
pad of Florisil®. After washing the pad of florisil repeatedly with the 
CH2Cl2:MeOH:H2O solvent system (20 mL), the combined filtrates were concentrated 
under reduced pressure to afford 27 and 28. 
Ethyl 2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-benzyloxy-hexadeca-
noyl]-2-deoxy-1-thio-!-D-glucopyranoside (177) was prepared from 176 using Method 
A and obtained as an amorphous solid in 84% yield.  Rf = 0.52 (toluene-acetone, 7/3, 
v/v); 
1
H-n.m.r.: ", 0.78 - 0.83 (m, 6H, 2 ! CH3 lipid), 1.11 (t, 3H, 
3
J = 7.4 Hz, CH3CH2S), 
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1.15 - 1.23 (m, 44H, 22 ! CH2 lipid), 1.43 - 1.64 (m, 4H, 2 ! CH2CHOBn), 2.29 (d, 2H, 
3
J = 5.5 Hz, CH2CO), 2.42 (dd, 1H, 
3
J = 4.9 Hz, 
2
J = 14.7 Hz, CH2
a
CO), 2.48 - 2.60 (m, 
3H, CH2
b
CO, CH3CH2S), 3.03 (s, 1H, OH), 3.20 (dd, 1H, 
3
J4,5 = 9.4 Hz, 
3
J5,6 = 4.5 Hz, H-
5), 3.48 (dd, 1H, 
3
J3,4 = 
3
J4,5 = 9.1 Hz, H-4), 3.58 - 3.67 (m, 1H, H-6a), 3.67 - 3.75 (m, 
2H, H-6b, CHOBn), 3.76 - 3.87 (m, 1H, CHOBn), 3.89 - 3.98 (m, 1H, H-2), 4.04 (m, 1H, 
OH), 4.38 - 4.48 (m, 3H, PhCH2, PhCH2
a
), 4.56 (d, 1H, 
2
J = 11.7 Hz, PhCH2
b
), 4.80 (dd, 
1H, 
3
J2,3 = 
3
J3,4 = 9.5 Hz, H-3), 6.37 (d, 1H, 
3
J1,2 = 9.2 Hz, H-1), 7.20 - 7.34 (m, 10H, 
aromatic) ppm, 
13
C-n.m.r.: !, 14.1 (x 2), 14.7, 22.7 (x 2), 24.0, 25.1, 29.4, 29.59, 29.61, 
29.65, 29.67, 29.70, 30.9, 31.9, 33.8 (x 2), 39.7, 41.2 (x 24),  52.0,  62.7, 69.7, 70.9, 71.0 
(x 2), 75.9, 77.2, 79.2 (x 2), 84.5, 127.6, 127.8, 127.9, 128.0, 128.4, 128.6, 137.8, 138.3, 
171.3, 172.3 ppm; HR-FAB MS [M+H]
+
 calcd for C54H90NO8S 912.6387, found 
912.6400.  
Methyl 2-[(R)-3-benzyloxy-hexadecan]amido-3-O-[(R)-3-benzyloxy-hexa-
decanoyl]-2-deoxy-"-D-glucopyranoside (156) was prepared from 155 using Method A 
and obtained as an amorphous solid in 90% yield.  Rf = 0.41 (toluene-acetone, 7/3, v/v); 
1
H-n.m.r.: !, 0.81 (t, 6H, 
3
J = 6.6 Hz, 2 ! CH3 lipid), 1.14- 1.27 (m, 44H, 22 ! CH2 lipid), 
1.33-1.61 (m, 4H, 2 ! CH2CHOBn), 2.25-2.31 (m, 2H, CH2CO), 2.36-2.44 (m, 1H, 
CH2
a
CO), 2.50-2.59 (m, 1H, CH2
b
CO), 3.21-3.26 (m, 1H, H-5), 3.28 (s, 3H, OCH3), 3.54 
(dd, 1H, 
3
J3,4 = 
3
J4,5 = 9.2 Hz, H-4), 3.63-3.75 (m, 3H, H-6a, H-6b, CHOBn), 3.76-3.87 
(m, 3H, CHOBn, H-2, OH), 4.14 (d, 1H, 
3
J = 8.3 Hz, NH), 4.38-4.46 (m, 3H, PhCH2, 
PhCH2
a
), 4.51 (d, 1H, 2J = 11.5 Hz, PhCH2
b
), 4.94 (dd, 1H, 
3
J2,3 = 
3
J3,4 = 9.5 Hz, H-3), 
6.32 (d, 1H, 
3
J1,2 = 9.0 Hz, H-1), 7.17-7.36 (m, 10H, aromatic) ppm, 
13
C-n.m.r.: !, 14.1 (x 
2), 22.7, 25.1, 25.2, 29.3, 29.6 (x 2), 29.7 (x 3), 30.9, 31.9, 33.9, 39.6, 41.5 (x 26),  53.5, 
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56.6, 62.3, 69.6, 71.1 (x 3), 75.1, 75.9 (x 3), 76.4, 102.0, 127.6, 127.7, 127.8, 128.0, 
128.4, 128.5, 137.8, 138.3, 172.4 (x 2) ppm. 
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